Engineered off-the-shelf immune cells and methods of use thereof
The production of 'off-the-shelf' immune cell therapies, including NK and T cells with engineered TCRs and CARs, addresses the scalability and cost issues of current cancer treatments, offering effective and safer allogeneic cell therapies for cancer and autoimmune diseases.
Patent Information
- Application Number
- JP2021573443
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-11
- Filing Date
- 2020-06-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-06-12
AI Technical Summary
Current cancer treatments, particularly those involving autologous adoptive cell transfer, are expensive, labor-intensive, and difficult to scale for widespread patient use, necessitating the development of allogeneic immune cell products that can be manufactured on a large scale and easily distributed.
The production of 'off-the-shelf' therapeutic immune cell populations, such as NK cells and T cells, is achieved through methods that include selecting stem or progenitor cells, introducing specific T cell receptors, and culturing them in feeder-free conditions with defined media and factors to induce differentiation, optionally incorporating chimeric antigen receptors (CARs) and suicide genes, and expressing invariant T cell receptors (TCRs).
This approach enables the widespread availability and utility of novel cell therapies by providing scalable, effective, and safer immune cell treatments for cancer and autoimmune diseases, reducing toxicity and recurrence risks.
Smart Images

Figure 0007580726000027 
Figure 0007580726000028 
Figure 0007580726000029
Abstract
Description
[Technical Field]
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 860,613, filed June 12, 2019, U.S. Provisional Patent Application No. 62 / 860,644, filed June 12, 2019, U.S. Provisional Patent Application No. 62 / 860,667, filed June 12, 2019, U.S. Provisional Patent Application No. 62 / 946,747, filed December 11, 2019, and U.S. Provisional Patent Application No. 62 / 946,788, filed December 11, 2019, which provisional applications are expressly incorporated herein by reference in their entireties. 1.Technical Field
[0002] Embodiments of the present disclosure relate to at least the fields of immunology, cell biology, molecular biology, and medicine, including at least cancer medicine. [Background technology]
[0003] 2. Background technology Cancer affects tens of millions of people worldwide and is the greatest threat to public health in the United States. Despite the existence of treatments, cancer patients continue to suffer from the ineffectiveness of these treatments, their toxicity, and the risk of recurrence. Therefore, novel cancer treatments are desperately needed. Over the past decade, immunotherapy has become a new generation of cancer medicine. In particular, cell-based therapies have shown great promise. A prominent example is chimeric antigen receptor (CAR)-engineered adoptive T cell therapy, which targets specific blood cells with remarkable efficacy.
[0004] However, the majority of current protocols for treatment consist of autologous adoptive cell transfer, in which immune cells taken from a patient are generated and used to treat only that one patient. Such procedures are costly, labor-intensive to manufacture, and difficult to widely supply to all patients in need. Therefore, there is a great demand for allogeneic immune cell products that can be manufactured on a large scale and easily distributed to treat a larger number of patients.
[0005] Despite the existence of treatments, cancer patients continue to suffer from the ineffectiveness of these treatments, their toxicity, and the risk of recurrence. Thus, there is a desperate need for new therapies for diseases such as cancer and autoimmune diseases. The present disclosure provides a solution to the long-standing need for a treatment, but also provides a treatment that can be more widely supplied or distributed. Summary of the Invention [Means for solving the problem]
[0006] Embodiments are provided to address the need for novel therapeutics, and more particularly, cell therapies that are not hampered by the difficulties associated with personalized therapies using autologous cells. The ability to produce "off-the-shelf" therapeutic cell populations, or cell populations that can be used to create therapeutic cell populations, increases the availability and utility of novel cell therapies.
[0007] Embodiments of the present disclosure relate to methods for generating or preparing a population of immune cells. The immune cells can be, for example, NK cells, T cells, iNKT cells, or other immune cells. In some embodiments, the immune cells are iNKT cells. In some embodiments, the immune cells are CD4 + Helper T cells, regulatory T (Treg) cells, CD8 +These include cytotoxic T cells, gamma-delta T cells, mucosal-associated invariant T (MAIT) cells, and other natural and adoptive T cells. Accordingly, aspects of the present disclosure relate to a method for preparing a population of T cells, comprising: a) selecting stem or progenitor cells; b) introducing one or more nucleic acids encoding at least one T cell receptor (TCR); and c) culturing the cells to induce differentiation of the cells into T cells, wherein a), b), and / or c) do not comprise contacting the cells with feeder cells or a population of feeder cells. In some embodiments, in c), the cells are cultured in a medium that is feeder-free. In some embodiments, the stem or progenitor cells are CD34 +In some embodiments, the stem or progenitor cells are cultured in medium comprising one or more of IL-3, IL-7, IL-6, SCF, MCP-4, EPO, TPO, FLT3L, and / or retronectin. In some embodiments, the stem or progenitor cells are cultured on a surface coated with retronectin, DLL4, DLL1, and / or VCAM1. In some embodiments, the cells are cultured in medium comprising one or more of 5-50 ng / ml hIL-3, 5-50 ng / ml IL-7, 0.5-5 ng / ml MCP-4, IL-6, 5-50 ng / ml hSCF, EPO, 5-50 ng / ml hTPO, and / or 10-100 ng / ml hFLT3L. In some embodiments, the cells are cultured in medium containing one or more of 10 ng / ml hIL-3, 20-25 ng / ml IL-7, 1 ng / ml MCP-4, IL-6, 15-50 ng / ml hSCF, EPO, 5-50 ng / ml hTPO, and / or 50 ng / ml hFLT3L. In some embodiments, the cells are cultured with one or more of IL-3, IL-7, IL-6, SCF, EPO, TPO, FLT3L, and / or retronectin for 12-72 hours. In some embodiments, the TCR comprises an iNKT TCR. In some embodiments, the TCR comprises an antigen-specific (e.g., cancer antigen-specific) TCR. In some embodiments, the TCR comprises a TCR that specifically recognizes the NY-ESO-1 antigen. In some embodiments, the NY-ESO-1 antigen is NY-ESO-1. 157-165In some embodiments, step c) comprises culturing the cells in a differentiation and / or expansion medium. In some embodiments, step c) comprises contacting the cells with one or more of DLL1, DLL4, VCAM1, VCAM5, and / or retronectin. In some embodiments, one or more of DLL1, DLL4, VCAM1, VCAM5, and / or retronectin are coated onto a tissue culture plate or microbead surface. In some embodiments, one or more of DLL1, DLL4, VCAM1, VCAM5, and / or retronectin are coated onto a tissue culture plate using a coating composition comprising 0.1-10 μg / ml of DLL4 and 0.01-1 μg / ml of VCAM1. In some embodiments, one or more of DLL1, DLL4, VCAM1, VCAM5, and / or retronectin are coated onto a tissue culture plate using a coating composition comprising 0.5 μg / ml of DLL4 and 0.1 μg / ml of VCAM1. In some embodiments, the expansion or differentiation medium comprises one or more of Iscove's MDM, serum albumin, insulin, transferrin, and / or 2-mercaptoethanol. In some embodiments, the expansion or differentiation medium comprises one or more of ascorbic acid, human serum, B27 supplement, Glutamax, Flt3L, IL-7, MCP-4, IL-6, TPO, and SCF. In some embodiments, the expansion or differentiation medium comprises one or more of 50-500 μM ascorbic acid, human serum, 1-10% B27 supplement, 0.1-10% Glutamax, 2-50 ng / ml Flt3L, 2-50 ng / ml IL-7, 0.1-1 ng / ml MCP-4, 0-10 ng / ml IL-6, 0.5-50 ng / ml TPO, and 1.5-50 ng / ml SCF. In some embodiments, the expansion or differentiation medium comprises one or more of 100 μM ascorbic acid, human serum, 4% B27 supplement, 1% Glutamax, 2-50 ng / ml Flt3L, 2-50 ng / ml IL-7, 0.1-1 ng / ml MCP-4, 0-10 ng / ml IL-6, 0.5-50 ng / ml TPO, and 1.5-50 ng / ml SCF.In some embodiments, the method further comprises stimulating and / or expanding the cells. In some embodiments, stimulating or expanding the cells comprises contacting the cells with an antigen that specifically binds to the TCR. In some embodiments, stimulating or expanding the cells comprises contacting the cells with an anti-CD3, anti-CD2, and / or anti-CD28 antibody, or an antigen-binding fragment thereof. In some embodiments, stimulating or expanding the cells comprises culturing the cells in an expansion medium. In some embodiments, the method comprises stimulating and / or expanding the cells by contacting the cells with α-GC. In some embodiments, the method further comprises contacting the cells with one or both of IL-15 and IL-7, and / or in these embodiments, the expansion medium comprises one or both of IL-15 or IL-7. In some embodiments, the expansion medium comprises 5-100 ng / ml IL-7 and / or 5-100 ng / ml IL-15. In some embodiments, the expansion medium comprises 10 ng / ml IL-7 and / or 50 ng / ml IL-15. In some embodiments, the method further comprises contacting the cells with one or more of human serum antibodies, Glutamax, a buffer, an antimicrobial agent, and N-acetyl-L-cysteine, and / or in these embodiments, the expansion medium comprises one or more of human serum antibodies, Glutamax, a buffer, an antimicrobial agent, and N-acetyl-L-cysteine. In some embodiments, the method further comprises activating the cells by contacting the cells with anti-CD3 and / or anti-CD28 coated beads. In some embodiments, the method further comprises transfecting the cells with a nucleic acid comprising a CAR molecule and / or an HLA-E gene. In some embodiments, the nucleic acid comprising a CAR molecule and / or an HLA-E gene is transfected into the cells by retroviral infection. In some embodiments, the nucleic acid molecule comprises a CAR molecule. In some embodiments, the CAR is specific for BCMA, CD19, CD20, or NY-ESO. In some embodiments, the method further comprises contacting the cells with retronectin.In some embodiments, a, b, c, or the entire method does not include contacting the cells with a population of feeder cells. In some embodiments, a, b, c, or the entire method does not include contacting the cells with a population of stromal cells. In some embodiments, a, b, c, or the entire method does not include contacting the cells with a Notch ligand or a fragment thereof.
[0008] Further embodiments relate to engineered invariant natural killer T (iNKT) cells or populations of engineered iNKT cells. Accordingly, aspects of the present disclosure relate to engineered invariant natural killer T (iNKT) cells that express at least one invariant natural killer (iNKT) T cell receptor (TCR), the engineered iNKT cells comprising one or more of: high levels of NKG2D; low or undetectable expression of KIR; and high levels of granzyme B. A further aspect relates to a population of engineered iNKT cells that express at least one iNKT TCR, the engineered iNKT cells comprising one or more of: at least 50% of the cells with high levels of NKG2D; less than 2% of the cells with high levels of KIR; and at least 67% of the cells with high levels of granzyme B. A further aspect relates to a method of preparing iNKT cells of the present disclosure, comprising: a) isolating CD34 from a plurality of hematopoietic stem or progenitor cells; + a) selecting the cells; b) introducing one or more nucleic acids encoding at least one human invariant natural killer (iNKT) T cell receptor (TCR); and c) culturing the cells to induce differentiation of the cells into iNKT cells.
[0009] Still further aspects relate to cells or populations of cells produced by the methods of the present disclosure. Also provided are methods of treating a patient with engineered cells (e.g., engineered T cells, iNKT cells, etc.), comprising administering to the patient a cell or population of cells of the present disclosure. A further aspect relates to a method of treating cancer in a patient, comprising administering a cell of the present disclosure. An additional aspect relates to a method for treating graft-versus-host disease (GVHD), comprising administering a cell of the present disclosure.
[0010] In some embodiments, the population of cells has high levels of NKG2D and is at least, at most, or about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 200 3, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) of cells. In some embodiments, the population of cells has high levels of KIR 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3. 1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6. 9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 , 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50%, or less than, at most, at least or about said % (or any derivable range therein) of cells.In some embodiments, the population of cells contains less than, at most, at least or about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%, or at most, at least or about said % (or any derivable range therein) of cells that have high levels of granzyme B. The terms "high" or "low" level or expression for the cell markers described herein can be relative to iNKT cells, naturally occurring T cells, T cells that are not naturally occurring iNKT, or cell types described herein.
[0011] In some embodiments, the cell further comprises a chimeric antigen receptor (CAR). In some embodiments, the CAR specifically binds BCMA. In some embodiments, the CAR specifically binds CD19. In some embodiments, the cell further comprises exogenous expression of HLA-E. In some embodiments, the cell further comprises an exogenous nucleic acid encoding a polypeptide comprising all or a fragment of a suicide gene, HLA-E, CAR, and / or iNKT TCR. In some embodiments, the genome of the cell has been modified to eliminate surface expression of at least one HLA-I or HLA-II molecule. In some embodiments, the invariant TCR gene product is an alpha TCR gene product. In some embodiments, the invariant TCR gene product is a beta TCR gene product. In some embodiments, both an alpha TCR gene product and a beta TCR gene product are expressed. In some embodiments, the exogenous suicide gene product or HLA-E gene product and / or the exogenous nucleic acid have one or more codons optimized for expression in the cell. In some embodiments, the suicide gene product is herpes simplex virus thymidine kinase (HSV-TK), purine nucleoside phosphorylase (PNP), cytosine deaminase (CD), carboxypeptidase G2, cytochrome P450, linamarase, beta-lactamase, nitroreductase (NTR), carboxypeptidase A, or inducible caspase 9. In some embodiments, the suicide gene is enzyme-based. In some embodiments, the suicide gene encodes thymidine kinase (TK) or inducible caspase 9. In some embodiments, the TK gene is a viral TK gene. In some embodiments, the TK gene is a herpes simplex virus TK gene. In some embodiments, the suicide gene product is activated by a substrate. In some embodiments, the substrate is ganciclovir, penciclovir, or a derivative thereof.
[0012] In some embodiments, culturing the cells to induce differentiation of the cells into iNKT cells comprises feeder-free culturing. In some embodiments, the iNKT TCR specifically binds to α-GC. In some embodiments, the method further comprises stimulating and / or expanding the cells by contacting the cells with an antigen that specifically binds to the iNKT TCR. In some embodiments, the method further comprises stimulating and / or expanding the cells by contacting the cells with α-GC. In some embodiments, the method further comprises contacting the cells with IL-15. In some embodiments, the method further comprises contacting the cells with one or more of human serum antibodies, Glutamax, a buffer, an antibacterial agent, and N-acetyl-L-cysteine. In some embodiments, the method further comprises activating the cells by contacting the cells with anti-CD3 and / or anti-CD28 coated beads. In some embodiments, the method further comprises transfecting the cells with a nucleic acid comprising a CAR molecule and / or an HLA-E gene. In some embodiments, the nucleic acid comprising a CAR molecule and / or an HLA-E gene is transfected into the cells by retroviral infection. In some embodiments, the method further comprises contacting the cells with Retronectin. + The cells are isolated from a healthy subject and / or a subject without cancer. In some embodiments, a, b, c, or the entire method does not include a step of contacting the cells with a population of feeder cells. In some embodiments, a, b, c, or the entire method does not include a step of contacting the cells with a population of stromal cells. In some embodiments, a, b, c, or the entire method does not include a step of contacting the cells with a Notch ligand or a fragment thereof.
[0013] A further aspect of the present disclosure relates to engineered invariant natural killer T (iNKT) cells that express at least one invariant natural killer (iNKT) T cell receptor (TCR) and a chimeric cell receptor (CAR) comprising: a) an extracellular binding domain, b) a single transmembrane domain, and c) a single cytoplasmic region comprising a primary intracellular signaling domain, wherein the at least one iNKT TCR is expressed from an exogenous nucleic acid and / or from an endogenous invariant TCR gene under the transcriptional control of a recombinantly modified promoter region. In some embodiments, the extracellular binding domain comprises a BCMA-binding domain. In some embodiments, the extracellular binding domain comprises a CD19-binding domain.
[0014] A further aspect is a method for preparing a population of engineered chimeric antigen receptor (CAR) invariant natural killer T (iNKT) cells, comprising: a) generating CD34 iNKT cells from a plurality of hematopoietic stem or progenitor cells; + a) selecting the cells; b) introducing one or more nucleic acids encoding at least one human invariant natural killer (iNKT) T cell receptor (TCR); c) isolating the isolated human CD34 + a) eliminating surface expression of one or more HLA-I and / or HLA-II molecules on the cells; and b) eliminating isolated CD34 cells expressing iNKT TCRs. + and e) introducing a nucleic acid encoding a CAR into the iNKT cells. In some embodiments, the CAR is a BCMA-CAR. In some embodiments, the CAR is a CD19-CAR.
[0015] A further aspect relates to a method of treating cancer in a patient having cancer, comprising administering to the patient an engineered iNKT cell or population of cells of the present disclosure. In some embodiments, the cancer is a lymphoma. In some embodiments, the cancer is a B-cell lymphoma. In other embodiments, the cancer is a cancer described herein.
[0016] In some embodiments, the CAR further comprises a spacer between the extracellular domain and the transmembrane domain. In some embodiments, the spacer comprises a CD8 hinge. In some embodiments, the transmembrane domain comprises the transmembrane domain from CD8. In some embodiments, the cytoplasmic region further comprises a costimulatory domain. In some embodiments, the costimulatory domain comprises a 4-1BB polypeptide. In some embodiments, the intracellular signaling domain comprises a CD3-zeta polypeptide. In some embodiments, the CAR molecule comprises SEQ ID NO: 72. In some embodiments, the spacer comprises SEQ ID NO: 83. In some embodiments, the CAR comprises an scFv. In some embodiments, the scFv comprises SEQ ID NO: 82. In some embodiments, the transmembrane domain comprises SEQ ID NO: 84. In some embodiments, the costimulatory domain comprises SEQ ID NO: 85. In some embodiments, the intracellular signaling domain comprises SEQ ID NO: 86. In some embodiments, the CAR molecule further comprises a self-cleaving peptide. In some embodiments, the self-cleaving peptide comprises SEQ ID NO: 87. In some embodiments, the CAR molecule further comprises a therapeutic control. In some embodiments, the therapeutic control comprises EGFR. In some embodiments, the therapeutic control comprises a truncated EGFR. In some embodiments, the therapeutic control is cleaved from the CAR molecule.
[0017] In some embodiments, the nucleic acid encoding the CAR molecule is introduced into cells using a recombinant vector.In some embodiments, the recombinant vector is a viral vector.In some embodiments, the viral vector is a lentivirus, a retrovirus, an adeno-associated virus (AAV), a herpesvirus, or an adenovirus.In some embodiments, the viral vector comprises a retroviral vector.
[0018] Any embodiment discussed with respect to cells can be applied to a population of such cells. In certain embodiments, the engineered iNKT cells comprise a nucleic acid comprising one, two, and / or three of the following: i) all or a portion of an invariant alpha T cell receptor coding sequence; ii) all or a portion of an invariant beta T cell receptor coding sequence; or iii) a suicide gene. Further embodiments include engineered iNKT cells comprising a nucleic acid having a sequence encoding i) all or a portion of an invariant alpha T cell receptor, ii) all or a portion of an invariant beta T cell receptor, and / or iii) a suicide gene product. In some embodiments, the engineered iNKT cells comprise a nucleic acid under the control of a heterologous promoter, meaning that the promoter is not the same genomic promoter that controls transcription of the nucleic acid. It is contemplated that the engineered iNKT cells comprise an exogenous nucleic acid comprising one or more coding sequences, some or all of which are under the control of a heterologous promoter in many embodiments described herein.
[0019] It is particularly noted that any embodiment discussed in connection with a CAR embodiment, a particular cell embodiment, or a cell population embodiment can be utilized with any other CAR, cell, or cell population embodiment. Furthermore, any embodiment utilized in connection with a particular method can be implemented in connection with any other method described herein. Furthermore, aspects of different methods described herein can be combined to achieve other methods and to produce or describe the use of any cell or cell population. In particular, it is contemplated that aspects of one or more embodiments can be combined with aspects of one or more other embodiments described herein. Furthermore, any method described herein may be expressed to indicate one or more uses for the cells or cell populations described herein. For example, the use of engineered iNKT cells or iNKT cell populations may be indicated from any method described herein.
[0020] In certain embodiments, there are engineered invariant natural killer T (iNKT) cells that express at least one invariant natural killer T cell receptor (iNKT TCR), where the at least one iNKT TCR is expressed from an exogenous nucleic acid and / or from an endogenous invariant TCR gene under the transcriptional control of a recombinantly modified promoter region. In some embodiments, the cell or population of cells further comprises an exogenous suicide gene product or a nucleic acid encoding a suicide gene. iNKT TCR refers to a "TCR that recognizes lipid antigens presented by CD1d molecules." In some embodiments, the iNKT TCR specifically binds to alpha-galactosylceramide (α-GC). The iNKT TCR may comprise an alpha-TCR, a beta-TCR, or both. In some cases, the TCR utilized may belong to the broader group of "invariant TCRs," such as MAIT cell TCRs, GEM cell TCRs, or gamma / delta TCRs, which result in HSC-engineered MAIT cells, GEM cells, or gamma / delta T cells, respectively.
[0021] Certain embodiments include engineered iNKT cells and T cell populations. Certain embodiments include engineered T cells, e.g., engineered iNKT or other T cell populations, including engineered clonal cells that contain either an altered genomic T cell receptor sequence or an exogenous nucleic acid encoding an invariant T cell receptor (TCR) and lack expression of one or more HLA-I or HLA-II genes. An "altered genomic T cell receptor sequence" refers to a sequence that has been altered by recombinant DNA technology. The term "clonal" cells refers to cells that have been engineered to express a clonal transgenic TCR. In some embodiments, the clonal cells are derived from the same progenitor cell. In some embodiments, a population of mixed clonal cells is considered to be present, and by a population of mixed clonal cells, it is meant that the population includes clonal cells that are derived from a set of progenitor cells, which may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or more progenitor cells (or any range derivable therein), including at least, or at most, the number of progenitor cells. The term "population" refers to the progeny of the cells in the population that were originally transfected / infected with the progenitor cells. In the case of cells containing exogenous nucleic acids or altered genomic DNA sequences, the clonal cells may arise from an original cell into which the exogenous nucleic acid was introduced. Some embodiments relate to a population of clonal cells, and by a population of clonal cells, it is meant that the population includes progeny cells derived from the same original cell. It is believed that some populations of cells may contain a mixture of different clonal cells, meaning that the population arose from different original cells that contain exogenous nucleic acid, but that may differ in distinguishable ways, such as the site of integration of the exogenous nucleic acid. A nucleic acid sequence that is introduced into a cell (either alone or as part of a longer nucleic acid sequence) and that becomes integrated such that progeny cells contain the integrated nucleic acid sequence is considered to be exogenous nucleic acid.An introduced nucleic acid sequence that is maintained extrachromosomally is also considered to be foreign nucleic acid.
[0022] In embodiments in which a portion of an alpha T cell receptor or a portion of a beta T cell receptor is utilized, the embodiment includes a functional portion of an alpha T cell receptor or a functional portion of a beta T cell receptor, and thus cells expressing both are considered to be functional T cells based at least on assays that assess their ability to recognize lipid antigens presented by CD1d molecules.
[0023] In some embodiments, the nucleic acid is an iNKT TCR-alpha or iNKT 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 19, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 2 9, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239 , 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299,300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360 , 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421 , 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523 2, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500 (or any range derivable therein) amino acids or consecutive amino acid residues;It includes sequences that are 100% identical (or any range derivable therein), at least said % identical, or at most said % identical.
[0024] In certain embodiments, the suicide gene is enzyme-based, meaning that the gene product of the suicide gene is an enzyme and that the suicide function depends on enzymatic activity. One or more suicide genes can be utilized in a single cell or a clonal population. In some embodiments, the suicide gene encodes herpes simplex virus thymidine kinase (HSV-TK), purine nucleoside phosphorylase (PNP), cytosine deaminase (CD), carboxypeptidase G2, cytochrome P450, linamarase, beta-lactamase, nitroreductase (NTR), carboxypeptidase A, or inducible caspase 9. Methods in the art for utilizing suicide genes can be used, such as those in U.S. Patent No. 8,628,767, U.S. Patent Application Publication Nos. 20140369979, 20140242033, and 20040014191, all of which are incorporated herein by reference in their entireties. In further embodiments, the TK gene is a viral TK gene, i.e., a TK gene from a virus. In certain embodiments, the TK gene is a herpes simplex virus TK gene. In some embodiments, the suicide gene product is activated by a substrate. Thymidine kinase is a suicide gene product that is activated by ganciclovir, penciclovir, or derivatives thereof. In certain embodiments, the substrate that activates the suicide gene product is labeled for detection. In some cases, the substrate can be labeled for imaging. In some embodiments, the suicide gene product can be encoded by the same or different nucleic acid molecules encoding one or both of TCR-alpha or TCR-beta. In certain embodiments, the suicide gene is sr39TK or inducible caspase 9. In alternative embodiments, the cell does not express an exogenous suicide gene.
[0025] In additional embodiments, the cells lack or have reduced surface expression of at least one HLA-I or HLA-II molecule. In some embodiments, the lack of surface expression of HLA-I and / or HLA-II molecules is achieved by disrupting genes encoding individual HLA-I / II molecules, or by disrupting a gene encoding B2M (beta 2 microglobulin), a common component of all HLA-I complex molecules, or by disrupting a gene encoding CIITA (class II major histocompatibility complex transactivator), an essential transcription factor that controls the expression of all HLA-II genes. In certain embodiments, the cells lack surface expression of one or more HLA-I and / or HLA-II molecules or express 50, 60, 70, 80, 90, 100% (or at least 50%) (or any range derivable therein) reduced levels of such molecules. In some embodiments, HLA-I or HLA-II is not expressed by iNKT cells because these cells have been engineered by gene editing. In some embodiments, the gene editing involved is CRISPR-Cas9. Instead of Cas9, CasX or CasY may be involved. Zinc finger nuclease (ZFN), TALEN, and Cpf1 are other gene editing techniques, all of which can be utilized. In other embodiments, iNKT cells contain one or more different siRNA or miRNA molecules to reduce the expression of HLA-I / II molecules, B2M and / or CIITA.
[0026] In some embodiments, the T cells contain a recombinant vector or nucleic acid from a recombinant vector that has been introduced into the cells. In certain embodiments, the recombinant vector is or was a viral vector. In further embodiments, the viral vector is or was a lentivirus, retrovirus, adeno-associated virus (AAV), herpesvirus, or adenovirus. It will be understood that the nucleic acid of certain viral vectors is integrated into the host genome sequence.
[0027] In some embodiments, the cells have not been exposed to a medium containing animal serum. In further embodiments, the cells are or have been frozen. In some embodiments, the cells are pre-frozen, where the cells are stable at room temperature for at least 1 hour. In some embodiments, the cells are pre-frozen, where the cells are stable at room temperature for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 hours (or any derivable range therein).
[0028] In certain embodiments, the cells or population of cells in solution comprise dextrose, one or more electrolytes, albumin, dextran, and / or DMSO. In further embodiments, the cells are in a solution that is sterile, non-purulent, and isotonic.
[0029] In certain embodiments, the T cells have been or are activated. In certain embodiments, the T cells are iNKT cells, where the iNKT cells have been activated with alpha-galactosylceramide (α-GC).
[0030] In embodiments involving a plurality of cells, the cell population comprises about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 In some embodiments, the cell population may comprise at least about 10 or more (or any range derivable therein), at least said number of cells, or at most said number of cells, which are engineered iNKT cells. 6 ~10 12In some embodiments, a population of cells having these numbers is believed to be produced from a single batch of cells and not the result of pooling separately produced batches of cells.
[0031] Certain embodiments include a population of T cells, such as iNKT cells, comprising clonal cells comprising one or more exogenous nucleic acids encoding a T cell receptor (TCR) and a thymidine kinase suicide gene product, wherein the clonal cells have been engineered not to express functional beta-2-microglobulin (B2M), and / or class II, major histocompatibility complex, or transactivator (CIITA), comprising a total of at least about 10 6 ~10 12 cells, at least about 10 2 ~10 6 The T cell population includes engineered cells. In certain instances, the cells are frozen in solution.
[0032] Many embodiments relate to methods of preparing T cells or populations of cells, particularly populations in which some or all of the cells are clonal, hi certain embodiments, the cell population comprises at least or at most 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% (or any range derivable therein) of the cells that are clonal, i.e., that percentage of cells that are derived from the same original cell as another cell in the population. In other embodiments, the population of cells comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 7, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, The present invention also includes a cell population comprised of cells derived from at least, or at most, 5, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 (or any range derivable therein) different parental cells.
[0033] Methods are provided for preparing, making, manufacturing, and / or using engineered T cells and cell populations. The methods, in embodiments, include one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more of the following steps: obtaining hematopoietic cells; obtaining hematopoietic progenitor cells; obtaining progenitor cells capable of becoming one or more hematopoietic cells; obtaining progenitor cells capable of becoming T cells, such as iNKT cells; selecting cells from a population of mixed cells using one or more cell surface markers; selecting cells from the population of cells using CD34 + Cell selection step: CD34 cells from a population of cells + Isolating CD34 cells +and CD34 - separating cells from each other; selecting cells based on cell surface markers other than or in addition to CD34; introducing one or more nucleic acids encoding a T cell receptor (TCR) into cells; infecting cells with a viral vector encoding a T cell receptor (TCR); transfecting cells with one or more nucleic acids encoding a T cell receptor (TCR); transfecting cells with an expression construct encoding a T cell receptor (TCR); integrating exogenous nucleic acids encoding a T cell receptor (TCR) into the genome of the cells; introducing one or more nucleic acids encoding a suicide gene product into cells; infecting cells with a viral vector encoding a suicide gene product; transfecting cells with one or more nucleic acids encoding a suicide gene product; transfecting cells with an expression construct encoding a suicide gene product; integrating exogenous nucleic acids encoding a suicide gene product into the genome of the cells. introducing into a cell one or more nucleic acids encoding one or more polypeptides and / or nucleic acid molecules for gene editing; infecting a cell with a viral vector encoding one or more polypeptides and / or nucleic acid molecules for gene editing; transfecting a cell with one or more nucleic acids encoding one or more polypeptides and / or nucleic acid molecules for gene editing; transfecting a cell with an expression construct encoding one or more polypeptides and / or nucleic acid molecules for gene editing; incorporating exogenous nucleic acids encoding one or more polypeptides and / or nucleic acid molecules for gene editing; editing the genome of a cell; editing the promoter region of a cell; editing the promoter and / or enhancer region for a TCR gene; abolishing expression of one or more genes; isolated human CD34 +abolishing expression of one or more HLA-I / II genes in cells; transfecting cells with one or more nucleic acids for gene editing; culturing the isolated or selected cells; expanding the isolated or selected cells; culturing the selected cells for one or more cell surface markers; or culturing the isolated CD34 expressing TCR. + Culturing cells; isolated CD34 + The steps include: expanding cells; culturing cells under conditions that produce or expand iNKT cells; culturing cells in a feeder-free system; culturing cells in an artificial thymic organoid (ATO) system to produce T cells; culturing cells in serum-free medium; culturing cells in an ATO system, wherein the ATO system comprises 3D cell aggregates containing a selected population of stromal cells that express Notch ligands and serum-free medium. It is particularly contemplated that one or more steps may not be included in certain embodiments.
[0034] Some embodiments include a method for preparing a population of clonal or engineered BCMA-CAR iNKT cells, comprising: a) isolating CD34 iNKT cells from human peripheral blood cells (PBMCs); + a) selecting the cells; b) introducing one or more nucleic acids encoding a human T cell receptor (TCR); c) isolating the isolated human CD34 + ablation of surface expression of one or more HLA-I / II genes in the cells; and d) an isolated CD34 expressing an iNKT TCR. + and e) introducing a nucleic acid encoding a BCMA-CAR into the iNKT cells, wherein the ATO system comprises 3D cell aggregates comprising a selected population of stromal cells that express a Notch ligand and serum-free medium.
[0035] In some embodiments, the method further comprises contacting the cells with IL-15 in an amount sufficient to expand the cell population. In some embodiments, the stem or progenitor cells or CD34 cells used to generate iNKT cells are + Cells: 5 x 10 8 In some embodiments, the stem or progenitor cells or CD34 cells used to generate iNKT cells are + Cells: 1 x 10 6 , 2 × 10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 , 7×10 6 , 8×10 6 , 9×10 6 , 1×10 7 , 2 × 10 7 , 3×10 7 , 4×10 7 , 5×10 7 , 6×10 7 , 7×10 7 , 8×10 7 , 9×10 7 , 1×10 8 , 2 × 10 8 , 3×10 8 , 4×10 8 , 5×10 8 , 6×10 8 , 7×10 8 , 8×10 8 , 9×10 8 , 1×10 9 , 2 × 10 9 , 3×10 9 , 4×10 9 , 5×10 9 , 6×10 9 , 7×10 9 , 8×10 9 , 9×10 9 , 1×10 10 , 2 × 10 10 , 3×10 10 , 4×10 10 , 5×10 10 , 6×10 10 , 7×10 10 , 8×10 10 , 9×1010 , 1×10 11 , 2 × 10 11 , 3×10 11 , 4×10 11 , 5×10 11 , 6×10 11 , 7×10 11 , 8×10 11 , 9×10 11 , 1×10 12 , 2 × 10 12 , 3×10 12 , 4×10 12 , 5×10 12 , 6×10 12 , 7×10 1212 , 8×10 12 , 9×10 12 , 1×10 13 , 2 × 10 13 , 3×10 13 , 4×10 13 , 5×10 13 , 6×10 13 , 7×10 13 , 8×10 13 , 9×10 13 , 1×10 14 , 2 × 10 14 , 3×10 14 , 4×10 14 , 5×10 14 , 6×10 14 , 7×10 14 , 8×10 14 , 9×10 14 , 1×10 15 , 2 × 10 15 , 3×10 15 , 4×10 15 , 5×10 15 , 6×10 15 , 7×10 15 , 8×10 15 , 9×10 15 , 1×10 16 , 2 × 10 16 , 3×10 16 , 4×10 16 , 5×10 16 , 6×10 16 , 7×10 16 , 8×10 16 , or 9 x 10 16It includes less than 100 cells or any derivable range therein.
[0036] In some embodiments of the present disclosure, at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, or 600 (or any derivable range therein) doses are produced by the methods of the present disclosure. 7 ~1×10 9 In some embodiments, each dose contains at least, at most, or exactly 1 x 10 engineered iNKT cells. 4 , 2 × 10 4 , 3×10 4 , 4×10 4 , 5×10 4 , 6×10 4 , 7×10 4 , 8×10 4 , 9×10 4 , 1×10 5 , 2 × 10 5 , 3×10 5 , 4×10 5 , 5×10 5 , 6×10 5 , 7×10 5 , 8×10 5 , 9×10 5 , 1×10 6 , 2 × 10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 , 7×10 6 , 8×10 6 , 9×10 6 , 1×10 7 , 2 × 10 7 , 3×10 7 , 4×10 7 , 5×10 7 , 6×10 7 , 7×10 7 , 8×10 7 , 9×10 7 , 1×10 8、2×10 8 、3×10 8 、4×10 8 、5×10 8 、6×10 8 、7×10 8 、8×10 8 、9×10 8 、1×10 9 、2×10 9 、3×10 9 、4×10 9 、5×10 9 、6×10 9 、7×10 9 、8×10 9 、9×10 9 、1×10 10 、2×10 10 、3×10 10 、4×10 10 、5×10 10 、6×10 10 、7×10 10 、8×10 10 、9×10 10 、1×10 11 、2×10 11 、3×10 11 、4×10 11 、5×10 11 、6×10 11 、7×10 11 、8×10 11 、9×10 11 、1×10 12 、2×10 12 、3×10 12 、4×10 12 、5×10 12 、6×10 12 、7×10 1212 、8×10 12 、9×10 12 、1×10 13 、2×10 13 、3×10 13 、4×10 13 、5×10 13 、6×10 13 、7×10 13 、8×10 13 、9×10 13 、1×10 14 、2×10 14 、3×1014 , 4×10 14 , 5×10 14 , 6×10 14 , 7×10 14 , 8×10 14 , 9×10 14 , 1×10 15 , 2 × 10 15 , 3×10 15 , 4×10 15 , 5×10 15 , 6×10 15 , 7×10 15 , 8×10 15 , 9×10 15 , 1×10 16 , 2 × 10 16 , 3×10 16 , 4×10 16 , 5×10 16 , 6×10 16 , 7×10 16 , 8×10 16 , or 9×10 16 In some embodiments, the cells that can be used to generate engineered iNKT cells are hematopoietic progenitor stem cells. The cells can be from peripheral blood mononuclear cells (PBMCs), bone marrow cells, fetal liver cells, embryonic stem cells, umbilical cord blood cells, induced pluripotent stem cells (iPS cells), or a combination thereof. In some embodiments, the iNKT cells are derived from hematopoietic stem cells. In some embodiments, the cells are derived from G-CSF-mobilized CD34 + In some embodiments, the cells are derived from cells from a human patient who does not have cancer. In some embodiments, the cells do not express an endogenous TCR.
[0037] In some embodiments, the method comprises administering to a subject a subject, comprising administering to a subject a method comprising administering to a subject a subject a CD34 - Isolating cells, or CD34 - Cells and CD34 + In some embodiments, the method further comprises isolating CD34 cells. + Although it involves further steps to manipulate the cells, CD34 - The cells can then be used to generate iNKT cells. Thus, in some embodiments, the CD34 -Cells may be used to serve this purpose.
[0038] Certain embodiments include a selected CD34 + The step of culturing the cells in a medium precedes the step of introducing one or more nucleic acids into the cells. The step of culturing the cells includes culturing selected CD34 + The method may include incubating the cells with a medium containing one or more growth factors. In some embodiments, the one or more growth factors include c-kit ligand, flt-3 ligand, and / or human thrombopoietin (TPO). In further embodiments, the medium includes c-kit ligand, flt-3 ligand, and TPO. In some embodiments, the concentration of the one or more growth factors is between about 5 ng / ml and about 500 ng / ml for each growth factor or for the sum of any and all of these specific growth factors. The concentration of a component or combination of components in the medium can be about, at least about, or at most about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 410, 420, 425, 430, 440, 441, 450, 460, 470, 475, 480, 490, 500 (or any derivable range) ng / ml or μg / ml.
[0039] In some embodiments, the nucleic acid may comprise a nucleic acid sequence encoding an α-TCR and / or a β-TCR, as discussed herein. In certain embodiments, one nucleic acid encodes both an α-TCR and a β-TCR. In additional embodiments, the nucleic acid further comprises a nucleic acid sequence encoding a suicide gene product. In some embodiments, the selected CD34 + The nucleic acids introduced into the cells encode an α-TCR, a β-TCR, and a suicide gene product. In another embodiment, the method involves introducing a nucleic acid encoding a suicide gene product into a selected CD34 + It also involves introducing into the cell, where a nucleic acid molecule distinct from the nucleic acid encoding at least one of the TCR genes encodes the suicide gene product.
[0040] As previously mentioned, in some embodiments, iNKT cells do not express HLA-I and / or HLA-II on their cell surface, which can be achieved by disrupting the expression of genes encoding beta-2-microglobulin (B2M), transactivator (CIITA), or HLA-I and HLA-II molecules. In certain embodiments, the method involves the expression of isolated human CD34 + The method involves eliminating the surface expression of one or more HLA-I / II molecules in a cell. In certain embodiments, eliminating the expression can be accomplished by gene editing of the genomic DNA of the cell. Some methods include introducing CRISPR and one or more guide RNAs (gRNAs) corresponding to B2M or CIITA into a cell. In certain embodiments, CRISPR or one or more gRNAs are transfected into a cell by electroporation or lipid-mediated transfection. Consequently, the method can involve introducing CRISPR and one or more gRNAs into a cell by transfecting a nucleic acid encoding the CRISPR and one or more gRNAs into the cell. In some embodiments, different gene editing techniques can be utilized.
[0041] Similarly, in some embodiments, one or more nucleic acids encoding a TCR receptor are introduced into a cell. This is accomplished by transfecting or infecting the cell with a recombinant vector, which may or may not be a viral vector as discussed herein. In some embodiments, the exogenous nucleic acid may be integrated into the genome of the cell.
[0042] In some embodiments, the cells are cultured in serum-free medium. In certain embodiments, the serum-free medium further comprises exogenously added ascorbic acid. In certain embodiments, the method involves adding ascorbic acid to the medium. In further embodiments, the serum-free medium further comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or all sixteen (or a derivable range thereof) of the following exogenously added components: FLT3 ligand (FLT3L), interleukin-7 (IL-7), stem cell factor (SCF), thrombopoietin (TPO), stem cell factor (SCF), IL-2, IL-4, IL-6, IL-15, IL-21, TNF-alpha, TGF-beta, interferon-gamma, interferon-lambda, TSLP, thymopentin, pleiotrophin, or midkine. In additional embodiments, the serum-free medium comprises one or more vitamins. In some cases, the serum-free medium comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the following vitamins (or a derivable range therefrom): biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid, nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B12, or a salt thereof. In certain embodiments, the medium comprises, or at least comprises, biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, or a combination or salt thereof. In additional embodiments, the serum-free medium comprises one or more proteins. In some embodiments, the serum-free medium comprises one, two, four, five, six or more of the following proteins (or any derivable range therein): albumin or bovine serum albumin (BSA), a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or a combination thereof.In other embodiments, the serum-free medium comprises one, two, three, four, five, seven, eight, nine, ten, or eleven of the following compounds: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, or a combination thereof. In further embodiments, the serum-free medium comprises B-27® supplement, XenoFree B-27® supplement, GS21™ supplement, or a combination thereof. In additional embodiments, the serum-free medium comprises or further comprises amino acids, monosaccharides, and / or inorganic ions. In some embodiments, the serum-free medium comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen of the following amino acids: arginine, cysteine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or a combination thereof. In other embodiments, the serum-free medium comprises one, two, three, four, five, or six of the following inorganic ions: sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or a combination or salt thereof. In additional embodiments, the serum-free medium comprises one, two, three, four, five, six, or seven of the following elements: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or a combination thereof.
[0043] In some methods, cells are cultured in an artificial thymic organoid (ATO) system. The ATO system involves three-dimensional (3D) cell aggregates, which are aggregates of cells. In certain embodiments, the 3D cell aggregates comprise a selected population of stromal cells that express Notch ligands. In some embodiments, the 3D cell aggregates are grown on a physical matrix or scaffold, and are then transfected with CD34. + In a further embodiment, the method comprises mixing the transduced cells with a selected population of stromal cells. +The method includes centrifuging the transduced cells and stromal cells to form a cell pellet that is placed on a physical matrix or scaffold. In certain embodiments, the stromal cells express a Notch ligand that is intact, partially, or modified DLL1, DLL4, JAG1, JAG2, or a combination thereof. In further embodiments, the Notch ligand is a human Notch ligand. In other embodiments, the Notch ligand is human DLL1. In some methods, the cells are not cultured in an ATO system. In some embodiments, the cells are cultured in a feeder-free system.
[0044] In a further aspect, stromal cells and CD34 + In certain embodiments, the ratio of stromal cells to CD34 cells is about, at least about, or at most about 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50 (or any range derivable therein). + The ratio of CD34 to CD44 is about 1:5 to 1:20. In certain embodiments, the stromal cells are a mouse stromal cell line, a human stromal cell line, a selected population of primary stromal cells, a selected population of stromal cells differentiated in vitro from pluripotent stem cells, or a combination thereof. In certain embodiments, the stromal cells are a selected population of stromal cells differentiated in vitro from hematopoietic stem or progenitor cells. + Co-culturing of the cells with stromal cells can occur for about, at least about, or at most about 1, 2, 3, 4, 5, 6, 7 days and / or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more weeks (or any range derivable therein). The stromal cells, in some embodiments, are irradiated prior to co-culturing.
[0045] In some embodiments, the feeder cells used in the methods are CD34- These CD34 - The cells were CD34 + The cells may be from the same population of cells as the selected population of cells. In additional embodiments, the cells may be activated. In certain embodiments, the method includes activating iNKT cells. In certain embodiments, the iNKT cells were activated and expanded with alpha-galactosylceramide (α-GC). The cells can be incubated or cultured with α-GC to activate and expand the cells. In some embodiments, the feeder cells were pulsed with α-GC.
[0046] In some methods, iNKT cells are selected that lack surface expression of one or more HLA-I or -II molecules. In some embodiments, selecting iNKT cells that lack surface expression of HLA-I and / or HLA-II molecules protects these cells from depletion by recipient immune cells.
[0047] The cells can be used immediately, or the cells can be stored for future use.In certain embodiments, the cells used to generate iNKT cells are frozen, and in some embodiments, the generated iNKT cells can be frozen.In some aspects, the cells are in a solution comprising dextrose, one or more electrolytes, albumin, dextran, and DMSO.In other embodiments, the cells are in a sterile, non-pyrogenic, and isotonic solution.
[0048] The number of cells produced by a production cycle is about, at least about, or at most about 10 cells. 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 1015 or more (or any range derivable therein), and these cells are, in some embodiments, engineered iNKT cells. In some cases, the cell population comprises at least about 10 6 ~10 12 In some embodiments, a population of cells having these numbers is produced from a single batch of cells and is not the result of pooling separately produced batches of cells, i.e., from a single production cycle.
[0049] In some embodiments, the cell populations are frozen and then thawed. These cell populations can be used to generate or comprise engineered iNKT cells.
[0050] The engineered iNKT cells can be used to treat patients. In some embodiments, the method includes introducing one or more additional nucleic acids into a cell population, which may or may not have been previously frozen and thawed. This use provides one of the advantages of producing off-the-shelf iNKT cells. In certain embodiments, the one or more additional nucleic acids encode one or more therapeutic gene products. Examples of therapeutic gene products include at least the following: 1. antigen recognition molecules, such as CARs (chimeric antigen receptors) and / or TCRs (T cell receptors); 2. costimulatory molecules, such as CD28, 4-1BB, 4-1BBL, CD40, CD40L, and ICOS; and / or 3. cytokines, such as IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-12, IL-17, IL-21, IL-23, IFN-γ, TNF-α, TGF-β, G-CSF, and GM-CSF; and 4. transcription factors, such as T-bet, GATA-3, RORγt, FOXP3, and Bcl-6. Therapeutic antibodies are also included, including chimeric antigen receptors, single-chain antibodies, monobodies, humanized antibodies, bispecific antibodies, single-chain FV antibodies, or combinations thereof.
[0051] Some embodiments include a method for preparing a cell population comprising engineered invariant natural killer (iNKT) T cells, the method comprising: a) isolating CD34 T cells from human peripheral blood cells (PBMCs); + b) selecting cells; and c) selecting CD34 cells in a medium containing growth factors including c-kit ligand, flt-3 ligand, and human thrombopoietin (TPO). + c) culturing the cells; and + d) transducing the cells with a lentiviral vector containing nucleic acid sequences encoding an α-TCR, a β-TCR, a thymidine kinase, and a suicide gene such as sr39TK; and e) transducing the selected CD34 + a) introducing Cas9 and gRNA for beta-2 microglobulin (B2M) and / or CTIIA into cells to disrupt expression of B2M and / or CTIIA; b) culturing the transduced cells in a 3D aggregate cell culture with an irradiated stromal cell line expressing an exogenous Notch ligand for 2-12 (e.g., 2-10 or 6-12) weeks to expand iNKT cells; c) selecting iNKT cells lacking surface expression of HLA-I and / or HLA-II molecules; and d) culturing the selected iNKT cells with irradiated feeder cells loaded with α-GC.
[0052] Some embodiments include: a) isolating CD34 from human peripheral blood cells (PBMCs); + b) selecting cells; and c) selecting CD34 cells in a medium containing growth factors including c-kit ligand, flt-3 ligand, and human thrombopoietin (TPO). + c) culturing the cells; and + d) transducing the cells with a lentiviral vector containing nucleic acid sequences encoding an α-TCR, a β-TCR, a thymidine kinase, and a reporter gene product; and e) transducing the cells with a lentiviral vector containing nucleic acid sequences encoding an α-TCR, a β-TCR, a thymidine kinase, and a reporter gene product. +e) introducing Cas9 and gRNA for beta-2 microglobulin (B2M) or CTIIA into cells to eliminate expression of B2M and / or CTIIA; f) culturing the transduced cells in 3D aggregate cell culture with an irradiated stromal cell line expressing an exogenous Notch ligand for 2-10 weeks to expand the iNKT cells; f) selecting iNKT cells lacking expression of B2M and / or CTIIA; and g) culturing the selected iNKT cells with irradiated feeder cells.
[0053] The disclosed methods involve the collection of at least 1×10 cells that may express a marker or have high or low levels of a particular marker, as described herein. 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 , 1×10 18 , 1×10 19 , 1×10 20 , or 1 × 10 21A population of cells can be produced that contains cells (or any derivable range therein). The cell population number can be the number obtained without cell sorting based on marker expression, without cell sorting based on NK marker expression, or without cell sorting based on T cell marker expression. Furthermore, the resulting population of cells may be at least 1 x 10 cells generated within a certain period of time, e.g., a period of time that is as short as, or as long as, or exactly 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 days or 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 weeks (or any derivable range therein). 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 , 1×10 18 , 1×10 19 , 1×10 20 , or 1 × 10 21 The population may comprise 100,000 or more cells (or any derivable range therein). A high or low expression level of a marker, such as an NK activator, inhibitor, or cytotoxic molecule, may be associated with high expression as determined by FACS analysis. In some embodiments, a high level is relative to non-NK cells or non-iNKT cells, or cells that are not T cells. In some embodiments, a high or low level is determined from FACS analysis.
[0054] Methods of treating a patient with iNKT cells or cell populations are also provided. In certain embodiments, the patient has cancer. In some embodiments, the patient has a disease or condition involving inflammation or autoimmunity associated with cancer or cancer treatment. In some embodiments, the patient has a disease or condition involving inflammation or autoimmunity unrelated to cancer or cancer treatment. In certain aspects, the cells or cell populations are allogeneic to the patient. In additional embodiments, the patient does not show signs of rejection or depletion of the cells or cell population. Some treatment methods further include administering to the patient a stimulatory molecule that activates iNKT cells (e.g., α-GC, alone or loaded on APCs), or a compound that triggers a suicide gene product.
[0055] In some embodiments, the cancer to be treated is multiple myeloma. In some embodiments, the cancer to be treated is leukemia. In some embodiments, the cells are derived from a patient without cancer. In some embodiments, the method further comprises administering an additional agent. In some embodiments, the additional agent comprises an IL-6R antibody or an IL-1R antagonist. In some embodiments, the IL-6R antibody comprises tocilizumab, or the IL-1R antagonist comprises anakinra. In some embodiments, the additional agent comprises a cytokine antagonist for the treatment of cytokine release syndrome. In some embodiments, the additional agent comprises a corticosteroid or an inhibitor of one or more of IL-2R, IL-1R, MCP-1, MIP1B, and TNF-alpha. In some embodiments, the additional agent comprises infliximab, adalimumab, golimumab, certolizumab, or emapalumab.
[0056] In some embodiments, the additional agent comprises an antigen to which an iNKT TCR specifically binds, such as an exogenous iNKT TCR.
[0057] In some embodiments, the antigen comprises α-GC. In some embodiments, the patient has previously received cancer treatment. In some embodiments, the previous treatment was toxic and / or ineffective. In some embodiments, the patient experiences at least one, two, three, four, or five immune-related adverse events in response to the previous cancer treatment. In some embodiments, the previous treatment comprises one or more of a proteasome inhibitor, an immunomodulatory agent, an anti-CD38 antibody, or a CAR-T cell therapy.
[0058] In some embodiments, the cancer is BCMA + In some embodiments, the cancer comprises malignant cells. + In some embodiments, the cancer comprises malignant B cells. + Contains malignant cells.
[0059] Treatment of cancer patients with iNKT cells can result in the killing of tumor cells in the cancer patient after administration of the cells or cell population to the patient. Combination treatment of iNKT cells with standard therapeutic regimens or other immunotherapy regimens can also be utilized. The methods and compositions are intended to include the exclusion of any of the embodiments described herein.
[0060] Throughout this application, the term "about" is used in accordance with its plain and ordinary meaning within the field of cell and molecular biology to indicate that a value includes the standard deviation of error for the device or method being utilized to determine the value.
[0061] The use of the words "a" or "an" when used with the term "comprising" can mean "one," but is also consistent with the meanings of "one or more," "at least one," and "one or more than one."
[0062] As used herein, the terms "or" and "and / or" are used to describe multiple components in combination or to describe multiple components that are mutually exclusive. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y and z)," or "x or y or z." It is specifically contemplated that x, y, or z may be specifically excluded from an embodiment.
[0063] The words "comprising" (and any form of comprising, e.g., "comprise" and "comprises"), "having" (and any form of having, e.g., "have" and "has"), "including" (and any form of including, e.g., "includes" and "include"), "characterized by" (and any form including "characterized as"), or containing (and any form of containing, e.g., "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0064] The compositions and methods for using them can "comprise," "consist essentially of," or "consist of" any of the components or steps disclosed throughout this specification. The phrase "consisting of" excludes any element, step, or component not specified. The phrase "consisting essentially of" limits the scope of the described subject matter to the specified materials or steps and those that do not materially affect its basic and novel characteristics. It is contemplated that embodiments described in the context of the term "comprising" may also be implemented in the context of the term "consisting of" or "consisting essentially of."
[0065] It is specifically contemplated that any limitation discussed with respect to one embodiment of the invention may apply to any other embodiment of the invention. Furthermore, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or utilize any composition of the invention. Aspects of the embodiments shown in the examples are also embodiments that may be implemented in conjunction with embodiments discussed elsewhere in different examples or elsewhere in this application.
[0066] Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating particular embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
[0067] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0068] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief explanation of the drawings]
[0069] [Figure 1] Figure 1 illustrates a schematic diagram of an example of the production and use of off-the-shelf universal hematopoietic stem cell (HSC) engineered iNKT (UHSC-iNKT) cell adoptive therapy.
[0070] [Figure 2] Figures 2A-2D show the generation of iNKT cells engineered with human HSCs in a BLT (human bone marrow-liver-thymus-transplanted NOD / SCID / γc- / - mice) humanized mouse model. (A) Example of experimental design. (B) FACS plot of spleen cells. HSC-iNKTBLT: iNKT cells engineered with human HSCs generated in BLT mice. hTC: human conventional T cells. Figures 2C-2D show the generation of NY-ESO-1-specific conventional T cells engineered with human HSCs in artificial thymic organoids (ATOs) in an in vitro culture system. (C) Example of experimental design. (D) Cell yield (n = 3-6). **P < 0.01 by Student's t-test.
[0071] [Figure 3-1]Figures 3A-3D demonstrate initial CMC studies of human HSC-engineered iNKT cells in healthy individuals and the high-yield, two-step generation of ATO-αGC in an in vitro culture system (HSC-iNKTATO cells were studied as a therapeutic alternative). HSC-iNKTATO: iNKT cells engineered with human HSCs generated in ATO culture. (A) Two-step ATO-αGC in vitro culture system. ATO: artificial thymic organoid; αGC: alpha-galactosylceramide, a potent agonist ligand that specifically stimulates iNKT cells. (B) Generation of HSC-iNKTATO cells in the ATO culture stage. 6B11 is a monoclonal antibody that specifically binds to the iNKT TCR. (C) Expansion of HSC-iNKTATO cells in the PBMC / αGC culture stage. (D) Output of HSC-iNKTATO cells. [Figure 3-2] Same as above.
[0072] [Figure 4] Figures 4A-4B provide initial pharmacological studies of the phenotype and functionality of human HSC-engineered iNKT cells (HSC-iNKTATO and HSC-iNKTBLT cells were studied as therapeutic surrogates). (A) Surface FACS staining. (B) Intracellular FACS staining. PBMC-iNKT: in vitro expanded endogenous iNKT cells derived from PBMCs of a healthy donor; PBMC-Tc: endogenous conventional T cells derived from PBMCs of a healthy donor.
[0073] [Figure 5-1]Figures 5A-5K provide initial efficacy studies of the tumor-killing efficacy of human HSC-engineered iNKT cells (HSC-iNKTATO and HSC-iNKTBLT cells were studied as therapeutic surrogates). (A-F) Hematological cancer models. (A) MM.1S-hCD1d-FG human multiple myeloma (MM) cell line. (B) In vitro tumor killing assay. (C) Analysis of luciferase activity of in vitro tumor killing (n=3). (D) In vivo tumor killing assay using the NSG mouse human MM metastasis model. (E-F) Live animal bioluminescence imaging (BLI) analysis of in vivo tumor killing. Representative BLI images (E) at day 14 and time-course measurements of whole-body luminescence (TBL; F) are shown (n=3-4). (5G-5K) Solid tumor models. (G) A375-hCD1d-FG human melanoma cell line. (H) In vivo tumor killing assay using the NSG mouse human melanoma solid tumor model. (I) Tumor weight (day 25). (J) FACS plot showing infiltration of HSC-iNKTBLT cells into the tumor site (day 25). (K) Quantification of J (n=4). **P<0.01, ***P<0.001 by Student's t-test. [Figure 5-2] Same as above.
[0074] [Figure 6] Figures 6A-6C show initial toxicology / tumorigenicity safety studies (HSC-iNKTBLT cells were studied as a therapeutic agent surrogate). (A) Mouse weight (n = 9-10). ns, not significant by Student's t-test. (B) Mouse survival (n = 9-10). (C) Mouse pathology. Various tissues were collected and analyzed by the UCLA Pathology Core (n = 9-10).
[0075] [Figure 7]Figures 7A-7D provide an initial safety study of the sr39TK gene for PET imaging and safety management (HSC-iNKTBLT cells were studied as a therapeutic surrogate). (A) Experimental design. (B) PET / CT images of BLT-iNKTTK mice before and after GCV treatment (n = 4-5). (C) FACS plots showing effective and specific depletion of HSC-iNKTBLT cells after GCV treatment (n = 4-5). (D) Quantification of the FACS plots in C (n = 4-5). ns, not significant; **P < 0.01 by Student's t-test.
[0076] [Figure 8-1] Figures 8A-8E illustrate an example of a manufacturing process for producing UHSC-iNKT cells. (A) Experimental design. (B) Lenti / iNKT-sr39TK vector-mediated iNKT TCR expression in HSCs. (C) CRISPR-Cas9 / B2M-CIITA-gRNA complex-mediated knockout of HLA-I / II expression in HSCs. (D) 2M2 / Tu39 mAb-mediated MACS negative selection of HLA-I / II cells. (E) 6B11 mAb-mediated MACS positive selection of HSC-iNKTATO cells. [Figure 8-2] Same as above.
[0077] [Figure 9] Figures 9A-9E provide examples of mechanism of action (MOA) studies. (A) Potential mechanism used by iNKT cells to target tumors. (B-C) Study of CD1d / TCR-mediated direct killing of tumor cells. (B) Experimental design. (C) Killing of MM.1S-hCD1d-FG human multiple myeloma cells (n=3). (D-E) Study of CD1d-independent targeting of tumor cells by activated NK cells. (D) Experimental design. (E) Killing of K562 tumor cells (n=2). αGC-loaded irradiated PBMCs were used as antigen-presenting cells (APCs). ns, not significant; *P<0.05; **P<0.01; ****P<0.0001 by one-way ANOVA.
[0078] [Figure 10-1]Figures 10A-10G demonstrate safety considerations. (A) Potential GvHD and HvG responses and engineered safety management strategies. (B) In vitro mixed lymphocyte culture (MLC) assay to study GvHD responses. (C) IFN-γ production in the MLC assay (n=3) showing no GvHD response induced by HSC-iNKTATO cells. PBMCs from three different healthy donors were included as responders. (D) In vitro mixed lymphocyte culture (MLC) assay to study HvG responses. (E) IFN-γ production in the MLC assay (n=3) showing a minor HvG response to HSC-iNKTATO cells. PBMCs from two different healthy donors were used in the experiment. (F) HSC-iNKTBLT cells were resistant to killing by NK cells from mismatched donors in in vitro mixed NK / iNKT cultures. (G) In vivo mixed lymphocyte adoptive transfer (MLT) assay to study GvHD and HvD responses. ns, not significant, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA. [Figure 10-2] Same as above.
[0079] [Figure 11] Figures 11A-11G demonstrate examples of combination therapy. (A) Experimental design for studying UHSC-iNKT cell therapy in combination with checkpoint blockade therapy. (B) UHSCCAR-iNKT cells. (C) A375-hCD1d-hCD19-FG human melanoma cell line. (D) Experimental design for studying the anti-tumor efficacy of UHSCCAR-iNKT cells. (E) UHSCTCR-iNKT cells. (F) A375-hCD1d-A2 / ESO-FG human melanoma cell line. (G) Experimental design for studying the anti-tumor efficacy of UHSCTCR-iNKT cells.
[0080] [Figure 12] FIG. 12 illustrates an example of a pharmacokinetic / pharmacodynamic (PK / PD) study.
[0081] [Figure 13]FIG. 13 shows an example of an iNKT-sr39TK lentiviral vector.
[0082] [Figure 14] FIG. 14 illustrates an example of a cell manufacturing process for the production of UHSC-iNKT cells.
[0083] [Figure 15] Figure 15 shows HSC-engineered off-the-shelf generic BCMA CAR-iNKT (UBCAR-iNKT) cell therapy for MM.
[0084] [Figure 16-1] Pilot CMC study. UBCAR-iNKT cells were investigated as a potential therapeutic agent. (A) Two-stage in vitro culture system. ATO: artificial thymic organoid; αGC: alpha-galactosylceramide, a potent agonist lipid antigen that specifically stimulates iNKT cells; BCMA-CAR: B cell maturation antigen-targeting chimeric antigen receptor. (B) Genetic modification rate of HSCs. (C) Generation of HSC-iNKT cells in ATO culture. 6B11 is a monoclonal antibody that specifically binds to the human iNKT TCR. (D) Expansion of HSC-iNKT cells with αGC. 2M2 is a monoclonal antibody that recognizes B2M; Tu39 is a monoclonal antibody that recognizes HLA-DR, DP, and DQ. (E) MACS purification of HLA-I / II-negative universal HSC-iNKT (UHSC-iNKT) cells. (F) Generation of UBCAR-iNKT cells by BCMA-CAR engineering and IL-15 amplification. BCMA-CAR-engineered peripheral blood conventional T (BCAR-T) cells were generated in parallel as a control. AY13 is a monoclonal antibody that recognizes the tEGFR marker co-expressed with BCMA-CAR. (G) Output of UBCAR-iNKT cells. Note that UBCAR-iNKT production was confirmed using G-CSF-mobilized CD34+ HSCs from two different donors. [Figure 16-2] Same as above.
[0085] [Figure 17]Pilot pharmacology study. UBCAR-iNKT cells were investigated as potential therapeutic agents. FACS plots are presented to demonstrate the phenotype and functionality of UBCAR-iNKT cells compared to those of BCAR-iNKT (HLA-I / II-positive BCMA-CAR-engineered HSC-iNKT) cells and BCAR-T (BCMA-CAR-engineered peripheral blood T) cells.
[0086] [Figure 18] Pilot in vitro efficacy and MOA study. UBCAR-iNKT cells were investigated as potential therapeutics. (A) In vitro direct tumor cell killing assay. (B) MM.1S-hCD1d-FG human multiple myeloma cell line and tumor cell killing mechanism. (C) Co-expression of BCMA and CD1d in the MM.1S-hCD1d-FG cell line, mimicking primary MM tumor cells. BM: bone marrow. (D) Tumor killing efficacy of UBCAR-iNKT cells (n=4). (E) CAR / TCR dual tumor killing mechanism of UBCAR-iNKT cells (n=4). PBMC-T: peripheral blood T cells (no CAR); UHSC-iNKT: iNKT cells (no CAR) engineered with universal HSCs (HLA-I / II-negative).
[0087] [Figure 19] Pilot in vivo efficacy and safety study. BCAR-iNKT cells were investigated as a therapeutic surrogate. (A) Experimental design. (B) Representative BLI images collected on day 40 (n=4). (C) Quantification of BLI images over time (n=4). TBL, whole body luminescence. (D) Survival curve (n=4). (E) Representative immunohistological images showing anti-human CD3 stained tissue sections from experimental mice on day 60 (n=4). Arrows indicate tissue-infiltrating CD3+ human T cells.
[0088] [Figure 20]Pilot immunogenicity study. UBCAR-iNKT cells were investigated as a potential therapeutic agent. (A) Potential GvHD and HvG responses, as well as engineered safety management strategies. (B) In vitro mixed lymphocyte culture (MLC) assay to study GvHD responses. (C) IFN-γ production in the MLC assay (n=4) demonstrating no GvHD response induced by UBCAR-iNKT cells. PBMCs from three different healthy donors were used as stimulators. N, PBMCs without stimulator. (D) In vitro MLC assay to study HvG responses. (E) IFN-γ production in the MLC assay (n=4) demonstrating no HvG response to UBCAR-iNKT cells. PBMCs from three different healthy donors were tested as responders. Data from one representative donor are shown (n=3).
[0089] [Figure 21] Pilot safety study - sr39TK gene for PET imaging and safety management. UBCAR-iNKT cells were investigated as a potential therapeutic agent. (A) In vitro GCV killing assay using UBCAR-iNKT cells. Cell counts are shown on day 4 after GCV treatment (n=5). GCV: ganciclovir, a drug that selectively kills cells expressing the sr39TK suicide gene. (B-D) In vivo PET imaging and GCV killing assay using BLT-iNKTTK mice (depicted in Figure 2A). (B) Experimental design. (C) Representative PET / CT images of BLT-iNKTTK mice before and after GCV treatment (n=4-5). (D) Quantification of FACS data showing effective and specific depletion of HSC-iNKT cells in BLT-iNKTTK mice after GCV treatment (n=4-5).
[0090] [Figure 22]Proposed CMC study. (A) Overview of CMC design. (B) Projection of the three development stages to translate a UBCAR-iNKT cell product to the clinic. The proposed TRAN1-11597 project is in the enclosed pre-IND stage. (C) Flow diagram showing the proposed pre-IND manufacturing process and in-process controls (IPCs), as well as product release assays.
[0091] [Figure 23] In vitro generation of allogeneic HSC-engineered iNKT (AlloHSC-iNKT) cells. (A) Experimental design for generating AlloHSC-iNKT cells in vitro. HSC, hematopoietic stem cells; CB, umbilical cord blood; PBSC, peripheral blood stem cells; αGC, α-galactosylceramide; lenti / iNKT-sr39TK, lentiviral vector encoding the iNKT TCR gene and the sr39TK suicide / PET imaging gene. (B-E) FACS monitoring of AlloHSC-iNKT cell generation. (B) Intracellular expression of iNKT TCR (identified as Vβ11+) in CD34+ HSC cells 72 hours after lentivector transduction. (C) Generation of iNKT cells (identified as iNKT TCR+TCRαβ+ cells) during stage 1 ATO differentiation culture. iNKT TCR was stained using the 6B11 monoclonal antibody. (D) Expansion of iNKT cells during stage 2 αGC expansion culture. (E) CD4 / CD8 coreceptor expression on AlloHSC-iNKT cells during stage 1 and stage 2 culture. DN, CD4 / CD8 double negative; CD4 SP, CD4 single positive; DP, CD4 / CD8 double positive; CD8 SP, CD8 single positive. (F) Single-cell TCR sequencing analysis of AlloHSC-iNKT cells. Peripheral blood mononuclear cells (PBMCs) derived conventional αβT (PBMC-Tc) and iNKT (PBMC-iNKT) cells from healthy donors were included as controls. The relative abundance of each unique T cell receptor sequence among the total unique sequences identified for each individual cell is represented as a sector of a pie chart. (G) Table summarizing experiments in which AlloHSC-iNKT cells were successfully generated. Representative of one (F) and more than 10 experiments (A–E).
[0092] [Figure 24] Characterization and gene profiling of AlloHSC-iNKT cells. (A-B) FACS characterization of AlloHSC-iNKT cells. (A) Surface marker expression. (B) Production of intracellular cytokines and cytotoxic molecules. PBMC-iNKT cells and PBMC-Tc cells were included as controls. (C-D) Antigen response of AlloHSC-iNKT cells. AlloHSC-iNKT cells were cultured for 7 days in the presence or absence of αGC (represented as αGC or vehicle, respectively). (C) Cell growth curve (n=3). (D) ELISA analysis of cytokine production (IFN-γ, TNF-α, IL-2, IL-4, and IL-17) 3 days after αGC stimulation (n=3). (E-I) Deep RNAseq analysis of AlloHSC-iNKT cells generated from CB- or PBSC-derived CD34+ HSCs (n=3 for each). Conventional CD8+ αβ T cells (PBMC-αβTc; n = 8), CD8+ iNKT cells (PBMC-iNKT; n = 3), γδ T cells (PBMC-γδT; n = 6), and NK cells (PBMC-NK; n = 2) derived from PBMCs of healthy donors were included as controls. (E) Principal component analysis (PCA) plot showing the ordination of all six cell types. (F-I) Heatmaps showing the expression of transcription factors (F), HLA molecules (G), immune checkpoint molecules (H), and NK activating and inhibitory receptors (I), as well as selected genes for all six cell types. Representative of one (E-I) and three (A-D) experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by Student's t-test.
[0093] [Figure 25]Tumor targeting of AlloHSC-iNKT cells via the NK pathway. (A-B) FACS analysis of surface NK marker expression and intracellular cytokine molecule production by AlloHSC-iNKT cells. PBMC-NK cells were included as a control. (B) Quantification of killer cell immunoglobulin-like receptor (KIR) expression in AlloHSC-iNKT cells compared with PBMC-NK cells and PBMC-iNKT cells (n = 7-9). (C-E) In vitro direct killing of human tumor cells by AlloHSC-iNKT cells. PBMC-NK cells were included as a control. Both fresh and frozen-thawed cells were studied. Five human tumor cell lines were studied: A375 (melanoma), K562 (myeloid leukemia), H292 (lung cancer), PC3 (prostate cancer), and MM.1S (multiple myeloma). All tumor cell lines were engineered to express a dual reporter of firefly luciferase and green fluorescent protein (FG). (C) Experimental design. (D) Tumor killing data of A375-FG human melanoma cells at 24 hours (n=4). (E) Tumor killing data of K562-FG human myeloid leukemia cells at 24 hours (n=4). (F-H) Tumor killing mechanism of AlloHSC-iNKT cells. NKG2D- and DNAM-1-mediated pathways were investigated. (F) Experimental design. (G) Tumor killing data of A375-FG human melanoma cells at 24 hours (tumor:iNKT ratio 1:2) (n=4). (H) Tumor killing data of K562-FG human myeloid leukemia cells at 24 hours (tumor:iNKT ratio 1:1) (n=4). (I-K) In vivo antitumor efficacy of AlloHSC-iNKT cells in an A375-FG human melanoma xenograft NSG mouse model. (I) Experimental design. BLI: bioluminescence imaging of live animals. (J) BLI images showing tumor burden in experimental mice over time. (K) Tumor size measurements over time (n=4-5). Representative of three experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA. See also Figure 30.
[0094] [Figure 26]Tumor targeting of CAR-engineered AlloHSC-iNKT cells. (A) Experimental design for generating BCMA CAR-engineered AlloHSC-iNKT (AlloBCAR-iNKT) cells in vitro. BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; BCAR, BCMA CAR; retro / BCAR-EGFR, retroviral vector encoding the BCMA CAR gene and epidermal growth factor receptor (EGFR) gene. (B) FACS detection of BCAR expression (identified as EGFR+) in AlloBCAR-iNKT 72 hours after retroviral transduction. PBMC T cells from a healthy donor transduced with the same retro / BCAR-EGFR vector were included as a staining control (represented as BCAR-T cells). (C-H) In vitro killing of human multiple myeloma cells by AlloBCAR-iNKT cells. MM.1S-CD1d-FG, a human MM.1S cell line engineered to overexpress human CD1d and a dual reporter of firefly luciferase and green fluorescence. PBMC-Tc cells, BCAR-T cells, and AlloHSC-iNKT cells were included as effector cell controls. (C) Experimental design. (D) FACS analysis of BCMA and CD1d expression in MM.1S-CD1d-FG cells. Primary bone marrow (BM) samples from MM patients were included as controls. (E) Diagram showing the triple tumor killing mechanism of AlloBCAR-iNKT cells mediated by NK-activating receptors, iNKT TCRs, and BCARs. (F) Tumor killing at 8 hours (effector:tumor ratio 5:1) (n=4). (G) ELISA analysis of IFN-γ production at 24 hours (n=3). (H) Tumor killing at a titrated effector:tumor (E:T) ratio at 24 hours (n=4). (I-L) In vivo antitumor efficacy of AlloBCAR-iNKT cells in the MM.1S-CD1d-FG human multiple myeloma xenograft NSG mouse model. Tumor-bearing mice injected with BCAR-T cells or no cells (vehicle) were included as controls. (I) Experimental design. (J) BLI images showing tumor burden in experimental mice over time. (K) Quantification of (J) (n=4). (L) Kaplan-Meier survival curves of experimental mice over a 4-month period after tumor challenge (n=4). Representative of two (I-L) and three (A-H) experiments.Data are expressed as mean ± SEM. ns, not significant; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by Student's t-test (H), or by one-way ANOVA (F, G, K), or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (J). See also Figure 31.
[0095] [Figure 27] Safety study of AlloHSC-iNKT cells. (A-B) Study of the graft-versus-host (GvH) response of AlloBCAR-iNKT cells using an in vitro mixed lymphocyte culture (MCL) assay. BCAR-T cells were included as responder cell controls. (A) Experimental design. PBMCs from four different healthy donors were used as stimulator cells. (B) ELISA analysis of IFN-γ production on day 4 (n=4). N, no stimulator cells. (C-E) Immunohistological analysis of tissue sections from experimental mice described in Figures 26I-26L. (C) Hematoxylin and eosin staining. Blank indicates tissue section collected from tumor-free NSG mice. Arrows indicate mononuclear cell infiltration. Bar: 200 μm. (D) Anti-human CD3 staining. CD3 staining is shown in brown. Bar: 100 μm. (E) Quantification of (D) (n=4). (F-H) In vivo regulated depletion of AlloHSC-iNKT cells via GCV treatment. GCV, ganciclovir. (F) Experimental design. (G) FACS detection of AlloHSC-iNKT cells in the liver, spleen, and lungs of NSG mice on day 5. (H) Quantification of (G) (n=4). Representative of two experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA (B) or Student's t-test (E, H). See also Figure 32.
[0096] [Figure 28]Immunogenicity of AlloHSC-iNKT cells. (A-E) Study of allogeneic NK cell responses to AlloHSC-iNKT cells using an in vitro MLC assay. AlloHSC-iNKT cells were cocultured with donor-mismatched PBMC-NK cells. PBMC-iNKT cells and PBMC-Tc cells were included as controls. (A) Experimental design. (B) FACS monitoring of live cell composition over time. (C) Quantification of (B) (n=3). (D) FACS detection of ULBP expression. (E) Quantification of (D) (n=5-6). (F-I) Study of allogeneic T cell responses to AlloHSC-iNKT cells using an in vitro MLC assay. Irradiated AlloHSC-iNKT cells (as stimulators) were cocultured with donor-mismatched PBMC cells (as responders). Irradiated PBMC-iNKT cells and PBMC-Tc cells were included as stimulator controls. (F) Experimental design. PBMCs from three different healthy donors were used as responders. (G) ELISA analysis of IFN-γ production on day 4 (n=3). (H) FACS detection of HLA-I and II expression. (I) Quantification of HLA-II+ cells from (H) (n=5-6). Representative of three experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA.
[0097] [Figure 29]Generation and characterization of HLA-I / II-negative universal iNKT (UHSC-iNKT) cells. (A) Experimental design for generating UHSC-iNKT cells and BCMA CAR-engineered UHSC-iNKT (UBCAR-iNKT) cells. gRNA, guide RNA; CRISPR, clustered regularly interspaced short palindromic repeats; Cas9, CRISPR-associated protein 9; B2M, beta-2-microglobulin; CIITA, class II major histocompatibility complex transactivator. (B-E) FACS monitoring of UHSC-iNKT cell and UBCAR-iNKT cell generation. (B) Intracellular expression of iNKT TCR (identified as Vβ11+) and surface depletion of HLA-I / II (identified as BM2-HLA-DR-) in CD34+ HSC cells at day 5 (72 hours after lentivector transduction and 48 hours after CRISPR / Cas9 gene editing). (C) Generation of iNKT cells (identified as iNKT TCR+TCRαβ+ cells) during stage 1 ATO differentiation culture. (D) Purification of HLA-I / II-negative UHSC-iNKT cells using a two-step MACS sorting strategy. (E) BCAR expression in UBCAR-iNKT cells (identified as EGFR+). PBMC T cells from a healthy donor transduced with the same retro / BCAR-EGFR vector were included as staining controls (represented as BCAR-T cells). (F-G) Study of allogeneic T cell responses to UBCAR-iNKT cells using an in vitro MLC assay. Irradiated UBCAR-iNKT cells (as stimulators) were cocultured with donor-mismatched PBMC cells (as responders). Irradiated AlloBCAR-iNKT cells and conventional BCAR-T cells were included as stimulator controls. (F) Experimental design. PBMCs from three different healthy donors were used as responders. (G) ELISA analysis of IFN-γ production on day 4 (n=3). (H-I) Study of allogeneic NK cell responses to UHSC-iNKT cells using an in vitro MLC assay. UHSC-iNKT cells were co-cultured with donor-mismatched PBMC-NK cells. PBMC-Tc cells were included as a control. (H) Experimental design. (I) FACS quantification of live UHSC-iNKT cells and PBMC-Tc cells (n=3).(J-M) In vivo antitumor efficacy of UBCAR-iNKT cells in the MM.1S-CD1d-FG human multiple myeloma xenograft NSG mouse model. (J) Experimental design. (K) BLI images showing tumor burden in experimental mice over time. (L) Quantification of (K) (n=5). (M) Kaplan-Meier survival curves of experimental mice over a 4-month period after tumor challenge (n=5). Representative of one (J-M) and three (B-I) experiments. Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA (G, I, L) or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (M). See also Figure 28 and Figure 33.
[0098] [Figure 30]Tumor targeting of AlloHSC-iNKT cells via the NK pathway; see Figure 25. A) Schematic diagram showing the engineered A375-FG, K562-FG, H292-FG, PC3-FG, and MM.1S-FG cell lines. Fluc, firefly luciferase; EGFP, enhanced green fluorescent protein. (B-D) Direct in vitro killing of human tumor cells by AlloHSC-iNKT cells (see Figures 25C-25E). PBMC-NK cells were included as a control. Both fresh and frozen-thawed cells were studied. Tumor killing data for H292-FG human lung cancer cells (B), PC3-FG human prostate cancer cells (C), and MM.1S-FG human multiple myeloma cells (D) are shown at 24 hours (n = 4 for each). (E-G) Mechanism of tumor killing by AlloHSC-iNKT cells (see Figures 25F-25H). NKG2D- and DNAM-1-mediated pathways were investigated. Tumor killing data are shown for H292-FG (tumor:iNKT ratio 1:2), PC3-FG (tumor:iNKT ratio 1:10), and MM.1S-FG (tumor:iNKT ratio 1:15) at 24 hours (n=4 for each). (H-I) In vivo antitumor efficacy of AlloHSC-iNKT cells in the A375-FG human melanoma xenograft NSG mouse model (mainly related to Figures 25I-25K). (H) BLI measurements of tumor burden over time (n=4 or 5). (I) Measurement of tumor weight at final harvest on day 18 (n=4 or 5). Representative of three experiments. Data are expressed as mean ± SEM. ns, not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (B-G, I) or by Student's t test (H).
[0099] [Figure 31]Tumor targeting of CAR-engineered AlloHSC-iNKT cells; see Figure 26. (A) Schematic showing BCMA-CAR design. SP, spacer; TM, transmembrane. (B-C) FACS characterization of AlloBCAR-iNKT cells. (B) Surface marker expression. (C) Production of intracellular cytokines and cytotoxic molecules. BCAR-T cells were included as a control. (D-E) Antitumor effector function of AlloHSC-iNKT cells. (D) FACS detection of CD69, perforin, and granzyme B in iNKT cells 24 hours after coculture with MM.1S-CD1d-FG tumor cells. (E) Quantification of (E) (n=3). Representative of three experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA.
[0100] [Figure 32]Safety study of AlloHSC-iNKT cells; pertains to Figure 27. (A) Quantification of infiltrated area in tissue sections (pertains to Figure 27C) (n=4). (B) In vitro GCV killing assay using AlloHSC-iNKT cells. Cell counts at day 4 after GCV treatment (n=6). (C-D) Study of graft-versus-host (GvH) responses of AlloHSC-iNKT cells using an in vitro mixed lymphocyte culture (MCL) assay. PBMC-Tc cells were included as responder cell controls. (C) Experimental design. PBMCs from four different healthy donors were used as stimulator cells. (D) ELISA analysis of IFN-γ production at day 4 (n=4). (E-J) Study of GvH responses of AlloHSC-iNKT cells using the NSG mouse model. Donor-matched PBMCs were included as controls. (E) Experimental design. AlloHSC-iNKT cells were tested. (F) Kaplan-Meier survival curves of experimental mice over time (n=5). (G) Anti-human CD3 staining of tissue sections from experimental mice. CD3 is shown in brown. Bar: 100 μm. (H) Quantification of (G) (n=4). (I) Experimental design. AlloHSC-iNKT cells mixed with donor-matched T cell-depleted PBMCs were tested. (J) Kaplan-Meier survival curves of experimental mice over time (n=5). Representative of two experiments. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by Student's t-test (A,H), or by one-way ANOVA (B,D), or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (F,J).
[0101] [Figure 33]Characterization of UHSC-iNKT cells; related to Figure 29. (A) FACS detection of surface marker expression and production of intracellular cytokines and cytotoxic molecules by UBCAR-iNKT cells. AlloBCAR-iNKT cells and BCAR-T cells were included as controls. (B-C) Study of GvH responses of UBCAR-iNKT cells using an in vitro mixed lymphocyte culture (MCL) assay. BCAR-T cells were included as responder cell controls. (B) Experimental design. PBMCs from three different healthy donors were used as stimulator cells. (C) ELISA analysis of IFN-γ production on day 4 (n=4). (D) In vitro GCV killing assay using UBCAR-iNKT cells. Cell counting on day 4 after GCV treatment (n=6). (E) Study of allogeneic T cell responses to UBCAR-iNKT cells using an in vitro MLC assay. ELISA analysis of IFN-γ production on day 4 (mainly related to Figures 29F and 29G) (n=3). (F) Study of allogeneic NK cell responses to UHSC-iNKT cells using an in vitro MLC assay. FACS monitoring of live cell composition over time (mainly pertaining to Figures 29H and 29I). (G-I) In vitro killing of human multiple myeloma MM.1S-CD1d-FG cells by BCAR-iNKT cells. PBMC-T cells, BCAR-T cells, and UHSC-iNKT cells were included as effector cell controls. (G) Experimental design. (H) Tumor killing at 16 hours (E:T ratio 2:1) (n=4). (I) Tumor killing at a titrated E:T ratio at 24 hours (n=4). Representative of three experiments. Data are expressed as mean ± SEM. ns, not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (C-E, H) or by Student's t test (I).
[0102] [Figure 34] MM recurrence in tumor-bearing mice treated with BCAR-T cells; related to Figure 29. BLI images showing MM tumor recurrence in multiple organs including spine, skull, femur, spleen, liver, and intestine 70 days after BCAR-T cell infusion. Representative of two experiments.
[0103] [Figure 35] CMC research - iTARGET cells, UiTARGET cells, and CAR-iTARGET cells. (A-B) Feeder-free ex vivo differentiation culture method for generating monoclonal iTARGET cells from PBMCs (A) or umbilical cord blood (CB) HSCs (B). By combining with HLA-I / II gene editing, iTARGET cells can be engineered to be HLA-I / II negative, resulting in universal iTARGET (UiTARGET) cells. UiTARGET cells can be further engineered with a CAR to become UCAR-iTARGET cells. The HLA-E gene can be included in the CAR gene delivery vector to achieve HLA-E expression in UCAR-iTARGET cells. The final cell product, UCAR-iTARGET cells, is HLA-I / II negative and HLA-E positive, and therefore suitable for allogeneic adoptive transfer. Note the large number of iTARGET cells and their derivatives that can be generated from PBMCs or CB HSCs of a single random healthy donor. (C-D) Generation of iTARGET cells in stage 1 and expansion of differentiated iTARGET cells in stage 2 from PBSCs (C) or CB HSCs (D). (E) Generation of UiTARGET cells by combining iTARGET cell culture with CRISPR B2M / CIITA gene editing. (F) Generation of CAR-iTARGET cells by combining iTARGET cell culture with CAR engineering. Generation of conventional CAR-T cells from peripheral blood T (PBMC-T) cells of a healthy donor was included as a control. Note the similar CAR engineering rates for generating CAR-iTARGET cells and CAR-T cells.
[0104] [Figure 36]Pharmacology studies of iTARGET and UiTARGET cells. Representative FACS plots are presented, showing the phenotypic (surface markers) and functional (intracellular production of effector molecules) analysis of iTARGET and UiTARGET cells. Native human iNKT (PBMC-iNKT) cells, conventional αβT (PBMC-T) cells, and NK (PBMC-NK) cells were isolated and expanded from peripheral blood of healthy donors and included as controls.
[0105] [Figure 37] Pharmacology study of BCMA CAR-engineered iTARGET (BCAR-iTARGET) cells. Representative FACS plots are presented, showing analysis of the phenotype (surface markers) and functionality (intracellular production of effector molecules) of BCAR-iTARGET cells. BCMA-CAR-engineered conventional αβT (BCAR-T) cells, generated by BCMA-CAR engineering of peripheral blood T cells from healthy donors, were included as a control.
[0106] [Figure 38] In vitro efficacy and MOA study of iTARGET cells. (A) Experimental design for the in vitro tumor cell killing assay. Three engineered human tumor cell lines were used in this study, including the human multiple myeloma cell line MM.1S-hCD1d-FG, the human melanoma cell line A375-hCD1d-FG, and the human chronic myeloid leukemia cancer cell line K562-hCD1d-FG. (B) Tumor-killing efficacy of iTARGET cells against MM.1S-hCD1d-FG tumor cells (n=4). (C) Tumor-killing efficacy of iTARGET cells against A375-hCD1d-FG and K562-hCD1d-FG tumor cells (n=3). Data are presented as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA.
[0107] [Figure 39]In vitro efficacy and MOA study of BCMA CAR-engineered iTARGET (BCAR-iTARGET) cells. (A) Experimental design for the in vitro tumor cell killing assay. (B) Schematic diagram showing the engineered MM.1S-hCD1d-FG human multiple myeloma cell line and A375-hCD1d-FG human melanoma cell line. (C) Tumor-killing efficacy of BCAR-iTARGET cells against A375-hCD1d-FG melanoma cells (n=3). (D) Tumor-killing efficacy of BCAR-iTARGET cells against MM.1S-hCD1d-FG melanoma cells. BCAR-T cells were included as a control. N=4. (E) Tumor-killing efficacy of BCAR-iTARGET cells against MM.1S-hCD1d-FG melanoma cells in the absence or presence of the cognate glycolipid antigen αGC. BCAR-T cells and non-CAR-engineered PBMC-T cells and iTARGET cells were included as controls. N=4. (F) Diagram showing the triple mechanism that can be exploited by CAR-iTARGET cells targeting tumor cells, including the CAR-mediated pathway, the iNKT TCR-mediated pathway, and the NK receptor-mediated pathway. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ****P<0.0001 by one-way ANOVA.
[0108] [Figure 40]Immunogenicity study. (A) Potential GvHD and HvG responses and engineered safety management strategies. (B) In vitro mixed lymphocyte culture (MLC) assay for studying GvHD responses. (C) IFN-γ production in the MLC assay showing no GvHD response induced by both iTARGET and UiTARGET cells (n=4). PBMCs from two mismatched healthy donors were used as stimulators. N, no PBMC stimulator. (D) In vitro MLC assay for studying HvG responses. (E) IFN-γ production in the MLC assay showing a significantly reduced HvG response to UiTARGET cells. PBMCs from two mismatched healthy donors were tested as responders. Data from one representative donor are shown (n=4). Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ****P<0.0001 by one-way ANOVA.
[0109] [Figure 41] Safety Study - sr39TK Gene for PET Imaging and Safety Management. (A) In vitro GCV killing assay using iTARGET cells. Cell counts are shown on day 4 after GCV treatment (n=5). GCV: ganciclovir, a drug that selectively kills cells expressing the sr39TK suicide gene. (B-D) In vivo PET imaging and GCV killing assay using BLT-iNKTTK mice. (B) Experimental design. (C) Representative PET / CT images of BLT-iNKTTK mice before and after GCV treatment (n=4-5). (D) Quantification of FACS data showing effective and specific depletion of HSC-iNKT cells in BLT-iNKTTK mice after GCV treatment (n=4-5). Data are expressed as mean ± SEM. ns, not significant; **P<0.01; ****P<0.0001 by one-way ANOVA (A) or Student's t-test (D).
[0110] [Figure 42]Properties of human iNKT cell products generated using various methods. Representative FACS plots are presented showing the properties of human iNKT cell products generated from human PBMC cultures, ATO-iNKT cell cultures, and iTARGET cell cultures.
[0111] [Figure 43] CMC Research - esoTARGET and UesoTARGET Cells. (A) Feeder-free ex vivo differentiation culture method for generating monoclonal esoTARGET cells from umbilical cord blood (CB) HSCs. By combining with HLA-I / II gene editing, esoTARGET cells can be engineered to be HLA-I / II negative, resulting in universal esoTARGET (UesoTARGET) cells that are suitable for allogeneic adoptive transfer. Note the large number of UesoTARGET cells that can be generated from CB HSCs of a single random healthy donor. (B) Generation of esoTARGET cells in stage 1 and expansion of differentiated esoTARGET cells in stage 2. Note the highly pure and homogenous esoTARGET cell product. (C) Generation of UesoTARGET cells by combining esoTARGET cell culture with CRISPR B2M / CIITA gene editing.
[0112] [Figure 44]Pharmacology study of esoTARGET cells. Representative FACS plots are presented, showing the phenotypic (surface markers; A and B) and functional (intracellular production of effector molecules; C) analysis of esoTARGET cells. Native conventional αβ T cells (PBMC-T) expanded from peripheral blood of healthy donors were included as a control. (A) FACS plot showing the surface expression of effector T cell markers on esoTARGET cells. Note that compared to native PBMC-T cells, esoTARGET cells were homogenous, monospecific (hTCRαβ+HLA-A2 ESO-dextramers+), more active (CD69hiCD62Llo), and interestingly, less "exhausted" (CTLA-4loPD-1lo). (B) FACS plot showing the expression of NK markers on esoTARGET cells. Note that compared to native PBMC-Tc cells, esoTARGET cells expressed higher levels of NK markers (CD56+), NK functional receptors (CD16+ / -), and NK activating receptors (NKG2DhiDNAM-1hi). (C) FACS plot showing intracellular production of cytokines in esoTARGET cells. Note that compared to native PBMC-Tc cells, esoTARGET cells produced significantly higher levels of effector cytokines (IL-2, IFN-γ, TNF-α) and cytotoxic molecules (granzyme B and perforin).
[0113] [Figure 45]In vitro efficacy and MOA study of esoTARGET cells. (A) Experimental design for the in vitro tumor cell killing assay. (B) Schematic diagram showing the engineered A375-A2-ESO-FG cell line. A375 is a human melanoma cell line. A375-A2-ESO-FG was generated by engineering the parental A375 cell line to stably overexpress HLA-A2, NY-ESO-1, and a dual reporter of firefly luciferase and enhanced green fluorescent protein. (C) Tumor killing efficacy of esoTARGET cells against NY-ESO-1 + A375-A2-ESO-FG tumor cells (n=4). esoT, human peripheral blood conventional αβ T cells engineered to express the same transgenic esoTCR as expressed by esoTARGET cells. Note that esoTARGET cells effectively killed NY-ESO-1+ tumor cells with efficacy comparable to or better than that of native conventional T (esoT) cells. (D-F) Tumor-killing efficacy of esoTARGET cells against NY-ESO-1- tumor cells (n=4). Three tumor cell lines were studied: A375 human melanoma cell line, MM.1S human multiple myeloma cell line, and K562 human chronic myeloid leukemia cancer cell line. All three tumor cell lines were engineered to express dual reporters of firefly luciferase and enhanced green fluorescent protein and are designated A375-FG, MM.1S-FG, and K562-FG. Note that esoTARGET cells killed all three NY-ESO-1- tumor cell lines with robust efficacy. Taken together, these results demonstrate that esoTARGET cells possess dual tumor-killing capabilities via an esoTCR / antigen-induced pathway and an esoTCR / antigen-independent (potentially NK) pathway. Data are presented as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA (C) or Student's t-test (D, E, F).
[0114] [Figure 46]Safety study of esoTARGET cells. The GvHD response of esoTARGET cells was assessed using an in vitro mixed lymphocyte culture (MCL) assay. (A) Experimental design. (B) IFN-γ production in the MCL assay, in contrast to that of esoT cells, demonstrates minimal alloreactivity of esoTARGET cells (n=3). esoT, allogeneic peripheral blood conventional αβ T cells engineered to express esoTCR. These results indicate that esoTARGET cells exhibit low alloreactivity and are suitable for developing off-the-shelf cell products. Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0115] [Figure 47] In vivo efficacy study of BCAR-iTARGET cells. (A) Experimental design to study the in vivo antitumor efficacy of BCAR-iTARGET cells in a human multiple myeloma (MM) xenograft NSG mouse model. (B-C) Live animal bioluminescence imaging (BLI) analysis of tumor growth. (B) Tumor growth. TBL, whole body luminescence. (C) Representative BLI image. N=2. Data are expressed as mean ± SEM.
[0116] [Figure 48] In vivo efficacy study of esoTARGET cells. (A) Experimental design to study the in vivo antitumor efficacy of esoTARGET cells in a human melanoma xenograft NSG mouse model. (B) Control A375-FG tumor growth (n=5-6). (C) Target A375-A2-ESO-FG tumor growth (n=5-6). Data are expressed as mean ± SEM. ns, not significant; *P<0.05; ***P<0.001; ****P<0.0001 by Student's t-test.
[0117] [Figure 49]CMC Research - iTANK and CAR-iTANK Cells. (A-B) Feeder-free ex vivo differentiation culture method for generating monoclonal iNKT TCR-armed NK (iTANK) cells from PBMCs (A) or umbilical cord blood (CB) HSCs (B). By combining with HLA-I / II gene editing, iTANK cells can be engineered to be HLA-I / II negative, resulting in universal iTANK (UiTANK) cells. UiTANK cells can be further engineered with a CAR to become UCAR-iTANK cells. The HLA-E gene can be included in the CAR gene delivery vector to achieve HLA-E expression in UCAR-iTANK cells. The final cell product, UCAR-iTANK cells, is HLA-I / II negative and HLA-E positive, and therefore suitable for allogeneic adoptive transfer. Note the large number of iTANK cells and their derivatives that can be generated from PBMCs or CB HSCs of a single random healthy donor. (C) Generation of iTANK cells in stage 1 and expansion of differentiated iTANK cells in stage 2. Data from PBSCs are shown. (D) Generation of CAR-iTANK cells by combining iTANK cell culture with CAR engineering. A BCMA CAR was used.
[0118] [Figure 50] Properties of human NK cell products generated using various methods. Representative FACS plots are presented to demonstrate the properties of iTANK cell products compared to native human NK cell products generated from human PBMC cultures.
[0119] [Figure 51]Pharmacology study of CAR-iTANK cells. Representative FACS plots are presented, showing the phenotypic (surface markers; A and B) and functional (intracellular production of effector molecules; C) analysis of CAR-iTANK cells. CAR-engineered peripheral blood conventional αβ T cells (CAR-T) were included as a control. CAR refers to BCMA-CAR. (A) FACS plot showing the surface expression of effector T cell markers on CAR-iTANK cells. Note that compared with conventional CAR-T cells, CAR-iTANK cells expressed the lowest levels of HLA-II. CAR-iTANK cells were also more active (CD69hiCD62Llo) and, interestingly, less "exhausted" (PD-1Llo). (B) FACS plot showing the expression of NK markers on iTANK cells. Note that compared with conventional CAR-T, CAR-iTANK cells expressed higher levels of NK markers (CD56hi) and NK activating receptors (NKG2Dhi). (C) FACS plot showing intracellular production of cytokines in CAR-iTANK cells. Note that CAR-iTANK cells produced significantly higher levels of effector cytokines (IL-2, IFN-γ, TNF-α) and cytotoxic molecules (granzyme B and perforin) compared to conventional CAR-T cells.
[0120] [Figure 52]In vitro efficacy and MOA study - CAR-iTANK cells. (A) Experimental design for the in vitro tumor cell killing assay. CAR refers to BCMA-CAR. (B) Schematic diagram showing the engineered MM.1S-hCD1d-FG cell line. MM.1S is a human multiple myeloma cell line (BCMA+). MM.1S-hCD1d-FG was generated by engineering the parental MM.1S cell line to stably overexpress human CD1d and dual reporters for firefly luciferase and enhanced green fluorescent protein. (C) Schematic diagram showing the engineered A375-hCD1d-FG cell line. A375 is a human melanoma cell line (BCMA-). A375-hCD1d-FG was generated by engineering the parental A375 cell line to stably overexpress human CD1d and dual reporters for firefly luciferase and enhanced green fluorescent protein. (D) Tumor-killing efficacy of iTANK cells against MM.1S-hCD1d-FG tumor cells (n=3). Note the lack of tumor cell killing by iTANK cells (not engineered with a CAR). (E) Tumor-killing efficacy of CAR-iTANK cells against MM.1S-hCD1d-FG tumor cells (n=4). CAR-engineered peripheral blood conventional αβT (CAR-T) cells were included as a control. Note that CAR-iTANK cells killed tumor cells more efficiently than CAR-T cells. (F) Tumor-killing efficacy of CAR-iTANK cells against A375-hCD1d-FG tumor cells (n=4). CAR-T cells were included as a control. Note that CAR-iTANK cells, unlike CAR-T cells, effectively killed BCMA-tumor cells. Taken together, these results demonstrated that CAR-iTANK cells can effectively kill tumors through both CAR-induced and CAR-independent (potentially NK pathway) mechanisms. Furthermore, CAR-iTANK cells are more effective than conventional CAR-T cells in CAR-induced killing. Data are expressed as mean ± SEM. ns, not significant; ***P<0.001; ****P<0.0001 by Student's t-test (D) or one-way ANOVA.
[0121] [Figure 53] CMC Research - esoTANK Cells. (A) Feeder-free ex vivo differentiation culture method for generating monoclonal esoTANK cells from umbilical cord blood (CB) HSCs. By combining with HLA-I / II gene editing, esoTANK cells can be engineered to be HLA-I / II negative, resulting in universal esoTANK (UesoTANK) cells that are suitable for allogeneic adoptive transfer. Note the large number of UesoTANK cells that can be generated from CB HSCs of a single random healthy donor. (B) Generation of esoTANK cells in stage 1 and expansion of differentiated esoTANK cells in stage 2. Note the highly pure and homogenous esoTANK cell product.
[0122] [Figure 54]Pharmacology study of esoTANK cells. Representative FACS plots are presented, showing the phenotypic (surface markers; A and B) and functional (intracellular production of effector molecules; C) analysis of esoTANK cells. Native conventional αβ T (PBMC-T) cells expanded from peripheral blood of healthy donors were included as a control. (A) FACS plot showing the surface expression of effector T cell markers on esoTANK cells. Note that compared to native PBMC-T cells, esoTANK cells were homogenous, monospecific (hTCRαβ+HLA-A2 ESO-dextramers+), more active (CD69hiCD62Llo), and interestingly, less "exhausted" (CTLA-4loPD-1lo). (B) FACS plot showing the expression of NK markers on esoTANK cells. Note that compared with native PBMC-Tc cells, esoTANK cells expressed higher levels of NK markers (CD56+), NK functional receptors (CD16+ / -), and NK activating receptors (NKG2DhiDNAM-1hi). (C) FACS plot showing intracellular production of cytokines in esoTANK cells. Note that compared with native PBMC-Tc cells, esoTANK cells produced significantly higher levels of effector cytokines (IL-2, IFN-γ, TNF-α) and cytotoxic molecules (granzyme B and perforin).
[0123] [Figure 55]In vitro efficacy and MOA study of esoTANK cells. (A) Experimental design for the in vitro tumor cell killing assay. (B) Schematic diagram showing the engineered A375-A2-ESO-FG cell line. A375 is a human melanoma cell line. A375-A2-ESO-FG was generated by engineering the parental A375 cell line to stably overexpress HLA-A2, NY-ESO-1, and a dual reporter of firefly luciferase and enhanced green fluorescent protein. (C) Tumor-killing efficacy of esoTANK cells against NY-ESO-1+A375-A2-ESO-FG tumor cells (n=4). Note that esoTANK cells effectively killed NY-ESO-1+ tumor cells. (D-F) Tumor-killing efficacy of esoTARGET cells against NY-ESO-1- tumor cells (n=4). Three tumor cell lines were studied: the A375 human melanoma cell line, the MM.1S human multiple myeloma cell line, and the K562 human chronic myeloid leukemia cancer cell line. All three tumor cell lines were engineered to express dual reporters, firefly luciferase and enhanced green fluorescent protein, and designated A375-FG, MM.1S-FG, and K562-FG. Note that esoTANK cells killed all three NY-ESO-1 tumor cell lines with robust efficacy. Taken together, these results demonstrate that esoTANK cells possess dual tumor-killing capabilities via an esoTCR / antigen-induced pathway and via an esoTCR / antigen-independent (potentially NK) pathway. Data are presented as mean ± SEM. ***P<0.001, ****P<0.0001 by Student's t-test.
[0124] [Figure 56]Safety study of esoTANK cells. The GvHD response of esoTARGET cells was assessed using an in vitro mixed lymphocyte culture (MCL) assay. (A) Experimental design. (B) IFN-γ production in the MLC assay, in contrast to that of esoT cells, demonstrates minimal alloreactivity of esoTANK cells (n=3). esoT, allogeneic peripheral blood conventional αβ T cells engineered to express esoTCR. These results indicate that esoTANK cells exhibit low alloreactivity and are suitable for developing off-the-shelf cell products. Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0125] [Figure 57] Generation of IL-15-enhanced BCAR-iTARGET (IL-15BCAR-iTARGET) cells. (A) Experimental design for generating IL15BCAR-iTARGET cell products. (B) Schematic of lenti / BCAR-iNKT-IL-15 and lenti / BCAR-iNKT lentivectors. (C) FACS plot showing detection of IL15BCAR-iTARGET (hTCRβ+6B11+) cells in cell culture over time. 6B11 is a monoclonal antibody that specifically stains the human iNKT TCR. BCAR-iTARGET cells were included as a control.
[0126] [Figure 58]In vitro antitumor efficacy of IL15BCAR-iTARGET cells. (A) Experimental design for studying the killing of MM.1S-hCD1d-FG human multiple myeloma cells by IL15BCAR-iTARGET cells. (B) Schematic diagram of the engineered human multiple myeloma cell line (MM.1S-hCD1d-FG). (C) Diagram showing the NK / TCR / CAR-mediated triple tumor killing mechanism carried out by IL15BCAR-iTARGET cells. (D) Tumor-killing efficacy of IL15BCAR-iTARGET cells and BCAR-iTARGET cells against MM.1S-hCD1d-FG tumor cells (n=5). (E) FACS detection of the expression of activation markers and cytotoxic molecules in IL15BCAR-iTARGET cells and BCAR-iTARGET cells cocultured with MM.1S-hCD1d-FG tumor cells. Data are presented as mean ± SEM. ns, not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA.
[0127] [Figure 59] In vivo antitumor efficacy of IL15BCAR-iTARGET cells. (A) Experimental design. (B) Tumor burden measured by BLI in experimental mice over time. (C) Quantification of B (n=3-4). (D) Quantification of tumor burden at day 34. (E) FACS plot showing persistence of iTARGET cells in peripheral blood at day 34. (F) Quantification of (E). Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0128] [Figure 60]Construction of gene delivery lentivectors. (A) Schematic of the lenti / iNKT-sr39TK lentivector. (B) Schematic of the lenti / iNKT-CAR19 and lenti / iNKT-BCAR lentivectors. (C) Titers of the indicated lentivectors as measured by transducing the HEK-293T-CD3 cell line. Note the comparable titers. (D) FACS analysis of CD34+ HSCs transduced with the indicated lentivectors. Note that the lenti / iNKT-CAR19 and lenti / iNKT-BCAR vectors mediated efficient co-expression of the iNKT TCR and CAR genes. Vβ11 stained the iNKT TCR, whereas Fab stained the CAR.
[0129] [Figure 61] Generation of HSC-engineered allogeneic iNKT (AlloiNKT), CAR-iNKT (AlloCAR-iNKT), and AlloBCAR-iNKT cells. (A) Schematic of the experimental design for producing the AlloiNKT cell product. (B) FACS plot showing detection of AlloiNKT cells (gated as CD3+6B11+ cells) in cell culture over time. (C) Schematic of the experimental design for generating the AlloCAR19-iNKT cell product. (D) FACS plot showing detection of AlloCAR19-iNKT cells (gated as CD3+6B11+ cells) in cell culture over time. (E) Schematic of the experimental design for generating the AlloBCAR-iNKT cell product. (F) FACS plot showing detection of AlloBCAR-iNKT cells (gated as CD3+6B11+ cells) in cell culture over time. (G) Table showing cell yield.
[0130] [Figure 62]Phenotype and functionality of AlloCAR-iNKT cells. (A) FACS plot showing coexpression of iNKT TCR (6B11+) and CAR (Fab+) in AlloCAR-iNKT cells. (B) Analysis of TCR Vα and Vβ CDR3 VDJ sequences in AlloCAR-iNKT cells, AlloCAR-iNKT cells, PBMC-iNKT cells, and PBMC-T cells. The relative abundance of each unique TCR sequence among the total unique sequences identified for the sample is represented as a sector of the pie chart. Note the lack of randomly recombined endogenous TCRs in AlloCAR-iNKT cells and AlloCAR-iNKT cells. (C) FACS plot showing the expression of surface markers and intracellular effector molecules in AlloCAR-iNKT cells. (D) Expansion of AlloCAR-iNKT cells in response to antigen (αGC) stimulation (n=3). (E) Expansion of AlloCAR19-iNKT cells in response to antigen (αGC) stimulation (n=3). Data are expressed as mean ± SEM. ***P<0.001, ****P<0.0001 by Student's t-test.
[0131] [Figure 63] In vitro efficacy and MOA study - AlloiNKT cells. (A) In vitro killing of MM.1S-CD1d-FG human multiple myeloma cells by AlloiNKT cells (n=4). (B) In vitro killing of A375-CD1d-FG human melanoma cells by AlloiNKT cells (n=3). (C) In vitro killing of K562-CD1d-FG human leukemia cells by AlloiNKT cells (n=3). Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA.
[0132] [Figure 64]In vitro efficacy and MOA study - AlloBCAR-iNKT cells. (A) Diagram showing the NK / TCR / CAR-mediated triple tumor killing mechanism utilized by AlloBCAR-iNKT cells. (B) In vitro killing of MM.1S-CD1d-FG human multiple myeloma cells by AlloBCAR-iNKT cells (n=3). (C) IFN production from (B) (n=3). (D) In vitro killing of MM.1S-CD1d-FG human multiple myeloma cells by AlloBCAR-iNKT cells compared to that of conventional BCAR-T cells (n=4). Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA (B, C) or by Student's t-test (D).
[0133] [Figure 65] In vitro antitumor efficacy and MOA study - AlloCAR19-iNKT cells. (A) In vitro killing of CD19+Raji-CD1d-FG human B-cell lymphoma cells by AlloCAR19-iNKT cells (n=3). (B) In vitro killing of CD19+Raji-CD1d-FG human B-cell lymphoma cells by AlloCAR19-iNKT cells compared with that of conventional CAR19-T cells (n=3). Data are expressed as mean ± SEM. ns, not significant; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA (A) or Student's t-test (B).
[0134] [Figure 66]In vivo antitumor efficacy and safety study - AlloBCAR-iNKT cells. (A) Experimental design. (B) Tumor burden measured by BLI in experimental mice over time. (C) Quantification of (B) (n=5). (D) Kaplan-Meier analysis of mouse survival (n=5). (E) FACS analysis of PD-1 surface expression and intracellular production of granzyme B and IFN-γ in AlloBCAR-iNKT cells and control BCAR-T cells isolated from the livers of experimental mice (n=4). (F-G) FACS analysis of biodistribution of AlloBCAR-iNKT cells (F) relative to conventional BCAR-T cells (G) in experimental mice (n=4). Data are expressed as mean ± SEM. ns, not significant, *P<0.05, ***P<0.001, ****P<0.0001 by Student's t test (C, E) or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (D).
[0135] [Figure 67] Immunogenicity study - AlloBCAR-iNKT cells. (A-B) Graft-versus-host (GvH) response. (A) Experimental design. (B) IFN-γ production (n=3). PBMCs from four random healthy donors were included as stimulators. (C-D) Host-versus-graft (HvG) response. (C) Experimental design. (D) IFN-γ production (n=3). PBMCs from four random healthy donors were included as responders. Data are presented as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0136] [Figure 68] Technological innovations enabling the development of UBCAR-iNKT cell products.
[0137] [Figure 69]Generation and characterization of allogeneic, HLA-I / II-negative "universal" BCAR-iNKT (UBCAR-iNKT) cells. (A) Experimental design for generating UBCAR-iNKT cells. (B) FACS plot showing detection of UBCAR-iNKT cells (gated as CD3+6B11+ cells) in cell culture over time. (C) FACS plot showing co-expression of iNKT TCR, CAR, and HLA-E in the UBCAR-iNKT cell product. (D) FACS plot showing lack of HLA-I / II expression in the majority of UBCAR-iNKT cells (unsorted). Conventional PBMC-derived BCAR-T cells and non-HLA gene-edited AlloBCAR-iNKT cells were included as controls. (E) Quantification of (D). N=4. (F-G) Immunogenicity of UBCAR-iNKT cells. (F) Experimental design to study the host-versus-graft (HvG) response of UBCAR-iNKT cells using a mixed lymphocyte culture (MCL) assay. (G) IFN-γ production (n=3). PBMCs from four random healthy donors were included as responders. Data are presented as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA.
[0138] [Figure 70]In vitro generation and gene profiling of NY-ESO-1-specific T (AlloesoT) cells engineered with off-the-shelf allogeneic HSCs. (A) Schematic design for generating AlloesoT cells in an in vitro off-the-shelf HSC-based TCR-engineered T cell generation system. (B) FACS detection of intracellular expression of HLA-A*02:01-NY-ESO-1157-165-specific TCR (identified as Vβ13.1+) in CD34+ HSC cells 72 hours after lentivector transduction. (C) Representative kinetics of AlloesoT cell development and differentiation from CD34+ HSCs at the indicated weeks. AlloesoT cells were gated as Vβ13.1+CD3+. (D) Yields of AlloesoT cells from eight different CB donors. (E) Analysis of TCR Vα and Vβ CDR3 VDJ sequences of AlloesoT and conventional αβT (PBMC-T) cells. The relative abundance of each unique T cell receptor sequence among the total unique sequences identified for the sample is represented as a sector of the pie chart. Representative of over 10 experiments. See also Figure 73.
[0139] [Figure 71]Characterization and antitumor potential of AlloesoT. (A) Characterization of AlloesoT. FACS plot showing the expression of surface markers, intracellular cytokines, and cytotoxic molecules from AlloesoT cells (identified as Vβ13.1+CD3+) compared with PBMC-esoT cells (identified as Vβ13.1+CD3+). (B) Antigen response of AlloesoT cells. AlloesoT cells were expanded for 7 days in the presence or absence of NY-ESO-1157-165 peptide (ESOp). Growth curve of AlloesoT expansion over time (n=3). (C-G) Study of NY-ESO-1-specific killing of multiple tumor cell lines by AlloesoT cells compared with PBMC-esoT cells. (C) Experimental design. (D-E) Luciferase activity analysis of in vitro tumor killing of A375-Fluc and A375-A2-ESO-Fluc (n=4). E:T, effector / target ratio. (F-G) Tumor killing data for PC3-A2-ESO-Fluc (n=4). E:T, effector / target ratio. (H-O) Study of the in vivo antitumor efficacy of Alloeso T cells against solid tumors in a human melanoma (A375-A2-ESO-Fluc) xenograft mouse model. (H) Experimental design. (I) Measurement of tumor size over time (n=4). (J) Kaplan-Meier analysis of mouse survival (n=7 or 8). (K) Biodistribution of PBMC-eso T quantified by final FACS analysis. (L) Biodistribution of Alloeso T quantified by final FACS analysis. (M) Quantification of PD-1 expression on tumor-infiltrating lymphocytes (n=4). (N) Expression of intracellular cytotoxic molecules in in vivo persistent T cells in the liver (n=4). (O) Expression of intracellular cytokines in in vivo persistent T cells in the liver (n=4). Representative of three experiments. See also Figures 74-76. Data are expressed as mean ± SEM. ns, not significant; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (D, E, F, G, I, K, L, M, N, and O) or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (J).
[0140] [Figure 72]Safety study of AlloesoT and reduced immunogenicity by gene editing. (A-B) In vitro mixed lymphocyte reaction (MLR) assay to study the GvH response of AlloesoT cells compared to conventional PBMC-esoT cells. (A) Experimental design. (B) ELISA analysis of IFN-γ in the supernatant of the MLR assay (n=3), showing no GvH response induced by AlloesoT cells. PBMCs from three different healthy donors were included as stimulators. (C-D) In vitro mixed lymphocyte reaction (MLR) assay to study the host-versus-graft (HvG) response of AlloesoT cells compared to PBMC-esoT cells. (C) Experimental design. (D) ELISA analysis of IFN-γ in the supernatant of the MLR assay (n=3), showing a lower HvG response induced by AlloesoT cells. PBMCs from three different healthy donors were included as responders. (E-G) Immunohistological analysis of tissue sections from experimental mice. (E) Hematoxylin and eosin staining. White dashed lines highlight areas with mononuclear cell infiltration. (F) Anti-human CD3 staining. CD3 is shown in red. Quantification of (E)(F) (n=5). (H) Schematic design for generating NY-ESO-1-specific T (UesoT) cells engineered with HLA-I / II-reduced universal HSCs in an off-the-shelf HSC-based TCR-engineered T cell generation system. (I) Kinetics of UesoT cell development and differentiation from CD34+ HSCs at the indicated weeks. UesoT cells were gated as Vβ13.1+CD3+. (J) FACS plot showing HLA-I and II expression of UesoT compared to AlloesoT. (K) Characterization of UesoT. FACS plots showing the expression of surface markers, intracellular cytokines, and cytotoxic molecules from Ueso T cells (identified as Vβ13.1+CD3+) compared to PBMC-eso T cells (identified as Vβ13.1+CD3+). (L) Study of NY-ESO-1-specific killing of PC3-A2-ESO-Fluc by Ueso T cells compared to Alloeso T cells and PBMC-eso T cells (n=4). (M-N) Quantification of reduced HLA-I (M) and HLA-II (N) expression in Ueso T cells compared to Alloeso T and PBMC-eso T (n=5).(O-P) ELISA analysis of IFN-γ in the supernatants of MLR assays (n=3) showing the reduced HvG response induced by UesoT cells. PBMCs from two different healthy donors were included as stimulators. (Q) UesoT (expressing HLA-E) resist NK killing compared to AlloesoT with HLA-I and II gene editing in coculture with NK cells (n=3). Representative of two experiments. See also Figures 77 and 78. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by one-way ANOVA (B) or by Student's t-test (E, H).
[0141] [Figure 73] Generation of NY-ESO-1-specific T (AlloesoT) cells engineered with off-the-shelf allogeneic HSCs; see Figure 70. (A) Design of lentiviral vectors carrying two versions of the NY-ESO-1-specific TCR. The HLA-A2*01-NY-ESO-1157-165-specific clone is represented as 1G4, and the HLA-B7*02-NY-ESO-160-72-specific clone is represented as 1E4. (B) Representative titers of lentivirus packaged with the indicated vectors. (C) Representative kinetics of development and differentiation of AlloesoT (B7) cells from CD34+ HSCs at the indicated weeks. AlloesoT (B7) cells were gated as ESO60-72HLA-B7Dextramer+CD3+. (D-E) Generation of TCR-engineered T cells in an off-the-shelf HSC-based system is independent of matching MHC expression. (D) Generation of allogeneic T cells from HLA-A2 and HLA-A2+CB HSC donors. (E) Generation of allogeneic T(B7) cells from an HLA-B7-CB HSC donor. Representative of three (C and E) and eight (D) experiments.
[0142] [Figure 74]Characterization of AlloesoT; related to Figure 71. (A-B) Characterization of AlloesoT. FACS plots showing expression of surface markers (A), intracellular cytokines, and cytotoxic molecules (B) from AlloesoT cells (identified as Vβ13.1+CD3+) compared to PBMC-esoT cells (identified as Vβ13.1+CD3+). Representative of eight experiments.
[0143] [Figure 75] In vitro antigen response and tumor-killing ability of AlloesoT; related to Figure 71. (A-C) Antigen response of AlloesoT cells. AlloesoT cells were expanded for 7 days in the presence or absence of NY-ESO-1157-165 peptide (ESOp). ELISA analysis of cytokine production on day 3: (A) IFN-γ, (B) TNF-α, and (C) IL-2 (n=3). (D-E) HLA-B7-restricted NY-ESO-1-specific killing of multiple tumor cell lines by AlloesoT(B7) cells compared with PBMC-esoT cells. (D) Luciferase activity analysis of in vitro tumor killing of A375-Fluc and A375-A2-ESO-Fluc (n=4). (E) In vitro tumor killing of PC3-Fluc and PC3-A2-ESO-Fluc (n=4). (F) In vitro tumor killing of K562-Fluc. (G) In vitro tumor killing of MM.1S-Fluc. Representative of six experiments.
[0144] [Figure 76]In vivo antitumor potential of AlloesoT; related to Figure 71. (A-D) Study of the in vivo antitumor efficacy of AlloesoT cells against solid tumors in a human melanoma (A375-A2-ESO-Fluc) xenograft mouse model. (A) Quantification of tumor weight at the final analysis (n=4). (B) Expression of intracellular cytotoxic molecules of in vivo persistent T cells in the liver (n=4). (C-D) Expression of intracellular cytokines of in vivo persistent T cells in the liver (n=4). (E-F) Study of the in vivo antitumor efficacy of AlloesoT cells against solid tumors in a human melanoma (PC3-A2-ESO-Fluc) xenograft mouse model. (E) Experimental design. (F) Measurement of tumor size over time (n=4). Representative of four experiments.
[0145] [Figure 77] Safety characterization of AlloesoT; pertains to Figure 72. (A) HLA-I expression in AlloesoT compared to PBMC-esoT. (B) HLA-II expression in AlloesoT compared to PBMC-esoT. (C-E) Immunohistological analysis of tissue sections from experimental mice. Quantification of mononuclear cell infiltration in H&E stained photographs (n=5).
[0146] [Figure 78] Generation and characterization of UesoT; see Figure 72. (A) Design of lentiviral vector carrying esoTCR (clone 1G4), HLA-E, and sr39TK. (B) Representative titers of viruses packaged with the indicated lentivectors. (C) FACS detection of intracellular expression of esoTCR (identified as Vβ13.1+) and HLA-E in CD34+ HSC cells 72 hours after lentivector transduction. (D) Characterization of UesoT. FACS plot showing expression of surface markers and intracellular cytokines from UesoT cells (identified as Vβ13.1+CD3+) compared to PBMC-esoT cells (identified as Vβ13.1+CD3+). Representative of three experiments.
[0147] [Figure 79]Generation of HSC-iNKT cells in BLT mice. (A) Experimental design for generating HSC-iNKT cells in the BLT humanized mouse model. (B) FACS monitoring of human immune cells (gated as hCD45+ cells), human ab T cells (gated as hCD45+hTCRab+ cells), and human iNKT cells (gated as hCD45+hTCRab+6B11+ cells) over time in the peripheral blood of BLT-iNKT mice and control BLT mice after HSC transfer (n=9–10).
[0148] [Figure 80] Generation of off-the-shelf AlloHSC-iNKT cells in the ATO culture system. (A) Experimental design for generating AlloHSC-iNKT cells in vitro. (B) Generation of iNKT cells (identified as iNKT TCR+TCRαβ+ cells) during stage 1 ATO differentiation culture. iNKT TCR was stained using 6B11 monoclonal antibody. (C) Expansion of iNKT cells during stage 2 αGC expansion culture.
[0149] [Figure 81] AlloHSC-iNKT cells reduce T cell alloreactivity in mixed lymphocyte reactions (MLR). (A) Study of iNKT cell function in an in vitro MLR assay (iNKT:R:S ratio 1:1:25). (B) IFN-γ secretion was significantly reduced upon addition of CD4-iNKT cells to a baseline MLR (n=3). Data are presented as mean ± SEM. ns, not significant; **P<0.01; ***P<0.001 by one-way ANOVA.
[0150] [Figure 82] AlloHSC-iNKT cells target allogeneic myeloid APCs. (A) Experimental design. (B) FACS detection of human dendritic cells (DCs) (gated as CD11c+CD14+) in an MLR assay. (C) Quantification of A (n=3). Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
[0151] [Figure 83] Effect of HSC-iNKT cells on reducing GvHD in NSG mice. (A) Experimental design to study the effect of HSC-iNKT cells on reducing GvHD. 1 × 10 PBMCs or 1 × 10 PBMCs mixed with 1 × 10 HSC-iNKT cells were injected intravenously into NSG mice on day 0. (B) Weekly RO bleeding. (C) Survival curves. (D) Repeated survival curves. Data are expressed as mean ± SEM. ns, not significant; *P<0.05; **P<0.01 by Student's t-test.
[0152] [Figure 84] Effect of HSC-iNKT cells on reducing immune cell infiltration in major organs. (A) Experimental design to study the effect of HSC-iNKT cells on reducing immune cell infiltration in major organs, including the lung, liver, heart, kidney, and spleen. 1 × 10 PBMCs or 1 × 10 PBMCs mixed with 1 × 10 HSC-iNKT cells were injected intravenously into NSG mice on day 0. (B) Immunohistological analysis of tissue sections from experimental mice. CD3 is shown in brown. Arrows indicate infiltrating CD3+ cells. (C) Quantification of (B) (n = 5). Data are presented as mean ± SEM. ns, not significant; *P < 0.05; **P < 0.01 by Student's t-test.
[0153] [Figure 85]Effect of HSC-iNKT cells on reducing GvHD in NSG mice. (A) Experimental design for studying the effect of HSC-iNKT cells on reducing GvHD. 1 × 10 PBMCs or 1 × 10 DCs mixed with 1 × 10 HSC-iNKT cells were injected intravenously into NSG mice on day 0. (B) Experimental design for studying the effect of HSC-iNKT cells on reducing GvHD. 1 × 10 PBMCs or 1 × 10 DC-depleted PBMCs mixed with 1 × 10 HSC-iNKT cells were injected intravenously into NSG mice on day 0.
[0154] [Figure 86] AML tumor cell killing ability of HSC-iNKT cells. (A) Experimental design to study U937 human AML killing by AlloHSC-iNKT cells. (B) Tumor killing data from (A) at 24 hours (n=4). (C) Experimental design to study HL60 human AML killing by AlloHSC-iNKT cells. (D) Tumor killing data from (A) at 24 hours (n=4). Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0155] [Figure 87] AML tumor cell killing ability of HSC-iNKT cells. (A) Experimental design to study CD1d-dependent killing of U937 human AML by AlloHSC-iNKT cells. (B) Tumor killing data from (A) at 24 hours (n=4) (E:T=1:5). Data are presented as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0156] [Figure 88]AML tumor cell killing ability of HSC-iNKT cells. (A) Experimental design to study U937 human AML killing by AlloHSC-iNKT cells. (B) Tumor killing data from (A) at 24 hours (n=4). (C) Experimental design to study U937 human AML killing by PBMCs. (D) Tumor killing data from (C) at 12 hours (n=4). (E) Experimental design to study U937 human AML killing by PBMCs and AlloHSC-iNKT cells. (F) Tumor killing data from (E) at 24 hours (n=4). Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0157] [Figure 89] AML tumor cell killing ability of HSC-iNKT cells. (A) Experimental design to study HL60 human AML killing by AlloHSC-iNKT cells. (B) Tumor killing data from (A) at 24 hours (n=4). (C) Experimental design to study HL60 human AML killing by PBMCs. (D) Tumor killing data from (C) at 12 hours (n=4). (E) Experimental design to study HL60 human AML killing by PBMCs and AlloHSC-iNKT cells. (F) Tumor killing data from (E) at 24 hours (n=4). Data are expressed as mean ± SEM. ns, not significant; ****P<0.0001 by one-way ANOVA.
[0158] [Figure 90]In vivo antitumor efficacy of HSC-iNKT cells against AML in a human xenograft mouse model. (A) Experimental design to study the in vivo antitumor efficacy of HSC-iNKT cells using the U937-FG human AML xenograft NSG mouse model. 1 x 106 U937-FG cells were intravenously injected into NSG mice on day 0, and 1 x 107 PBMCs or 1 x 107 PBMCs mixed with 2 x 107 HSC-iNKT cells were intravenously injected into NSG mice on day 3. (B) BLI images showing tumor burden in experimental mice over time. (C) Quantification of (B) (n = 5–8). (D) Kaplan-Meier analysis of mouse survival (n = 5–8). Data are expressed as mean ± SEM. ns, not significant, **P<0.01, ****P<0.0001 by one-way ANOVA (C) or by log-rank (Mantel-Cox) test adjusted for multiple comparisons (D). DETAILED DESCRIPTION OF THE INVENTION
[0159] T cells, including conventional and non-conventional T cells (i.e., iNKT or NK T cells), play certain specific roles in mediating and orchestrating immune responses against cancer and are therefore attractive therapeutic targets for the treatment of cancer and other diseases. Natural killer (NK) cells are part of the innate immune system that mediate transient, rapid immune responses against malignant cells without prior sensitization; more importantly, these cells play a crucial role in tumor immunosurveillance. Recently, NK-based immunotherapy has shown promising promise, offering an alternative to conventional T cell-based therapy. NK cells have great potential as allogeneic off-the-shelf cell therapy candidates because they offer several unique therapeutic features: (1) they do not require strict HLA matching, thus reducing the risk of graft-versus-host disease (GVHD); (2) they have the ability to detect malignant cells regardless of antibody or MHC, thereby providing a frontline immune response; and (3) they possess fundamental mechanisms for inducing targeted cell death, including the release of cytotoxic molecules such as perforin and granzymes, activating apoptosis receptors on cancer cells leading to cell death, and interacting with cytotoxic T cells to release cytotoxic cytokines. Despite their therapeutic potential, current approaches to NK cell therapy have been limited, in part, by the challenges associated with large-scale production of highly purified NK cells.
[0160] Currently, human NK cells are freshly isolated from human peripheral blood. Additionally, NK cell enrichment can be achieved by negatively selecting NK cells from peripheral blood mononuclear cells (PBMCs) using a magnetic bead-based method, followed by positively selecting these cells using flow cytometry cell sorting. NK cells can then be further expanded by supplementing with appropriate cytokines. While expansion can be achieved by this method, the fold expansion is limited by the low number of NK cells in the PBMCs. Another method involves generating NK cells from HSCs derived from either bone marrow (BM) or UCB. Culture requires the use of mouse-derived stromal cells as a "feeder layer" to generate NK cells from HSCs. However, the use of mouse feeder cells may pose a risk of xenogeneic contamination and is difficult to comply with GMP regulations.
[0161] Therefore, novel methods that can reliably generate large homogenous populations of NK cells using feeder-free differentiation systems are crucial for the development of off-the-shelf NK cell therapies.
[0162] T cells recognize antigens through T cell receptor (TCR) molecules on their surface. All TCR molecules presented by T cells are encoded by a single TCR gene (comprising two genes encoding the two subunits of the TCR molecule; referred to in this document as TCR gene). The TCR genes of T cells are generated by a random genomic V / D / J recombination process during T cell development and are therefore unique to each T cell. Based on the genomic composition of their TCR genes, T cells can be divided into two broad categories: alpha-beta T (αβT) cells and gamma-delta T (γδT) cells. Alpha-beta T cells are classified into subtypes: 1) CD4 + Helper T cells (CD4 T cells; or T H cells) and CD8 +1) conventional αβ T cells, which include type 1 invariant natural killer T (iNKT) cells, type 2 natural killer T (type 2 NKT) cells, and mucosal-associated invariant T (MAIT) cells; and 2) non-conventional αβ T cells, which include type 1 invariant natural killer T (iNKT) cells, type 2 natural killer T (type 2 NKT) cells, and mucosal-associated invariant T (MAIT) cells, among others.
[0163] Conventional αβ CD8 T (CD8 T) cells: CD8 T cells recognize protein-peptide antigens presented by polymorphic major histocompatibility complex (MHC) class I molecules. CD8 T cells are potent cytotoxic cells for killing target pathogenic cells. CD8 T cells are also called cytotoxic T lymphocytes (CTLs).
[0164] Conventional αβ CD4 T (CD4 T) cells: CD4 T cells recognize protein-peptide antigens presented by polymorphic MHC class II molecules. CD4 T cells are T helper (T) cells that orchestrate immune responses. H Based on their specialized functions, CD4 T cells are divided into further subtypes: T H 1. T H 2. T H 17, T FH , T H 9. T REG It can be classified into, etc.
[0165] Type 1 invariant natural killer T (iNKT) cells: iNKT cells recognize glycolipid antigens presented by the nonpolymorphic, nonclassical MHC class I-like molecule CD1d. Therefore, iNKT cells do not cause graft-versus-host disease (GvHD) when adoptively transferred to allogeneic recipients. The iNKT TCR contains an invariant alpha chain (Vα14-Jα18 in mice; Vα24-Jα18 in humans) and a select few beta chains (predominantly Vβ8 / Vβ7 / Vβ2 in mice; predominantly Vβ11 in humans). Both mouse and human iNKT cells respond to the synthetic agonist glycolipid ligand alpha-galactosylceramide (αGC, or α-GC, or α-GalCer).
[0166] Type 2 natural killer T (NKT) cells: Type 2 NKT cells are also CD1d restricted. Type 2 NKT cells have a more diverse TCR repertoire and their antigens are less well defined.
[0167] A feeder-free ex vivo differentiation culture method is demonstrated to generate genetically engineered T (TARGET) and natural killer (TANK) cells armed with off-the-shelf monoclonal TCRs with high purity and yield.
[0168] The production procedure involves 1) genetically modifying HSCs to express a selected monoclonal TCR gene, 2) ex vivo differentiation of the genetically modified HSCs into monoclonal TCR-armed T or NK cells without the use of feeder cells, and 3) in vitro / ex vivo expansion of the cells. Expansion methods also include TCR stimulation (e.g., with TCR cognate antigens or anti-CD3 / CD28 antigens). The cell culture methods and compositions described herein can be combined with HLA-I / II gene editing and HLA-E genetic engineering to produce HLA-I / II-negative, HLA-E-positive universal cells suitable for allogeneic adoptive transfer and therefore available as off-the-shelf cell products.
[0169] In addition to the antigen specificity provided by the monoclonal TCR, the cells can be further engineered to express additional targeting molecules to enhance their disease targeting capabilities. Such targeting molecules can be chimeric antigen receptors (CARs), other T cell receptors (TCRs), natural or synthetic receptors / ligands, or others. The resulting U CAR-cells, U TCR-cells, or U The X-cells can then be utilized for off-the-shelf disease-targeted cell therapy.
[0170] Functionally enhanced cells and derivatives can be obtained by further engineering the cells and their derivatives to overexpress genes encoding T cell costimulatory factors or to disrupt genes encoding T cell inhibitory factors.
[0171] HSCs can be isolated from umbilical cord blood or G-CSF-mobilized peripheral blood (CB HSCs or PBSCs), or can be derived from embryonic or induced pluripotent stem cells (ES-HSCs or iPS-HSCs), expressing human CD34 + Refers to hematopoietic progenitor and stem cells. The selected monoclonal TCR gene may encode a conventional αβ TCR (CD4 TCR or CD8 TCR), an invariant NKT (iNKT) TCR, a non-invariant NKT TCR, a MAIT TCR, a γδ TCR, or other TCR. I. Definition
[0172] The present disclosure encompasses, in some embodiments, "HSC-iNKT cells," which are invariant natural killer T (iNKT) cells engineered from hematopoietic stem cells (HSCs) and / or hematopoietic progenitor cells (HPCs), and methods of making and using these cells. As used herein, "HSCs" is used to refer to HSCs, HPCs, or both HSCs and HPCs.
[0173] The term "therapeutically effective amount," as used herein, refers to an amount that is effective to alleviate, ameliorate, or prevent at least one symptom or sign of the disease or condition being treated.
[0174] The term "exogenous TCR" refers to a TCR gene or TCR gene derivative that is transferred into a cell (i.e., by gene transfer / transduction / transfection techniques) or is the progeny of a cell that has received the TCR gene or gene derivative. The exogenous TCR gene is inserted into the genome of the recipient cell. In some embodiments, the insertion is random insertion. Random insertion of a TCR gene is readily achieved by methods known in the art. In some embodiments, the TCR gene is inserted into an endogenous locus (e.g., an endogenous TCR locus). In some embodiments, the cell comprises one or more TCR genes that have been inserted into a locus that is not an endogenous locus. In some embodiments, the cell further comprises a heterologous sequence, such as a marker or resistance gene.
[0175] The term "chimeric antigen receptor" or "CAR" refers to an engineered receptor that grafts any specificity onto immune effector cells. These receptors are used to graft the specificity of monoclonal antibodies onto T cells, and the transfer of their coding sequences is facilitated by retroviral or lentiviral vectors. These receptors are called chimeric because they are composed of parts from different sources. The most common form of these molecules is a fusion of a single-chain variable fragment (scFv) derived from a monoclonal antibody fused to the CD3-zeta transmembrane and endodomains; the CD28 or 41BB intracellular domains; or a combination thereof. Such molecules result in signal transduction in response to recognition of their target by the scFv. An example of such a construct is 14g2a-zeta, a fusion of an scFv derived from the hybridoma 14g2a (which recognizes the disialoganglioside GD2). When T cells express this molecule (as achieved, for example, by oncoretroviral vector transduction), they recognize and kill target cells (e.g., neuroblastoma cells) that express GD2. To target malignant B cells, researchers have redirected T cell specificity using chimeric immune receptors specific for the B cell lineage molecule CD19. The variable portions of immunoglobulin heavy and light chains are fused by a flexible linker to form scFvs. A signal peptide precedes this scFv, directing the nascent protein to the endoplasmic reticulum and subsequent surface expression (where it is cleaved). The flexible spacer allows the scFv to be oriented in various directions for antigen binding. The transmembrane domain is a typical hydrophobic alpha helix, usually derived from the original molecule's signaling domain, which protrudes into the cell and transmits the desired signal.
[0176] The term "antigen" refers to any substance that can cause the immune system to produce antibodies against it or to which T cells respond. In some embodiments, an antigen is a peptide that is 5-50 amino acids in length, or at least, at most, or exactly 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, or 300 amino acids, or any derivable range therein.
[0177] The term "allogeneic to the recipient" is intended to refer to cells that are not isolated from the recipient. In some embodiments, the cells are not isolated from the patient. In some embodiments, the cells are not isolated from a genetically compatible individual (e.g., a related person with a compatible genotype).
[0178] The term "inactive" refers to not producing undesired clinical toxicity. This clinical toxicity can be on-target or off-target. "Inactive" can be based on known or predicted clinical safety data.
[0179] The terms "xeno-free (XF)" or "animal component-free (ACF)" or "animal-free," when used with respect to a medium, extracellular matrix, or culture condition, refer to a medium, extracellular matrix, or culture condition that is essentially free of xenogeneic animal-derived components. When culturing human cells, any proteins from non-human animals, such as mice, become xenogeneic components. In certain embodiments, the xeno-free matrix can be essentially free of any non-human animal-derived components and thus can be free of mouse feeder cells and Matrigel™. Matrigel™ is a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins, including laminin (the major component), collagen IV, heparin sulfate proteoglycan, and entactin / nidogen.
[0180] The term "defined," when used with respect to a medium, extracellular matrix, or culture conditions, refers to a medium, extracellular matrix, or culture conditions in which the nature and amount of substantially all components are known.
[0181] "Chemically defined media" refers to media in which the chemical nature and amounts of nearly all components are known. These media are also called synthetic media. An example of a chemically defined medium is TeSR™.
[0182] As used herein, cells are substantially free of a particular reagent or element, e.g., serum, signal transduction inhibitors, animal components or feeder cells, exogenous genetic or vector elements, when the cells contain less than 10% of these elements, and are "essentially free" of a particular reagent or element when the cells contain less than 1% of these elements. However, even more desirable are cell populations in which less than 0.5% or less than 0.1% of the total cell population contains exogenous genetic or vector elements.
[0183] A culture, matrix, or medium is "essentially free" of certain reagents or elements, such as serum, signaling inhibitors, animal components, or feeder cells, if the culture, matrix, or medium has levels of these reagents below detectable levels using conventional detection methods known to those of skill in the art, or if these reagents were not added exogenously to the culture, matrix, or medium. Serum-free medium is essentially free of serum.
[0184] "Peripheral blood cells" refers to the cellular components of blood, including red blood cells, white blood cells, and platelets, found in the circulating pool of blood.
[0185] "Hematopoietic stem and progenitor cells" or "hematopoietic progenitor cells" refer to cells that are committed to the hematopoietic lineage but have the capacity for further hematopoietic differentiation, including hematopoietic stem cells, multipotent hematopoietic stem cells (blood cell progenitors), myeloid progenitor cells, megakaryocyte progenitor cells, erythroid progenitor cells, and lymphoid progenitor cells. "Hematopoietic stem cells (HSCs)" are multipotent stem cells that give rise to all blood cell types, including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells) and lymphoid lineages (T cells, B cells, NK cells). In this disclosure, HSCs refer to both "hematopoietic stem and progenitor cells" and "hematopoietic progenitor cells."
[0186] Hematopoietic stem and progenitor cells may or may not express CD34. Hematopoietic stem cells may co-express CD133 and may be negative for CD38, positive for CD90, negative for CD45RA, negative for lineage markers, or a combination of these. Hematopoietic progenitor / progenitor cells express CD34( + ) / CD38( + ) cells and CD34( + ) / CD45RA( + ) / lin( - )CD10 + (common lymphoid progenitor cells), CD34( + )CD45RA( + )lin( - )CD10(- )CD62L(hi) (lymphoid-predominant multipotent progenitor cells), CD34( + )CD45RA( + )lin( - )CD10( - )CD123 + (granulocyte-monocyte progenitor cells), CD34( + )CD45RA( - )lin( - )CD10( - )CD123 + (common myeloid progenitor cells), or CD34( + )CD45RA( - )lin( - )CD10( - )CD123 - (megakaryocytes - erythroid progenitor cells).
[0187] A "vector" or "construct" (sometimes called a gene delivery or gene transfer "vehicle") refers to a macromolecule, complex of molecules, or viral particle containing a polynucleotide to be delivered to a host cell either in vitro or in vivo. The polynucleotide may be a linear or circular molecule.
[0188] A common type of vector, a "plasmid," is an extrachromosomal DNA molecule that can replicate independently of chromosomal DNA. In certain cases, plasmids are circular and double-stranded.
[0189] "Expression construct" or "expression cassette" refers to a nucleic acid molecule capable of directing transcription. An expression construct includes at least a promoter or a structure functionally equivalent to a promoter. Additional elements, such as enhancers, and / or transcription termination signals, may also be included.
[0190] The term "exogenous," when used with reference to a protein, gene, nucleic acid, or polynucleotide within a cell or organism, refers to a protein, gene, nucleic acid, or polynucleotide that has been introduced into the cell or organism by artificial means, or, with reference to a cell, refers to a cell that has been isolated and then introduced into another cell or organism by artificial means. An exogenous nucleic acid can be from a different organism or cell, or can be one or more additional copies of a nucleic acid that is naturally present in the organism or cell. An exogenous cell can be from a different organism, or from the same organism. As a non-limiting example, an exogenous nucleic acid is in a different chromosomal location than that of the native cell, or is differently flanked by different nucleic acid sequences than those found in nature.
[0191] The term "corresponding to" is used herein to mean that a polynucleotide sequence is homologous (i.e., identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contrast, the term "complementary to" is used herein to mean that a complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For purposes of illustration, the nucleotide sequence "TATAC" corresponds to the reference sequence "TATAC" and is complementary to the reference sequence "GTATA."
[0192] A "gene," "polynucleotide," "coding region," "sequence," "segment," "fragment," or "transgene" "encoding" a particular protein is a nucleic acid molecule that, when placed under the control of appropriate regulatory sequences in vitro or in vivo, is transcribed and, if necessary, translated into a gene product, e.g., a polypeptide. The coding region may be present in either cDNA, genomic DNA, or RNA form. If present in DNA form, the nucleic acid molecule may be single-stranded (i.e., the sense strand) or double-stranded. The boundaries of a coding region are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A gene can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. A transcription termination sequence will typically be located 3' to the gene sequence.
[0193] The term "cell" is used herein in its broadest sense in the art and refers to a living organism that is a structural unit of tissue in a multicellular organism, is surrounded by a membrane structure that isolates it from the outside, has the ability to self-replicate, and contains genetic information and a mechanism for expressing it. As used herein, a cell may be a naturally occurring cell or an artificially modified cell (e.g., a fused cell, a genetically modified cell, etc.).
[0194] As used herein, the term "stem cell" refers to the cell that has the ability of self-renewal and pluripotency or multipotency. Typically, stem cell can regenerate injured tissue. Stem cell in this specification can be, but is not limited to, embryonic stem (ES) cell, induced pluripotent stem cell or tissue stem cell (also called tissue-specific stem cell or somatic stem cell).
[0195] Embryonic stem (ES) cells are pluripotent stem cells derived from early embryos. ES cells were first established in 1981, and have been used to produce knockout mice since 1989. Human ES cells were established in 1998, and are now becoming available for regenerative medicine.
[0196] Unlike ES cells, tissue stem cells have limited differentiation potential. They reside in specific locations within tissues and possess undifferentiated intracellular structures. Therefore, their pluripotency is usually low. Tissue stem cells have a higher nucleus / cytoplasm ratio and few intracellular organelles. Most tissue stem cells have low pluripotency, a long cell cycle, and the ability to proliferate beyond the lifespan of an individual. Based on the site from which they originate, tissue stem cells are divided into categories such as skin, digestive, bone marrow, nervous, and the like. Tissue stem cells in the skin system include epidermal stem cells, hair follicle stem cells, and the like. Tissue stem cells in the digestive system include pancreatic (common) stem cells, hepatic stem cells, and the like. Tissue stem cells in the bone marrow system include hematopoietic stem cells, mesenchymal stem cells, and the like. Tissue stem cells in the nervous system include neural stem cells, retinal stem cells, and the like.
[0197] "Induced pluripotent stem cells," commonly abbreviated as iPS cells or iPSCs, refer to a type of pluripotent stem cell that is artificially prepared from non-pluripotent cells, usually mature somatic cells, or terminally differentiated cells, such as fibroblasts, hematopoietic cells, muscle cells, neurons, epidermal cells, or the like, by introducing certain factors called reprogramming factors.
[0198] "Isolated," as used herein, for example with respect to cells and / or nucleic acids, means altered or removed by human intervention from the natural state.
[0199] "Pluripotent" refers to stem cells that have the ability to differentiate into any cell that makes up one or more tissues or organs, or in particular any of the three germ layers: endoderm (the lining of the stomach, the digestive tract, the lungs), mesoderm (muscle, bone, blood, urogenital tract), or ectoderm (epidermal tissue and the nervous system). As used herein, "pluripotent stem cells" refer to cells that can differentiate into cells derived from any of the three germ layers, e.g., the direct descendants of totipotent cells or induced pluripotent cells.
[0200] With respect to nucleic acid molecules, "operably linked" means that two or more nucleic acid molecules (e.g., a transcribed nucleic acid molecule, a promoter, and an enhancer element) are connected in a manner that allows for transcription of the nucleic acid molecule. With respect to peptide and / or polypeptide molecules, "operably linked" means that two or more peptide and / or polypeptide molecules are connected in a manner that results in a single polypeptide chain, i.e., a fusion polypeptide, having at least one property of each peptide and / or polypeptide component of the fusion. Fusion polypeptides are particularly chimeric, i.e., composed of heterologous molecules.
[0201] Embodiments of the present disclosure relate to HSC cells engineered to function as iNKT cells with NKT cell T cell receptors (TCRs), which also have imaging and suicide targeting capabilities and are resistant to targeted depletion of host immune cells. In some embodiments, such cells are generated in an artificial thymic organoid (ATO) in vitro culture system, which supports the differentiation of TCR-engineered HSCs into clonal T cells with high efficiency and high yield. In some embodiments, such cells are not generated in an ATO culture system. In some embodiments, such cells are generated using a culture system that does not contain feeder cells (i.e., is "feeder-free"). II. Genetic engineering of hematopoietic stem cells (HSCs) and invariant NKT cells ( U HSC-iNKT cells) Embodiments of the present disclosure utilize cells (e.g., HSCs) that are modified to function as invariant NKT cells, where the cells are engineered to have one or more characteristics that make the cells suitable for general use (use in individuals other than the individual from which the original cells were obtained) without an adverse immune response in the recipient of the cells. The present disclosure encompasses engineered invariant natural killer T (iNKT) cells that contain a nucleic acid comprising i) all or a portion of an iNKT alpha T-cell receptor gene, ii) all or a portion of an iNKT beta T-cell receptor gene, and iii) a suicide gene, where the genome of the cell has been altered to abolish surface expression of at least one HLA-I or HLA-II molecule. III. Detailed Description of Cell Culture Methods A. TARGET CELL CULTURE METHOD EMBODIMENTS 1. Step 1: Target cell differentiation
[0202] In some embodiments, fresh or frozen / thawed CD34 + HSCs are cultured in stem cell culture medium (basal medium supplemented with a cytokine cocktail including IL-3, IL-7, IL-6, SCF, EPO, TPO, FLT3L, and others) in retronectin-coated flasks for 12–72 hours, after which the TCR gene delivery vector is added and cultured for an additional 12–48 hours.
[0203] In some embodiments, the TCR gene-modified HSCs are then differentiated into TARGET cells in differentiation medium without feeders for 4-10 weeks. Non-tissue culture-treated plates are coated with TARGET culture coating (TARGETc) materials (DLL-1 / 4, VCAM-1 / 5, retronectin, and others). CD34 +HSCs were suspended in TARGET expansion (TARGETe) medium (basal medium containing serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, SCF, TPO, IL-3, IL-6, Flt3 ligand, human LDL, UM171, and additives), seeded into coated wells of a plate, and cultured for 3–7 days. The TARGETe medium was replaced with fresh medium every 3–4 days. The cells were then collected and suspended in TARGET maturation (TARGETm) medium (basal medium containing serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, SCF, TPO, IL-3, IL-6, IL-7, IL-15, Flt3 ligand, ascorbic acid, and additives). The TMM medium was replaced with fresh medium once or twice a week. 2. Phase 2: Target cell amplification
[0204] In some embodiments, differentiated TARGETS are stimulated with TCR cognate antigens (proteins, peptides, lipids, fluorophore-antigens, small molecules, and others) or non-specific TCR stimulating reagents (anti-CD3 / anti-CD28 antibodies or antibody-coated beads, concanavalin A, PMA / ionomycin, and others) and expanded in T cell culture medium for up to one month. Cultures can be supplemented with T cell-supportive cytokines (IL-2, IL-7, IL-15, and others). 3.TARGET cell derivative
[0205] In some embodiments, TARGET cells can be further engineered to express additional transgenes. In one embodiment, such transgenes encode disease-targeting molecules, such as chimeric antigen receptors (CARs), T cell receptors (TCRs), and other natural or synthetic receptors / ligands. In another embodiment, such transgenes can encode T cell regulatory proteins, such as IL-2, IL-7, IL-15, IFN-γ, TNF-α, CD28, 4-1BB, OX40, ICOS, FOXP3, and others. Transgenes can be introduced into TARGET cells or their progenitor cells (HSCs, newly differentiated TARGET cells, and expanding TARGET cells) at various culture stages after expansion.
[0206] In some embodiments, gene editing tools (CRISPR, TALEN, zinc finger, and others) can be used to further engineer TARGET cells to disrupt selected genes. In one embodiment, the disrupted genes encode T cell immune checkpoint inhibitors (PD-1, CTLA-4, TIM-3, LAG-3, and others). Deletion of these negative regulatory genes can enhance the ability of TARGET cells to fight disease, thereby making TARGET cells resistant to disease-induced anergy and tolerance.
[0207] In some embodiments, TARGET cells or enhanced TARGET cells can be further engineered to be suitable for allogeneic adoptive transfer, thereby making them suitable for use as off-the-shelf cell products. In one embodiment, genes encoding MHC molecules or MHC expression / presentation regulatory molecules (MHC molecules, B2M, CIITA (class II transcription activator-regulated induction of MHC class II mRNA expression), and others) are used. The lack of MHC molecule expression on TARGET cells renders them resistant to allogeneic host T cell-mediated depletion. In another embodiment, MHC class I-deficient TARGET cells are further engineered to overexpress HLA-E genes, which confers resistance to host NK cell-mediated depletion on these cells.
[0208] TARGET cells and derivatives can be used fresh or cryopreserved for further use. Additionally, various intermediate cell products generated during TARGET cell culture can be quiesced for cryopreservation, stored, and recovered for continuous production. 4. New Features and Benefits
[0209] Embodiments of the present disclosure provide an in vitro differentiation method that does not require xenogeneic feeder cells. This new method significantly improves the process for scale-up production and GMP-compliant manufacturing of therapeutic cells for human applications.
[0210] The cell product, TARGET cells, display a phenotype / functionality that is distinct from that of their natural counterparts, T cells, and also distinct from that of their counterparts, T cells, generated using other ex vivo culture methods (e.g., ATO culture methods), making the TARGET cells a unique cell product.
[0211] Unique features of TARGET cell differentiation culture include: 1) it is ex vivo and feeder-free; 2) it does not support TCR V / D / J recombination, and therefore there is no randomly rearranged endogenous TCR, and therefore no GvHD risk; 3) it supports differentiation synchronization of transgenic TARGET cells, thereby eliminating the presence of undifferentiated progenitor cells and other lineages of bystander immune cells; 4) as a result, the TARGET cell product contains a homogenous and pure population of monoclonal TCR-armed T cells, with no escaped random T cells, no other lineages of immune cells, and no undifferentiated progenitor cells; therefore, there is no need for a purification step; 5) high yield, approximately 10 12 TARGET cells (1,000–10,000 doses) can be generated from PBSCs of healthy donors, resulting in approximately 10 11 TARGET cells (100-1,000 doses) can be generated from CB HSCs of healthy donors. 6) Unique phenotype of TARGET cells - transgenic TCR + endogenous TCR - CD3 + (Note: These unique characteristics of TARGET cell differentiation culture make it distinct from other methods for generating off-the-shelf T cell products, including T cell cultures based on healthy donor PBMCs, ATO cultures, and others. See Figure 8.) 5. Exemplary Cell Culture Media
[0212] Examples of cell culture media that can be used to generate the engineered immune cells of the present disclosure are provided. a. Stem cell culture stage (D0~D2)
[0213] Basal medium: X-VIVO15 trademark (Lonza)
[0214] Supplements: hFlt3-L 50ng / ml, hSCF 50ng / ml, hTPO 50ng / ml, hIL-3 10ng / ml b. Lymphoid progenitor cell amplification stage (W1-W2)
[0215] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0216] Coating material: StemSpan™ Lymphoid Differentiation Coating Material (100X) (Stemcell Technologies). Contains: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml), and other supplements.
[0217] Supplement: StemSpan™ Lymphoid Progenitor Expansion Supplement (10X) (Stemcell Technologies). Contains: hFlt3L (20 ng / ml), hIL-7 (25 ng / ml), hMCP-4 (1 ng / ml), hTPO (5 ng / ml), hSCF (15 ng / ml), and other supplements. cT cell progenitor maturation stage (W3-W4)
[0218] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0219] Coating material: StemSpan™ Lymphoid Differentiation Coating Material (100X) (Stemcell Technologies). Contains: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml), and other supplements.
[0220] Supplement: StemSpan™ Lymphoid Progenitor Expansion Supplement (10X) (Stemcell Technologies). Contains: hFlt3L (20 ng / ml), hIL-7 (25 ng / ml), and other supplements. dT cell activation stage (W5)
[0221] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0222] Coating material: StemSpan™ Lymphoid Differentiation Coating Material (100X) (Stemcell Technologies). Contains: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml), and other supplements.
[0223] supplement:
[0224] 1) StemSpan™ Lymphoid Progenitor Expansion Supplement (10X) (Stemcell Technologies). Contains: hFlt3L (20 ng / ml), hIL-7 (20 ng / ml), hIL-15 (10 ng / ml), and other supplements.
[0225] 2) ImmunoCult™ Human CD3 / CD28 / CD2 T Cell Activator (Stemcell Technologies). Contains: ahCD3 Ab clone: OKT3 (1 μg / ml), ahCD28 Ab clone: CD28.2 (1 μg / ml), ahCD2 Ab clone: RPA-2.10 (1 μg / ml). eT cell expansion stage (W6)
[0226] Basal medium: T cell medium. Contains: X-vivo15 serum-free medium (Lonza, Allendale NJ), 5% (vol / vol) GemCell human serum antibody AB (Gemini Bio Products, West Sacramento CA), 1% (vol / vol) Glutamax-100X (Gibco Life Technologies), 10 mM HEPES buffer (Corning), 1% (vol / vol) penicillin / streptomycin (Corning), 12.25 mM N-acetyl-L-cysteine (Sigma).
[0227] Supplements: hIL7 (10 ng / ml), hIL15 (50 ng / ml)
[0228] Other essential ingredients: 100ng / ml α-galactosylceramide (KRN7000) (Avanti Polar Lipids, SKU#867000P-1mg), ahCD3 Ab clone: OKT3 (5ug / ml), ahCD28 Ab clone: CD28.2 (5ug / ml). B. TANK Cell Culture Method Embodiments 1. Stage 1: TANK cell differentiation
[0229] In some embodiments, fresh or frozen / thawed CD34 + HSCs are cultured in stem cell culture medium (basal medium supplemented with a cytokine cocktail, including IL-3, IL-7, IL-6, SCF, EPO, TPO, FLT3L, and others) in retronectin-coated flasks for 12-72 hours, after which the TCR gene delivery vector is added and cultured for an additional 12-48 hours.
[0230] In some embodiments, the TCR gene-modified HSCs are then differentiated into TANK cells in differentiation medium for 2-4 weeks without feeders. Non-tissue culture-treated plates are coated with TANK culture coating (TANKc) material (DLL-1 / 4, VCAM-1 / 5, retronectin, and others). CD34 +HSCs are suspended in TANK expansion (TANKe) medium (basal medium containing B27 supplement, ascorbic acid, Glutamax, human serum AB / albumin, Flt3 ligand, IL-6, IL-7, SCF, TPO, EPO, leukemia inhibitory factor, GM-CSF, and others), seeded into coated wells in a plate, and cultured for 7–10 days. The TANKe medium is replaced with fresh medium every 3–5 days. The cells are then collected and suspended in TANK maturation (TANKm) medium (basal medium containing B27 supplement, ascorbic acid, Glutamax, human serum AB / albumin, Flt3 ligand, IL-6, IL-7, IL-15, SCF, TPO, leukemia inhibitory factor, and others), and cultured for an additional 7–10 days. The TANKm medium is replaced with fresh medium every 3–5 days. 2. Stage 2: TANK cell expansion
[0231] In some embodiments, differentiated TANKs are stimulated with TCR cognate antigens (proteins, peptides, lipids, fluorophore-antigens, small molecules, and others) or nonspecific TCR stimulating reagents (anti-CD3 / anti-CD28 antibodies or antibody-coated beads, concanavalin A, PMA / ionomycin, and others) and expanded in T cell culture medium for up to one month. Cultures can be supplemented with T cell-supportive cytokines (IL-2, IL-7, IL-15, and others). 3.TANK cell derivative
[0232] In some embodiments, TANK cells can be further engineered to express additional transgenes. In one embodiment, such transgenes encode disease-targeting molecules, such as chimeric antigen receptors (CARs), T cell receptors (TCRs), and other natural or synthetic receptors / ligands. In another embodiment, such transgenes can encode T cell regulatory proteins, such as IL-2, IL-7, IL-15, IFN-γ, TNF-α, CD28, 4-1BB, OX40, ICOS, FOXP3, and others. Transgenes can be introduced into TANK cells or their progenitor cells (HSCs, newly differentiated TANK cells, and expanding TANK cells) at various culture stages after expansion.
[0233] In some embodiments, TANK cells can be further engineered to disrupt selected genes using gene editing tools (CRISPR, TALEN, zinc finger, and others). In one embodiment, the disrupted gene encodes a T cell immune checkpoint inhibitor (PD-1, CTLA-4, TIM-3, LAG-3, and others). Deletion of these negative regulatory genes can enhance the ability of TANK cells to fight disease, thereby rendering them resistant to disease-induced anergy and tolerance.
[0234] In some embodiments, TANK cells or expanded TANK cells can be further engineered to be suitable for allogeneic adoptive transfer, thereby making them suitable for use as off-the-shelf cell products. In one embodiment, genes encoding MHC molecules or MHC expression / presentation regulatory molecules (MHC molecules, B2M, CIITA (class II transcription activator-regulated induction of MHC class II mRNA expression), and others) are engineered. The lack of MHC molecule expression on TANK cells renders them resistant to allogeneic host T cell-mediated depletion. In another embodiment, MHC class I-deficient TANK cells are further engineered to overexpress HLA-E genes, which confers resistance to host NK cell-mediated depletion on these cells.
[0235] TANK cells and derivatives can be used fresh or cryopreserved for further use. Additionally, various intermediate cell products generated during TANK cell culture can be quiesced for cryopreservation, stored, and recovered for continuous production. 4. New Features and Benefits
[0236] This new method is suitable for processing for the scale-up and GMP-compliant manufacturing of therapeutic natural killer cells for human applications.
[0237] The cell product, TANK cells, represent a novel type of NK cell that follows a distinct developmental pathway and displays a distinct phenotype / functionality that is distinct from natural human NK cells expanded from peripheral blood or NK cells generated using other ex vivo culture methods (e.g., iPS cell-derived NK cells or CB-derived NK cells).
[0238] Unique features of the TANK cell culture method and ____ include: 1) Designer TANK cell differentiation culture medium that supports differentiation of TANK cells in 2-3 weeks (much faster than TARGET cell differentiation culture and ATO T cell differentiation culture). 2) It does not support TCR V / D / J recombination, and therefore lacks randomly rearranged endogenous TCRs and therefore no GvHD risk. 3) It supports differentiation synchronization of transgenic TANK cells, thereby eliminating the presence of undifferentiated progenitor cells and other lineages of immune cells. 4) As a result, the TANK cell product contains a homogenous and pure population of monoclonal TCR-armed T cells. There are no escaped random T cells, no other lineages of immune cells, and no undifferentiated progenitor cells. Therefore, there is no need for a purification step. 5) High yield, approximately 10 12 TANK cells (1,000–10,000 doses) can be generated from PBSCs of healthy donors, resulting in approximately 10 11TANK cells (100–1,000 doses) can be generated from CB HSCs of healthy donors. (Note: These unique characteristics of TANK cell differentiation culture make it distinct from those from other methods for generating NK cell products, including NK cell cultures based on PBMCs of healthy donors, CB-derived NK cell cultures, iPS-derived NK cell cultures, and others.) 5. Exemplary Cell Culture Media
[0239] Examples of cell culture media that can be used to generate the engineered immune cells of the present disclosure are provided. a. Stem cell culture stage (D0~D2)
[0240] Basal medium: X-VIVO15 trademark (Lonza)
[0241] Supplements: hFlt3-L 50ng / ml, hSCF 50ng / ml, hTPO 50ng / ml, hIL-3 10ng / ml b. Amplification stage (W1)
[0242] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0243] Coating materials: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml)
[0244] Supplements: 100 μM ascorbic acid, 5% human serum AB (Gemini CAT #800-120), 4% XenoFree B27 (ThermoFisher Scientific, #17504044), 1% Glutamax (ThermoFisher Scientific, #35050-061), hFlt3L (50 ng / ml), hIL-7 (50 ng / ml), hMCP-4 (1 ng / ml), hIL-6 (10 ng / ml), hTPO (50 ng / ml), hSCF (50 ng / ml), and other supplements. c. Mature stage (W2)
[0245] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0246] Coating materials: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml)
[0247] Supplements: 100 μM ascorbic acid, 5% human serum AB (Gemini CAT #800-120), 4% XenoFree B27 (ThermoFisher Scientific, #17504044), 1% Glutamax (ThermoFisher Scientific, #35050-061), hFlt3L (50 ng / ml), hIL-7 (50 ng / ml), hIL-15 (50 ng / ml), and other supplements. d. Activation stage (W3)
[0248] Base medium: StemSpan™ SFEM II (Stem Cell Technologies). Contains: Iscove's MDM, bovine serum albumin, recombinant human insulin, human transferrin (iron-saturated), 2-mercaptoethanol, and supplements.
[0249] Coating materials: hDLL4 (50 μg / ml), hVCAM1 (10 μg / ml)
[0250] Supplements: 100 μM ascorbic acid, 5% human serum AB (Gemini CAT #800-120), 4% XenoFree B27 (ThermoFisher Scientific, #17504044), 1% Glutamax (ThermoFisher Scientific, #35050-061), hFlt3L (50 ng / ml), hIL-7 (50 ng / ml), hIL-15 (50 ng / ml), and other supplements.
[0251] Antibody activators: ahCD3 Ab clone: OKT3 (1 ug / ml), ahCD28 Ab clone: CD28.2 (1 ug / ml), ahCD2 Ab clone: RPA-2.10 (1 ug / ml) e. Amplification step (W4)
[0252] Basal medium: T cell medium. Contains: X-vivo15 serum-free medium (Lonza, Allendale NJ), 5% (vol / vol) GemCell human serum antibody AB (Gemini Bio Products, West Sacramento CA), 1% (vol / vol) Glutamax-100X (Gibco Life Technologies), 10 mM HEPES buffer (Corning), 1% (vol / vol) penicillin / streptomycin (Corning), 12.25 mM N-acetyl-L-cysteine (Sigma).
[0253] Supplements: hIL7 (10 ng / ml), hIL15 (50 ng / ml)
[0254] Other essential ingredients: 100ng / ml α-galactosylceramide (KRN7000) (Avanti Polar Lipids, SKU#867000P-1mg), ahCD3 Ab clone: OKT3 (5ug / ml), ahCD28 Ab clone: CD28.2 (5ug / ml). IV.iNKT cells
[0255] In certain embodiments, the engineered iNKT cells of the present disclosure are produced from other types of cells to enhance their activity as iNKT cells. iNKT cells are a small subpopulation of αβ T lymphocytes that possess several characteristics that make them useful for off-the-shelf cell therapy, including at least making them useful for cancer treatment. Non-iNKT cells are engineered to function as iNKT cells because of the following advantages of iNKT cells:
[0256] 1) iNKT cells have the remarkable ability to target multiple types of cancers, independent of tumor antigen and MHC restriction (Fujii et al., 2013). iNKT cells recognize glycolipid antigens presented by non-polymorphic CD1d, which allows iNKT cells to escape MHC restriction. Although the natural ligands of iNKT cells have not yet been identified, it has been suggested that iNKT cells can recognize certain conserved glycolipid antigens derived from many tumor tissues. CD1d + Directly presented by tumor cells or CD1d - In the case of tumors, iNKT cells can be stimulated by recognizing these glycolipid antigens, which are indirectly cross-presented by tumor-infiltrating antigen-presenting cells (APCs), such as macrophages or dendritic cells (DCs). + Tumors and CD1d - Both tumors can respond.
[0257] 2) iNKT cells can attack tumor cells using multiple mechanisms (Vivi et al., 2012; Fujii et al., 2013). iNKT cells target CD1d receptors for cytotoxicity. +Although iNKT cells can directly kill tumor cells, their most potent antitumor activity is due to their immunoadjuvant effect. iNKT cells remain quiescent before stimulation but immediately produce large amounts of cytokines, primarily IFN-γ, after stimulation. IFN-γ activates NK cells to kill MHC-negative tumor target cells. Meanwhile, iNKT cells also activate DCs, which then stimulate CTLs to kill MHC-positive tumor target cells. Therefore, iNKT cell-induced antitumor immunity can effectively target multiple types of cancers, regardless of tumor antigen and MHC restriction, thereby effectively preventing tumor immune evasion and minimizing the chance of tumor recurrence.
[0258] 3) iNKT cells do not cause graft-versus-host disease (GvHD). Because iNKT cells do not recognize incompatible MHC molecules and protein self-antigens, these cells should not cause GvHD. This view is strongly supported by clinical data analyzing donor-derived iNKT cells in patients with hematologic cancers undergoing allogeneic bone marrow or peripheral blood stem cell transplants. These clinical data showed a positive correlation between the level of transplanted allogeneic iNKT cells in patients and the graft-versus-leukemia effect and a negative correlation with GvHD (Haraguchi et al., 2004; de Lalla et al., 2011).
[0259] 4) iNKT cells can be engineered to evade host-versus-graft (HvG) depletion. With the availability of powerful gene editing tools such as the CRISPR-Cas9 system, it is now possible to genetically modify iNKT cells to make them resistant to targeted depletion of host immune cells: knockout of the beta2-microglobulin (B2M) gene eliminates the expression of HLA-I molecules on iNKT cells, resulting in the loss of host CD8 + Knockout of the CIITA gene abolishes the expression of HLA-II molecules on iNKT cells, resulting in the escape of T cell-mediated killing, and inhibits CD4 +This avoids T cell-mediated killing. Both the B2M and CIITA genes are recognized good targets for the CRISPR-Cas9 system in human primary cells (Ren et al., 2017; Abrahimi et al., 2015). Eliminating HLA-I expression on iNKT cells allows them to be targeted by host NK cells. However, iNKT cells appear to be inherently resistant to killing by allogeneic NK cells. However, this concern can be addressed by delivering NK inhibitory genes, such as HLA-E, to iNKT cells, if necessary. Thus, embodiments of the present disclosure relate to cells lacking the B2M and / or CIITA genes.
[0260] 5) iNKT cells are strongly associated with cancer. Compelling evidence suggests a significant role for iNKT cells in tumor surveillance in mice, where iNKT cell deficiency predisposes mice to cancer and adoptive transfer or stimulation of iNKT cells can confer protection against cancer (Vivier et al., 2012; Berzins et al., 2011). In humans, iNKT cells are often reduced in patients with solid tumors (including melanoma, colon, lung, breast, and head and neck cancer) and hematologic cancers (including leukemia, multiple myeloma, and myelodysplastic syndromes), whereas increased iNKT cell numbers are associated with a better prognosis (Berzins et al., 2011). Although administration of α-GalCer-loaded DCs and ex vivo-expanded allogeneic iNKT cells has shown promising clinical benefit in some patients with lung and head and neck cancer, the increase in iNKT cells was transient and the clinical benefit was short-lived, likely due to the limited number of iNKT cells used for transfer and their subsequent depletion (Fujii et al., 2012; Yamasaki et al., 2011). It seems reasonable to propose, therefore, that an "off-the-shelf" iNKT cell product that allows for the transfer of sufficient iNKT cells in multiple doses may provide patients with the best opportunity to fully realize the potential of iNKT cells to combat their disease.
[0261] However, the development of allogeneic off-the-shelf iNKT cell products is significantly hindered by their availability. These cells are extremely rare and highly variable in humans (approximately 0.001–1% in human blood), making it extremely difficult to grow therapeutic numbers of iNKT cells from allogeneic human donor blood cells. Therefore, novel methods that can reliably generate large, homogenous populations of iNKT cells are essential for the development of off-the-shelf iNKT cell therapies.
[0262] In light of this shortage of iNKT cells in sufficient quantities for clinical application, embodiments of the present disclosure encompass engineering non-iNKT cells such that the resulting engineered cells function as iNKT cells. In certain embodiments, the cells that function as iNKT cells are further modified to have one or more desired properties. In certain embodiments, the non-iNKT cells are genetically modified to express an iNKT T cell receptor (TCR) by transduction of the non-iNKT cells.
[0263] In embodiments of the present disclosure, iNKT cells produced from other types of cells are engineered to have one or more properties that make them suitable for general use. In certain embodiments, the cells are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. In some embodiments, the cells are hematopoietic stem cells. In some embodiments, the cells are hematopoietic progenitor cells. In some embodiments, the cells are human cells. In some embodiments, the cells are CD34 + In some embodiments, the cells are human CD34 + In some embodiments, the cell is a recombinant cell. In some embodiments, the cell is in culture.
[0264] In some embodiments, the iNKT TCR nucleic acid molecule is from human invariant natural killer T cells. In some embodiments, the iNKT TCR nucleic acid molecule comprises one or more nucleic acid sequences obtained from a human iNKT TCR. In some embodiments, the iNKT TCR nucleic acid sequence can be obtained from any subset of iNKT cells, such as the CD4 / DN / CD8 subset, or a subset that produces Th1, Th2 or Th17 cytokines and includes double-negative iNKT cells. In some embodiments, the iNKT TCR nucleic acid sequence is obtained from iNKT cells from donors who had or have cancer, such as melanoma, renal cancer, lung cancer, prostate cancer, breast cancer, lymphoma, leukemia, hematological malignancies and the like. In some embodiments, the iNKT TCR nucleic acid molecule has a TCR-alpha sequence from one iNKT cell and a TCR-beta sequence from a different iNKT cell. In some embodiments, the iNKT cell from which the TCR-alpha sequence is obtained and the iNKT cell from which the TCR-beta sequence is obtained are from the same donor. In some embodiments, the donor of the iNKT cell from which the TCR-alpha sequence is obtained is different from the donor of the iNKT cell from which the TCR-beta sequence is obtained. In some embodiments, the TCR alpha sequence and / or the TCR-beta sequence is codon-optimized for expression. In some embodiments, the TCR-alpha sequence and / or the TCR-beta sequence is modified to encode a polypeptide having one or more amino acid substitutions, deletions and / or truncations compared to the polypeptide encoded by the unmodified sequence. In some embodiments, the iNKT TCR nucleic acid molecule encodes a T cell receptor that recognizes alpha-galactosylceramide (alpha-GalCer) presented on CD1d. In some embodiments, the iNKT TCR nucleic acid molecule comprises one or more sequences selected from the group consisting of: gtgggcgatagaggttcagccttagggaggctgcattttggagctgggactcagctgattgtcatacctgacatc (SEQ ID NO: 1); gccagcggtgatgctcggggggggggaaataccctctattttggaaaaggaagccggctcattgttgtagaggat (SEQ ID NO: 2); gccagcggggggacagtccattctggaaatacgctctattttggagaaggaagccggctcattgttgtagaggat (SEQ ID NO: 3); gccagcggtgatacgggacaaacaaacacagaagtcttctttggtaaaggaaccagactcacagttgtagaggat (SEQ ID NO: 4); gccagcggtgaggggacagcaaacacagaagtcttctttggtaaaggaaccagactcacagttgtagaggat (SEQ ID NO: 5); gccagcggtgaggcagggaacacagaagtcttctttggtaaaggaaccagactcacagttgtagaggat (SEQ ID NO: 6); gtgagcgacagaggctcaaccctggggaggctatactttggaagaggaactcagttgactgtctggcctgatatccag (SEQ ID NO: 7); agcagtgacctccgaggacagaacacagatacgcagtattttggcccaggcacccggctgacagtgctcgaggac (SEQ ID NO: 第八); agcagtgaattaaaggaaacaggggttcaagagacccagtacttcgggccaggcacgcggctcctggtgctcgaggac (SEQ ID NO: 9); agcagtgtatctcagggcggcactgaagctttctttggacaaggcaccagactcacagttgtagaggac (SEQ ID NO: 10); agcagtgtatctcagggcggcactgaagctttctttggacaaggcaccagactcacagttgtagaggac (SEQ ID NO: 11); agcagtgaccggacaggcgtgaacactgaagctttctttggacaaggcaccagactcacagttgtagaggac (SEQ ID NO: 12); It should be noted that there is an error in the original text where "配列番号8" is not in a standard format. It is assumed that it should be "SEQ ID NO: 8" in English translation. Also, the "第八" in the translation of "配列番号8" is a placeholder for the correct English translation which should be "SEQ ID NO: 8". Please check and correct the original text for a more accurate translation.agcagtgaaccggacagggggggggctgaagctttctttggacaaggcaccagactcacagttgtagaggac (SEQ ID NO: 13); atgaaaaagcatctgacgaccttcttggtgattttgtggctttatttttatagggggaatggcaaaaaccaagtggagcagagtcctcagtccctgatcatcctggagggaaagaactgcactcttcaatgcaattatacagtgagccccttcagcaacttaaggtggtataagcaagatactgggagaggtcctgtttccctgacaatcatgactttcagtgagaacacaaagtcgaacggaagatatacagcaactctggatgcagacacaaagcaaagctctctgcacatcacagcctcccagctcagcgattcagcctcctacatctgtgtggtgagcgacagaggctcaaccctggggaggctatactttggaagaggaactcagttgactgtctggcctgatatccagaaccctgaccctgccgtgtaccagctgagagactctaaatccagtgacaagtctgtctgcctattcaccgattttgattctcaaacaaatgtgtcacaaagtaaggattctgatgtgtatatcacagacaaaactgtgctagacatgaggtctatggacttcaagagcaacagtgctgtggcctggagcaacaaatctgactttgcatgtgcaaacgccttcaacaacagcattattccagaagacaccttcttccccagcccagaaagttcctgtgatgtcaagctggtcgagaaaagctttgaaacagatacgaacctaaactttcaaaacctgtcagtgattgggttccgaatcctcctcctgaaagtggccgggtttaatctgctcatgacgctgcggctgtggtccagctga (SEQ ID NO: 14);atgaaaaagcatctgacaacattcctggtcattctgtggctgtacttctaccgaggcaacggcaaaaatcaggtggagcagtccccacagtccctgatcattctggaggggaagaactgcactctgcagtgtaattacaccgtgtctccctttagtaacctgcgctggtataaacaggacaccggacgaggacccgtgagcctgacaatcatgactttctcagagaacacaaagagcaatggacggtacaccgctacactggacgcagataccaaacagagctccctgcacatcacagcatctcagctgtcagatagcgcctcctacatttgcgtggtctctgaccgagggagtaccctgggccgactgtattttggaagggggacccagctgacagtgtggcccgacatccagaacccagatcccgccgtctaccagctgcgcgacagcaagtctagtgataaaagcgtgtgcctgttcacagactttgattctcagactaatgtctctcagagtaaggacagtgacgtgtacattactgacaaaaccgtcctggatatgaggagcatggacttcaagtcaaacagcgccgtggcttggtcaaacaagagcgacttcgcatgcgccaatgcttttaacaattcaatcattccagaggataccttctttcctagcccagaatcaagctgtgacgtgaagctggtcgagaaaagtttcgaaactgataccaacctgaattttcagaacctgtctgtgatcggcttcagaatcctgctgctgaaggtcgccggctttaatctgctgatgacactgagactgtggtcctcttga(SEQ ID NO: 15);atgactatcaggctcctctgctacatgggctttttctgggggcaggcctcatggaagctgacatctaccagaccccaagataccttgttatagggacaggaaagaagatcactctggaatgttctcaaaccatgggccatgacaaaaatgtactggtatcaacaagatccaggaatggaactacacctcatccactattcctatggagttaattccacagagaagggagatctttcctctgagtcaacagtctccagaataaggacggagcatttcccctgaccctggagtctgccaggccctcacatacactactctacctcagtactctgtgccagc (sequence number 16), atgaccatccggctgctgtgctacatggcttcttttctggggcaggcctgatggaagccgacatctaccagactccagatacctggtcatcggaaccggagaaaattacactggagtgtcccag acaatgggccacgataagatgtactggtatcagcaggacctgggatggaactgcacctgatccattactcctatggcgtgaactctaccgagaagggcgacctgagcagcgaatccaccgtctctcgaattaggacagagcactttcctctgactctggaaagcgcccgaccaagtcatacatcagtacctgtgcgctagc(sequence number 17);gtagcggttgggccccaagacccagtacttcgggccaggcacgcggctcctggtgctc(sequence number 18);gtggcagtcggacctcaggagacccagtacttcggacccggcaccgcctgctggtgctg(sequence number 19);agtgggccagggtacgagcagtacttcgggccgggacaggctcacggtcaca(sequence number 20);tcaggacccggctcagcagtattcggccccggaactcggctgaccgtgacc(sequence number 21);agtccccaattaaacactgaagctttctttggacaaggcaccagactcacagttgta (SEQ ID NO: 22); tctccacagctgaacaccgaggccttcttcgggcagggcacaaggcttaccgtggtg (SEQ ID NO: 23); agtgaattgcgggcgctcgggcccagctcctataattcacccctccactttgggaacgggaccaggctcactgtgaca (SEQ ID NO: 24); tccgaactccgagccctggggcctagct cctacaatagccccctgcactttggcaacggaaccaggctgacggtcacc (SEQ ID NO: 25); agtgaacaggggactactgcgggagctttctttggacaaggcaccagactcacagttgta (SEQ ID NO: 26);tccgaacagggaaccacagcaggagccttcttcggtcagggaacaagactgacagtcgtg (SEQ ID NO: 27);agtgagtcacgacatgcgacaggaaacaccatatattttggagagggaagt tggctcactgttgta (SEQ ID NO: 28); agcgagagcaggcacgcaaccgggaacaccatatactttggcgagggctcctggctgactgtggtg (SEQ ID NO: 29); agtgtacccgggaacgacaggggcaatgaaaaactgttttttggcagtggaacccagctctctgtcttg (SEQ ID NO: 30), tccgtgcctggcaacgatagaggtaacgagaagctgtttttcggatccggcacacagctgtctgtcctg ( SEQ ID NO: 31);agtgaaggggggggccttaagctagccaaaaacattcagtacttcggcgccgggacccggctctcagtgctg (SEQ ID NO: 32);agtgagggagggggactgaagctggctaagaatattcagtacttcggcgccggcactagactgtctgtgctg (SEQ ID NO: 33);agtgaattcgcctcttcggtacgtggaaacaccatatattttggagagggaagttggctcactgttgta (SEQ ID NO: 34);tctgagttcgcgagcagcgtccggggtaataccatttacttcggggaaggcagctggctgaccgtggtg (SEQ ID NO: 35); agtgcggcattaggccgggagacccagtacttcgggccaggcacgcggctcctggtgctc (SEQ ID NO: 36); tctgcagcccttggccgagagactcagtacttcggccctggcacaagactgctcgtgctc (SEQ ID NO: 37); agtgcctccgggggtgaatcctacgagcagtacttcgggccgggcaccaggctcacggtcaca (SEQ ID NO: 38); agcgcctccggaggagagtcatacgaacagtatttcggccctggcacacgcctcactgtgacc (SEQ ID NO: 39) 39);agcggtcgggtctcggggggcgattccctcatagcgtttctaggccaagagacccagtacttcgggccaggcacgcggctcctggtgctc (SEQ ID NO: 40);tcaggacgagtgtccggaggggatagcctcatcgcatttctggggcaggaaactcagtacttcggacccggaaca cgcctcctggtgctg (SEQ ID NO: 41);agtgtacccgggaacgacaggggcaatgaaaaactgttttttggcagtggaacccagctctctgt cttg (SEQ ID NO: 42);tccgtgcctggcaacgatagaggtaacgagaagctgtttttcggatccggcacacagctgtctgtcctgSEQ ID NO: 43);gaggacctgaacaaggtgttcccacccgaggtcgctgtgtttgagccatcagaagcagagatctcccacacccaaaaggccacactggtgtgcctggccacaggcttcttccctgaccacgtggagctgagctggtgggtgaatgggaaggaggtgcacagtggggtcagcacggacccgcagcccctcaaggagcagcccgccctcaatgactccagatactgcctgagcagccgcctgagggtctcggccaccttctggcagaacccccgcaaccacttccgctgccaagtccagttctacgggctctcggagaatgacgagtggacccaggatagggccaaacccgtcacccagatcgtcagcgccgaggcctggggtagagcagactgtggctttacctcggtgtcctaccagcaaggggtcctgtctgccaccatcctctatgagatcctgctagggaaggccaccctgtatgctgtgctggtcagcgcccttgtgttgatggccatggtcaagagaaaggatttctga (SEQ ID NO: 44);and (SEQ ID NO: 45);
[0265] In some embodiments, the iNKT TCR nucleic acid molecule encodes a polypeptide comprising an amino acid sequence selected from the group consisting of: MKKHLTTFLVILWLYFYRGNGKNQVEQSPQSLIILEGKNCTLQCNYTVSPFSNLRWYKQDTGRGPVSLTIMTFSENTKSNGRYTATLDADTKQSSLHITASQLSDSASYICVVSDRGSTLGRLYF GRGTQLTVWPDIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNL SVIGFRILLLKVAGFNLLMTLRLWSS (SEQ ID NO: 46);MTIRLLCYMGFYFLGAGLMEADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSYGVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCAS (SEQ ID NO: 47);VAVGPQETQYFGPGTRLLVL (SEQ ID NO: 48);SGPGYEQYFGPGTRLTVT (SEQ ID NO: 49);SPQLNTEAFFGQGTRLTVV (SEQ ID NO: 50);SELRALGPSS YNSPLHFGNGTRLTVT (SEQ ID NO: 51); SEQGTTAGAFFGQGTRLTVV (SEQ ID NO: 52); SESRHATGNTIYFGEGSWLTVV (SEQ ID NO: 53); SVPGNDRGNEKLFFGSGTQLSVL (SEQ ID NO: 54); SEGGGLKLAKNIQYFGAGTRLSVL (SEQ ID NO: 55); SEFASSVRGNTIYFGEGSWLTVV (SEQ ID NO: 56); SAALGRETQYFGPGTRLLVL (SEQ ID NO: 57); SASGGESYEQYFGPGTRLTVT (SEQ ID NO: 58); SGRVSGGDS LIAFLGQETQYFGPGTRLLVL (SEQ ID NO: 59); SVPGNDRGNEKLFFGSGTQLSVL (SEQ ID NO: 60); and EDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF (SEQ ID NO: 61).In some embodiments, the engineered cells lack exogenous oncogenes such as Oct4, Sox2, Klf, c-Myc, and the like.
[0266] In some embodiments, the engineered cells are functional iNKT cells. In some embodiments, the engineered cells are capable of producing one or more cytokines and / or chemokines, such as IFN-gamma, TNF-alpha, TGF-beta, GM-CSF, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-15, IL-17, IL-21, RANTES, eotaxin, MIP-1-alpha, MIP-1-beta, and the like. In some embodiments, the engineered cells are capable of producing IL-15.
[0267] Donor HSPCs can be obtained from the donor's bone marrow, peripheral blood, amniotic fluid, or umbilical cord blood. The donor can be an autologous donor, i.e., the subject to be treated with HSPC-iNKT cells, or an allogeneic donor, i.e., a donor different from the subject to be treated with HSPC-iNKT cells. In some embodiments where the donor is an allogeneic donor, the tissue (HLA) type of the allogeneic donor is preferably compatible with that of the subject to be treated with HSPC-iNKT cells derived from donor HSPCs.
[0268] According to the present disclosure, HSPCs are transduced with one or more exogenous iNKT TCR nucleic acid molecules. As used herein, "iNKT TCR nucleic acid molecule" includes a nucleic acid molecule encoding the alpha chain of the iNKT T cell receptor (TCR-alpha), the beta chain of the iNKT T cell receptor (TCR-beta), or both. As used herein, "iNKT T cell receptor" refers to a receptor expressed by iNKT cells that recognizes alpha-GalCer presented on CD1d. Using methods in the art, the TCR-alpha and TCR-beta sequences of iNKT TCRs can be cloned and / or recombinantly engineered. For example, iNKT cells can be obtained from a donor, and the TCR-alpha and TCR-beta genes of the iNKT cells can be cloned, as described herein. The cloned iNKT TCR can be obtained from any mammal, including humans, non-human primates, such as monkeys, mice, rats, hamsters, guinea pigs and other rodents, rabbits, cats, dogs, horses, cows, sheep, goats, pigs, and the like. In some embodiments, the cloned iNKT TCR is a human iNKT TCR. In some embodiments, the iNKT TCR clone comprises a human iNKT TCR sequence and a non-human iNKT TCR sequence.
[0269] In some embodiments, the cloned TCR can have a TCR-alpha chain from one iNKT cell and a TCR-beta chain from a different iNKT cell. In some embodiments, the iNKT cell from which the TCR-alpha chain is obtained and the iNKT cell from which the TCR-beta chain is obtained are from the same donor. In some embodiments, the donor of the iNKT cell from which the TCR-alpha chain is obtained is different from the donor of the iNKT cell from which the TCR-beta chain is obtained. In some embodiments, the sequence encoding the TCR-alpha chain and / or the sequence encoding the TCR-beta chain of the TCR clone is modified. In some embodiments, the modified sequence may encode the same polypeptide sequence as the unmodified TCR clone, e.g., the sequence is codon-optimized for expression. In some embodiments, the modified sequence may encode a polypeptide having a sequence different from that of the unmodified TCR clone, e.g., the modified sequence encodes a polypeptide sequence with one or more amino acid substitutions, deletions, and / or truncations.
[0270] In certain embodiments, iNKT cells produced from HSPC cells are further modified to have one or more characteristics, including making the cells suitable for allogeneic use or more suitable for allogeneic use than if the cells had not been further modified to have one or more characteristics. The present disclosure optionally encompasses iNKT cells that are suitable for allogeneic use. In some embodiments, the iNKT cells are non-alloreactive and express an exogenous iNTK TCR. These cells are useful for "off-the-shelf" cell therapy, avoiding the need for the use of a patient's own iNKT cells or other cells. Thus, this method provides a more cost-effective and less labor-intensive cellular immunotherapy.
[0271] In some embodiments, iNKT cells are engineered to be HLA-negative to achieve safe and successful allogeneic engraftment without causing graft-versus-host disease (GvHD) and without being rejected by host immune cells (HvG rejection). In certain embodiments, allogeneic HSC-iNKT cells do not express endogenous TCRs and do not cause GvHD because expression of the transgenic iNKT TCR gene prevents recombination of endogenous TCRs by allelic exclusion. In certain embodiments, allogeneic iNKT cells do not express HLA-I and / or HLA-II molecules on their cell surface and do not express host CD8 + and CD4 + Resistant to T cell-mediated allograft depletion and depletion targeted to the sr39TK immunogen.
[0272] Thus, in certain embodiments, the engineered iNKT cells express no surface HLA-I or HLA-II molecules, which is achieved by disruption of genes encoding proteins associated with HLA-I / II expression, including, but not limited to, beta-2-microglobulin (B2M), major histocompatibility complex II transactivator (CIITA), or HLA-I / II molecules. In some implementations, the iNKT cells have been engineered by gene editing, with or without CRISPR-Cas9, such that HLA-I or HLA-II is not expressed on the surface of the iNKT cells.
[0273] When iNKT cells are modified to exhibit any type of one or more characteristics, they may contain nucleic acid from a recombinant vector introduced into them. The vector may be a non-viral vector, such as a plasmid, or may be a viral vector, such as a lentivirus, retrovirus, adeno-associated virus (AAV), herpes virus, or adenovirus.
[0274] The iNKT cells of the present disclosure may or may not have been exposed to one or more specific conditions before, during, or after their production. In certain cases, the cells are not or have not been exposed to a medium containing animal serum. The cells may be frozen. The cells may be present in a solution containing dextrose, one or more electrolytes, albumin, dextran, and / or DMSO. Any solution in which the cells are present may be sterile, non-purulent, and isotonic. The cells may be activated and expanded by any method, such as by activation with alpha-galactosylceramide (α-GC).
[0275] Aspects of the present disclosure relate to engineered iNKT cells. In some embodiments, the cells comprise a genomic mutation. In some embodiments, the genomic mutation comprises a mutation in one or more endogenous genes in the genome of the cell, where the one or more endogenous genes comprise B2M, CIITA, TRAC, TRBC1, or TRBC2 genes. In some embodiments, the mutation is a loss-of-function mutation. In some embodiments, the inhibitor is an expression inhibitor. In some embodiments, the inhibitor comprises an inhibitory nucleic acid. In some embodiments, the inhibitory nucleic acid comprises one or more of an siRNA, shRNA, miRNA, or antisense molecule. In some embodiments, the cells comprise an activity inhibitor. In some embodiments, after modification, the cells lack detectable expression of one or more of B2M, CIITA, TRAC, TRBC1, or TRBC2 proteins. In some embodiments, the cells comprise an inhibitor or genomic mutation of B2M. In some embodiments, the cells comprise an inhibitor or genomic mutation of CIITA. In some embodiments, the cells comprise an inhibitor or genomic mutation of TRAC. In some embodiments, the cells comprise an inhibitor or genomic mutation of TRBC1. In some embodiments, the cells contain an inhibitor or genomic mutation of TRBC2. In some embodiments, at least 90% of the genomic DNA encoding B2M, CIITA, TRAC, TRBC1, and / or TRBC2 is deleted. In some embodiments, at least or at most 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99, or 100% (or any range derivable therein) of the genomic DNA encoding B2M, CIITA, TRAC, TRBC1, and / or TRBC2 is deleted. In other embodiments, deletions, insertions, and / or substitutions are made in the genomic DNA. In some embodiments, the cells are descendants of human stem or progenitor cells.
[0276] iNKT cells to be modified to be HLA-negative can be genetically modified by any suitable method. The genetic mutations of the present disclosure, such as those in the CIITA and / or B2M genes, can be introduced by methods known in the art. In certain embodiments, engineered nucleases can be used to introduce endogenous nucleic acid sequences for genetic modification of any cell mentioned herein. Genome editing, or genome editing with engineered nucleases (GEEN), is a type of genetic engineering in which DNA is inserted, replaced, or removed from the genome using artificially engineered nucleases, or "molecular scissors." The nucleases create specific double-strand breaks (DSBs) at desired locations in the genome, and the cells' endogenous mechanisms are used to repair the induced breaks through the natural processes of homologous recombination (HR) and non-homologous end joining (NHEJ). Non-limiting examples of engineered nucleases include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR / Cas9 systems, and engineered meganucleases that re-engineer homing endonucleases. Any of the engineered nucleases known in the art can be used in certain embodiments of the methods and compositions.
[0277] Engineered iNKT cells can be modified using methods that utilize RNA interference. Genetic analysis typically involves interfering with a gene or protein in a sequence-specific manner and monitoring its effects on the organism to understand its function. However, in some organisms, site-specific mutagenesis is difficult or impossible, making it necessary to use more indirect methods, such as silencing the gene of interest with small RNA interference (siRNA). However, gene disruption by siRNA can be variable and incomplete. Genome editing with nucleases such as ZFNs differs from siRNA in that engineered nucleases can alter DNA binding specificity and, therefore, can in principle cleave any target location within the genome, introducing modifications to the endogenous sequence of genes that cannot be specifically targeted by conventional RNAi. Furthermore, the specificity of ZFNs and TALENs is enhanced because two ZFNs are required to recognize the target's location and then direct it to the adjacent sequence.
[0278] Meganucleases can be used to modify engineered iNKT cells. Meganucleases commonly found in microbial species have the unique property of having very long recognition sequences (>14 bp), which inevitably makes them highly specific. This can be exploited to create site-specific DSBs in genome editing, but a challenge is that not enough meganucleases are known to address all possible target sequences, and it may never become known. To overcome this challenge, mutagenesis and high-throughput screening methods have been used to create meganuclease variants that recognize unique sequences. Others have fused various meganucleases to create hybrid enzymes that recognize new sequences. Still others have attempted to alter the DNA-interacting amino acids of meganucleases to engineer sequence-specific meganucleases, a method called rationally designed meganucleases (U.S. Patent No. 8,021,867, incorporated herein by reference). Meganucleases have the advantage of being less toxic to cells compared to methods such as ZFNs, presumably due to their more stringent DNA sequence recognition, but constructing sequence-specific enzymes for all possible sequences is expensive and time-consuming, unless one is able to benefit from the combinatorial possibilities available with methods such as ZFNs and TALENs.
[0279] In contrast to meganucleases, the concept behind ZFNs and TALENs is based more on nonspecific DNA-cleaving enzymes, which are then linked to specific DNA sequence-recognition peptides, such as zinc fingers and transcription activator-like effectors (TALEs). One approach was to find an endonuclease in which the DNA recognition site and cleavage site are distant from each other, a situation rarely seen among restriction enzymes. Once this enzyme was discovered, its cleavage portion, which lacks recognition ability and is therefore highly nonspecific, could be isolated. This portion could then be linked to a sequence-recognition peptide that can provide extremely high specificity. An example of a restriction enzyme with such properties is FokI. In addition, FokI has the advantage that it requires dimerization to have nuclease activity, which means that specificity is dramatically increased because each nuclease partner recognizes a unique DNA sequence. To enhance this effect, FokI nucleases were designed that can function exclusively as heterodimers and have enhanced catalytic activity. Nucleases functioning as heterodimers avoid the potential for unwanted homodimeric activity, thus increasing DSB specificity.
[0280] Although the nuclease moieties of both ZFNs and TALENs have similar properties, differences exist between these engineered nucleases in their DNA recognition peptides. ZFNs rely on Cys2-His2 zinc fingers, while TALENs rely on TALEs. Both of these DNA recognition peptide domains share the property that they are naturally found in combinations within their proteins. Cys2-His2 zinc fingers typically occur in repeats spaced 3 bp apart and are found in diverse combinations within various nucleic acid-interacting proteins, such as transcription factors. TALEs, on the other hand, are found in repeats with a one-to-one recognition ratio between amino acids and recognized nucleotide pairs. Because both zinc fingers and TALEs occur in a repetitive pattern, various combinations can be experimented with to generate a wide variety of sequence specificities. Zinc fingers are more established in these respects, as well as in techniques such as modular assembly (zinc fingers correlating with triplet sequences are joined in a line to cover the required sequence), OPEN (low stringency selection of peptide domains against triplet nucleotides in a bacterial system followed by high stringency selection of peptide combinations against the final target), and bacterial one-hybrid screening of zinc finger libraries, among others, which have been used to generate site-specific nucleases.
[0281] Therefore, embodiments of the present disclosure may or may not include targeting of one or more specific endogenous sequences to reduce or knock out the expression of the endogenous sequences.In certain embodiments, the disruption of one or more of the following genes can prevent the rearrangement of endogenous TCR.For example, to generate guide RNA or siRNA, the following sequences are provided as examples for targeting the aforementioned genes:
[0282] B-2 microglobulin (B2M) (also known as IMD43) is located at 15q21.1 and has the following mRNA sequence: [ka]
[0283] The human class II major histocompatibility complex transactivator (CIITA) gene is located at 16q13.13 and has the following mRNA sequence: [ka] [ka]
[0284] The human T cell receptor alpha chain (TRAC) mRNA sequence is as follows: [ka]
[0285] The human T cell receptor beta chain (TRBC1) mRNA sequence is as follows: [ka]
[0286] The human TRBC2 T-cell receptor beta constant 2 (TCRB2) sequence is as follows: [ka]
[0287] In certain embodiments, inhibitory nucleic acids or any method known in the art for inhibiting gene expression of CIITA and / or B2M are contemplated. Examples of inhibitory nucleic acids include, but are not limited to, siRNA (small interfering RNA), short hairpin RNA (shRNA), double-stranded RNA, antisense oligonucleotides, ribozymes, and nucleic acids encoding same. Inhibitory nucleic acids can inhibit gene transcription or prevent translation of gene transcripts in cells. Inhibitory nucleic acids can be 16 to 1000 nucleotides in length, and in certain embodiments, 18 to 100 nucleotides in length. Nucleic acid can have at least or at most 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,40,50,60,70,80,90 or any range of nucleotides that can be derived from these numbers.The siRNA that naturally exists in living animals is not "isolated", but synthetic siRNA or siRNA that is partially or completely separated from the coexisting materials in its natural state is "isolated".Isolated siRNA can exist in substantially purified form or can exist in non-natural environment, for example, the cell that siRNA is delivered to.
[0288] Inhibitory nucleic acid is well known in the art.For example, siRNA and double-stranded RNA are described in United States Patent (USP) No. 6,506,559 and United States Patent (USP) No. 6,573,099, and United States Patent Application Publication No. 2003 / 0051263, No. 2003 / 0055020, No. 2004 / 0265839, No. 2002 / 0168707, No. 2003 / 0159161 and No. 2004 / 0064842, and all of these references are incorporated herein by reference in their entirety.
[0289] In particular, the inhibitory nucleic acid may be capable of reducing protein or mRNA expression by at least 10%, 20%, 30% or 40%, more particularly by at least 50%, 60% or 70%, and most particularly by at least 75%, 80%, 90%, 95% or more, or any range or value between the aforementioned percentages.
[0290] Further embodiments include synthetic nucleic acids that are protein inhibitors. The inhibitors can be between 17 and 25 nucleotides in length and comprise a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of the mature mRNA. In certain embodiments, the inhibitor molecule is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. Furthermore, the inhibitor molecule has a sequence (5'-3') that is 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9, or 100% complementary to the 5'-3' sequence of mature mRNA, particularly mature, naturally occurring mRNA, such as B2M, CIITA, TRAC, TRBC1, or TRBC2, or at least the above percentages, or any range derivable therein. Those skilled in the art can use a portion of the probe sequence that is complementary to the sequence of the mature mRNA as the sequence for the mRNA inhibitor. Furthermore, that portion of the probe sequence can be modified so that it is still 90% complementary to the sequence of the mature mRNA.
[0291] In some embodiments, iNKT cells or progenitor or stem cells may contain one or more suicide genes. When engineered iNKT cells contain one or more suicide genes for subsequent depletion, if desired, the suicide genes may be of any suitable type. The iNKT cells of the present disclosure may express a suicide gene product, which may be based on an enzyme, for example. Examples of suicide gene products include herpes simplex virus thymidine kinase (HSV-TK), purine nucleoside phosphorylase (PNP), cytosine deaminase (CD), carboxypeptidase G2, cytochrome P450, linamarase, beta-lactamase, nitroreductase (NTR), carboxypeptidase A, or inducible caspase 9. Thus, in certain cases, the suicide gene may encode thymidine kinase (TK). In certain cases, the TK gene is a viral TK gene, such as the herpes simplex virus TK gene. In certain embodiments, the suicide gene product is activated by a substrate, such as ganciclovir, penciclovir, or a derivative thereof.
[0292] In a particular embodiment, the suicide gene is sr39TK, and an example of the corresponding sequence is as follows:
[0293] sr39TK cDNA sequence (codon-optimized): [ka]
[0294] sr39TK amino acid sequence: [ka]
[0295] In some embodiments, engineered iNKT cells can be imaged or otherwise detected. In certain cases, the cells contain an exogenous nucleic acid encoding a polypeptide having a substrate that can be labeled for imaging, and the imaging can be fluorescent imaging, radioactive imaging, colorimetric imaging, etc. In certain cases, the cells are detected by positron emission tomography. In at least some cases, the cells express the sr39TK gene, a positron emission tomography (PET) reporter / thymidine kinase gene, which allows these genetically modified cells to be tracked by PET imaging and elimination of these cells by the sr39TK suicide gene function.
[0296] A population of engineered iNKT cells is encompassed by the present disclosure. In certain embodiments, the iNKT clonal cells comprise an exogenous nucleic acid encoding an iNKT T cell receptor (T cell receptor) and lack surface expression of one or more HLA-I or HLA-II molecules. The iNKT cells may comprise an exogenous nucleic acid encoding a suicide gene, including a suicide gene based on an enzyme such as thymidine kinase (TK). The TK gene may be a viral TK gene, such as the herpes simplex virus TK gene. In cells of the population, the suicide gene may be activated by a substrate, such as ganciclovir, penciclovir, or a derivative thereof. The cells may comprise an exogenous nucleic acid encoding a polypeptide having a substrate that can be labeled for imaging; in some cases, the suicide gene product is a polypeptide having a substrate that can be labeled for imaging. In certain embodiments, the suicide gene is sr39TK.
[0297] In certain embodiments of the iNKT cell population, the iNKT cells do not express surface HLA-I or HLA-II molecules, for example, because expression of genes encoding beta-2-microglobulin (B2M), major histocompatibility complex class II transactivator (CIITA), and / or HLA-I or HLA-II molecules is disrupted. In certain cases, the iNKT cells have been engineered by gene editing so that HLA-I or HLA-II is not expressed on the cell surface of the iNKT cells. Gene editing may or may not involve CRISPR-Cas9.
[0298] In certain cases for iNKT cell populations, the iNKT cells comprise nucleic acid sequences from a recombinant vector, e.g., a viral vector (including at least a lentivirus, retrovirus, adeno-associated virus (AAV), herpesvirus, or adenovirus), introduced into the cells.
[0299] In certain embodiments, the cells of the iNKT cell population may have been exposed to, or have not been exposed to, one or more certain conditions. In certain cases, for example, the cells of the population are not exposed to, or have not been exposed to, a medium containing animal serum. The cells of the population may or may not be frozen. In some cases, the cells of the population are in a solution containing dextrose, one or more electrolytes, albumin, dextran, and / or DMSO. The solution may contain dextrose, one or more electrolytes, albumin, dextran, and DMSO. The cells may be in a solution that is sterile, non-purulent, and isotonic. In certain cases, the iNKT cells have been activated, for example, with alpha-galactosylceramide (α-GC). In certain aspects, the cell population comprises at least about 10 2 ~10 6 The cell population may, in some cases, comprise a total of at least about 10 clonal cells. 6 ~10 12 The cell may contain cells.
[0300] Certain embodiments include a population of invariant natural killer T (iNKT) cells comprising clonal iNKT cells comprising one or more exogenous nucleic acids encoding an iNKT T cell receptor (T cell receptor) and thymidine kinase suicide, wherein the clonal iNKT cells have been engineered to not express functional beta-2-microglobulin (B2M), major histocompatibility complex class II transactivator (CIITA), and / or HLA-I and HLA-II molecules, and the population comprises a total of at least about 10 6 ~10 12 cells, at least about 10 2 ~10 6 The iNKT cell population contains clonal cells. In some cases, the cells are frozen in solution. V.CAR embodiment A. Antigen binding region
[0301] The antigen-binding region can be a single-chain variable fragment (scFv) derived from an antigen-specific antibody. In some embodiments, the antigen-binding region is a BCMA-binding region. In some embodiments, the antigen-binding region is a CD19-binding region. In some embodiments, the antigen-binding region is a NY-ESO-1-binding region. A "single-chain Fv" or "scFv" antibody fragment is a single-chain variable fragment (scFv) derived from an antigen-specific antibody. In some embodiments, the antigen-binding region is a BCMA-binding region. In some embodiments, the antigen-binding region is a CD19-binding region. In some embodiments, the antigen-binding region is a NY-ESO-1-binding region. H and V L In some embodiments, the antigen-binding domain comprises V domains, and these domains are present in a single polypeptide chain. In some embodiments, the antigen-binding domain is separated by a peptide linker that can facilitate the formation of a desired structure for antigen binding by the scFv. H Domains and V L Further included between domains.
[0302] The variable region of the antigen-binding domain of the polypeptide of the present disclosure is designated as V H and / or V LAmino acids within the CDR1, CDR2, and / or CDR3 regions can be mutated to modify one or more binding characteristics (e.g., affinity) of an antibody. The term "CDR" refers to the complementarity-determining region, based on portions of the variable chains in immunoglobulins (antibodies) and T-cell receptors, produced by B cells and T cells, respectively; these molecules bind to their specific antigens. Because most sequence variations associated with immunoglobulins and T-cell receptors are found in the CDRs, these regions are sometimes referred to as hypervariable regions. Mutations can be introduced by site-directed mutagenesis or PCR-mediated mutagenesis, and the effect on antibody binding or other functional properties of interest can be assessed by appropriate in vitro or in vivo assays. Preferably, conservative modifications are introduced, typically altering no more than one, two, three, four, or five residues within the CDR regions. Mutations can be amino acid substitutions, additions, or deletions.
[0303] Framework modifications can be added to the antibody to reduce immunogenicity, such as by "backmutating" one or more framework residues to the corresponding germline sequence.
[0304] Antigen-binding domains can be Vs that either bind to the same antigen (multivalent) or different antigens (multispecific). H and V L It is also contemplated that antigen-binding domains with domain pairs can be multimerized to become multispecific or multivalent.
[0305] The binding affinity of the antigen-binding region, such as the variable region (heavy and / or light chain variable region) or CDRs is at least 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, or 10 -13In some embodiments, the K of an antigen-binding region, such as a variable region (heavy and / or light chain variable region), or of a CDR may be M. D is at least 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, or 10 -13 M (or any derivable range among these).
[0306] Binding affinity, K A , or K D can be determined by methods known in the art, for example, by biosensors based on surface plasmon resonance (SRP), by equilibrium binding exclusion assays (KinExA), by optical scanners for microarray detection based on polarization-modulated oblique incidence reflectance difference (OI-RD), or by ELISA.
[0307] In some embodiments, the antigen-binding region is humanized. In some embodiments, a polypeptide comprising a humanized binding region has a binding affinity or expression level in a host cell that is equal to, better than, or at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 106, 106, 108, 109, 110, 115, or 120% greater than a polypeptide comprising a non-humanized binding region, such as a binding region from a mouse. VI. Cell preparation and culture
[0308] In certain embodiments, iNKT cells and / or their progenitor cells can be specifically formulated and / or cultured in a particular medium (whether or not they are in an in vitro culture system) at any stage in the process of generating iNKT cells. The cells can be formulated in a manner that makes them suitable for delivery to a recipient without adverse effects.
[0309] In certain embodiments, the medium can be prepared using any of media used as basal media for culturing animal cells, such as AIM V, X-VIVO-15, NeuroBasal, EGM2, TeSR, BME, BGJb, CMRL 1066, Glasgow MEM, Improved MEM Zinc Option, IMDM, Medium 199, Eagle MEM, αMEM, DMEM, Ham, RPMI-1640, and Fischer's medium, as well as any combination thereof, but the medium is not particularly limited as long as it can be used to culture animal cells. In particular, the medium can be xeno-free or chemically defined.
[0310] The medium can be serum-containing or serum-free, or xeno-free. To prevent contamination by components derived from different animals, the serum can be derived from the same animal as that of the stem cells. Serum-free medium refers to a medium that does not contain raw serum or unpurified serum, and therefore can include a medium that contains purified blood-derived components or animal tissue-derived components (e.g., growth factors).
[0311] The medium may or may not contain any serum substitute. Serum substitutes may include materials that suitably contain albumin (e.g., lipid-rich albumin, bovine albumin, albumin substitutes such as recombinant or humanized albumin, plant starch, dextran, and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, or equivalents thereof. Serum substitutes can be prepared, for example, by the methods disclosed in International Publication No. 98 / 30679 (incorporated herein in its entirety). Alternatively, any commercially available material can be used more conveniently. Commercially available materials include knockout serum replacement (KSR), chemically-defined lipid concentrated (Gibco), and glutamax (Gibco).
[0312] In further embodiments, the medium may be a serum-free medium suitable for cell development. For example, the medium may contain B-27® supplement, Xenofree B-27® supplement (available on the World Wide Web at thermofisher.com / us / en / home / technical-resources / media-formulation.250.html), NS21 supplement (Chen et al., J Neurosci Methods, 2008 Jun 30; 171(2): 239-247, which is incorporated herein in its entirety), GS21™ supplement (available on the World Wide Web at amsbio.com / B-27.aspx), or a combination thereof, at a concentration effective for producing T cells from the 3D cell aggregates.
[0313] In certain embodiments, the medium may contain one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more of the following: vitamins, e.g., biotin; DL-alpha-tocopherol acetate; DL-alpha-tocopherol; vitamin A (acetate); proteins, e.g., BSA (bovine serum albumin) or human albumin, fatty acid-free fraction V; catalase; human recombinant insulin; human transferrin; superoxide dismutase; other components, e.g., corticosterone; D-galactose; ethanolamine HCl; glutathione (reduced); L-carnitine HCl; linoleic acid; linolenic acid; progesterone; putrescine 2HCl; sodium selenite; and / or T3 (triiodo-l-thyronine).
[0314] In some embodiments, the medium further comprises a vitamin. In some embodiments, the medium comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen (and any range derivable therein) of biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid, nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B12, or the medium comprises a combination thereof, or a salt thereof. In some embodiments, the medium comprises or consists essentially of biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid, nicotinamide, pyridoxine, riboflavin, thiamine, inositol, and vitamin B12. In some embodiments, the vitamin comprises or consists essentially of biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, or a combination or salt thereof. In some embodiments, the medium further comprises a protein. In some embodiments, the protein comprises albumin or bovine serum albumin, a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or a combination thereof. In some embodiments, the medium further comprises one or more of the following: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, or a combination thereof. In some embodiments, the medium includes one or more of the following: B-27® supplement, XenoFree B-27® supplement, GS21™ supplement, or a combination thereof. In some embodiments, the medium includes or further comprises amino acids, monosaccharides, and inorganic ions. In some embodiments, the amino acids include arginine, cysteine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or a combination thereof.In some embodiments, the inorganic ions comprise sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or combinations or salts thereof. In some embodiments, the medium further comprises one or more of the following: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or combinations thereof. In certain embodiments, the medium comprises or consists essentially of one or more vitamins discussed herein, and / or one or more proteins discussed herein, and / or one or more of the following: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite or triiodo-I-thyronine, B-27® supplement, XenoFree B-27® supplement, GS21™ supplement, amino acids (e.g., arginine, cysteine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine), monosaccharides, inorganic ions (e.g., sodium, potassium, calcium, magnesium, nitrogen, and / or phosphorus) or salts thereof, and / or molybdenum, vanadium, iron, zinc, selenium, copper, or manganese.
[0315] In further embodiments, the medium may include exogenously added ascorbic acid. The medium may also include one or more exogenously added fatty acids or lipids, amino acids (e.g., non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvate, buffers, and / or inorganic salts.
[0316] One or more of the media components can be added at a concentration of at least, at most, or about 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, μg / ml, mg / ml, or any range derivable therein.
[0317] The medium used can be supplemented with at least one exogenously added cytokine at a concentration of about 0.1 ng / mL to about 500 ng / mL, more particularly 1 ng / mL to 100 ng / mL, or at least, at most, or about 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, μg / ml, mg / ml, or any range derivable therein. Suitable cytokines include, but are not limited to, FLT3 ligand (FLT3L), interleukin 7 (IL-7), stem cell factor (SCF), thrombopoietin (TPO), IL-2, IL-4, IL-6, IL-15, IL-21, TNF-alpha, TGF-beta, interferon-gamma, interferon-lambda, TSLP, thymopentin, pleiotrophin, and / or midkine. In particular, the culture medium may contain at least one of FLT3L and IL-7. More particularly, the culture may contain both FLT3L and IL-7.
[0318] Other culture conditions can be appropriately specified. For example, the culture temperature can be about 20-40°C, e.g., at least, at most, or about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40°C (or any range derivable therein), although the temperature can be higher or lower than these values. The CO2 concentration can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% (or any range derivable therein), e.g., about 2%-10%, e.g., about 2-5%, or any range derivable therein. The oxygen partial pressure can be at least or about 1, 5, 8, 10, or 20%, or any range derivable therein.
[0319] In certain embodiments, allogeneic HSC-manipulated HLA-negative iNKT cells are specifically formulated. The cells may or may not be formulated as a cell suspension. In certain cases, the cells are formulated in a single-dose form. The cells may be formulated for systemic or local administration. In some cases, the cells are formulated for storage before use, and the cell formulation may include one or more cryopreservatives, such as DMSO (e.g., 5% DMSO). The cell formulation may also include albumin, including human albumin, with certain formulations including 2.5% human albumin. The cells may be specifically formulated for intravenous administration; for example, the cells are formulated for intravenous administration over less than one hour. In certain embodiments, the cells are in a formulated cell suspension that is stable at room temperature for 1, 2, 3, or 4 hours or longer after thawing.
[0320] In some embodiments, the method further comprises priming the T cells. In some embodiments, the T cells are primed with antigen-presenting cells. In some embodiments, the antigen-presenting cells present a tumor antigen.
[0321] In certain embodiments, the foreign TCR of iNKT cells can be of any defined antigen specificity. In some embodiments, this TCR can be selected based on the absence or reduced alloreactivity to the intended recipient (examples include certain virus-specific TCRs, xeno-specific TCRs, or cancer-testis antigen-specific TCRs). In examples where the foreign TCR is non-alloreactive, during T cell differentiation, the foreign TCR suppresses the rearrangement and / or expression of the endogenous TCR locus through a developmental process called allelic exclusion, resulting in T cells that express only the non-alloreactive foreign TCR and are therefore non-alloreactive. In some embodiments, the selection of the foreign TCR can not necessarily be defined based on the lack of alloreactivity. In some embodiments, the endogenous TCR genes have been modified by genome editing so that they do not express proteins. Gene editing methods, such as those using the CRISPR / Cas9 system, are known in the art and are described herein.
[0322] In some embodiments, the isolated iNKT cells or populations thereof comprise one or more chimeric antigen receptors (CARs). Examples of tumor cell antigens to which CARs can be directed include, for example, at least 5T4, 8H9, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CA9, CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, the EGFR family, including ErbB2 (HER2), EGFRvIII, EGP2, EGP40, ERBB3, ERBB4, ErbB3 / 4, EPCAM, Ep ... hA2, EpCAM, folate receptor-a, FAP, FBP, fetal AchR, FRα, GD2, G250 / CAIX, GD3, glypican-3 (GPC3), Her2, IL-13Rα2, lambda, Lewis-Y, kappa, KDR, MAGE, MCSP, mesothelin, Muc1, Muc16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSC1, PSCA, PSMA, ROR1, SP17, survivin, TAG72, TEM, carcinoembryonic antigen, HMW-MAA, AFP, CA-125, ETA, tyrosinase, MAGE, laminin receptor, HPV Examples of the CAR include E6, E7, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, EphA3, telomerase, SAP-1, BAGE family, CAGE family, GAGE family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PAME, SSX-2, Melan-A / MART-1, GP100 / pmel17, TRP-1 / -2, P. polypeptide, MC1R, prostate-specific antigen, β-catenin, BRCA1 / 2, CML66, fibronectin, MART-2, TGF-βRII, or VEGF receptor (e.g., VEGFR2). CARs can be first-, second-, third-, or later-generation CARs. CARs can be bispecific for any two non-identical antigens, or specific for more than two non-identical antigens. VII. Additional Modifications and Polypeptide Embodiments
[0323] In addition, the polypeptides of the present disclosure can be chemically modified. The glycosylation of the polypeptide can be modified to increase the affinity of the polypeptide for an antigen, for example, by modifying one or more glycosylation sites within the polypeptide sequence (U.S. Patent Nos. 5,714,350 and 6,350,861).
[0324] 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 for any of SEQ ID NOs: 46 to 61 or 81 to 88, or for any of SEQ ID NOs: 1 to 45 or 62 to 66 , 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, Regions or fragments of the polypeptides of the present disclosure, or nucleic acids of the present disclosure encoding the polypeptides, that may have an amino acid sequence with, at least, or at most 6, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 or more amino acid substitutions, consecutive amino acid additions, or consecutive amino acid deletions are contemplated.
[0325] Alternatively, a region or fragment of a polypeptide of the present disclosure may have an amino acid sequence that comprises, consists of, or is 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% (or any range derivable therein) identical, at least said % identical, or at most said % identical to any of SEQ ID NOs: 46-61 or 81-88, or to a polypeptide encoded by any of SEQ ID NOs: 1-45 or 62-66. Further, in some embodiments, the region or fragment is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 , 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 1 05, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187、188、189、190、191、192、193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 68, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 An amino acid region of 9,500 or more consecutive amino acids, which is selected from the group consisting of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 11 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th , 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 8 5th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th , 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 1 13th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th , 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 13 8th place, 139th place, 140th place, 141st place, 142nd place, 143rd place, 144th place, 145th place, 146th place, 147th place, 148th place, 149th place, 150th place,151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350,351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432 2, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473 73rd, 474th, 475th, 476th, 477th, 478th, 479th, 480th, 481st, 482nd, 483rd, 484th, 485th, 486th, 487th, 488th, 489th, 490th, 491st, 492nd, 493rd digit, 494th digit, 495th digit, 496th digit, 497th digit, 498th digit, 499th digit, 500th digitこで, 1st digit, または, によりコードされるポリペプチドのN end, にある). 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 2 4, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,and / or a polypeptide encoded by any of SEQ ID NOS: 1-45 or 62-66. 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 , 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 9 7, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 1 29, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 16 0, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 , 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400, 500, 550, 1000, 1500, or 2000 or more consecutive amino acids or nucleic acids, or any range derivable therein, and at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%,It may be 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% similar, identical or homologous.
[0326] Polypeptides of the present disclosure may be at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 , 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 4, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145 , 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 2 08, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239 9, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 2, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614 or 615 substitutions (or any range derivable therein).
[0327] The substitutions may be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 1 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102 , 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 65, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196 6, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227 , 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258,259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 54 0, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, It may be at amino acid position 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 650, 700, 750, 800, 850, 900, 1000, 1500 or 2000 (or any derivable range therein).
[0328] The polypeptides described herein include those having at least, at most, or exactly the same amino acid sequence as at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 200, 210, 2 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 , 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 , 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 1 91, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222 2, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400, 500,It may be of fixed length, such as 550, 1000 or more (or any derivable range therein).
[0329] Substitution variants typically contain the replacement of one amino acid with another at one or more sites in the protein, and can be designed to modulate one or more properties of the polypeptide, with or without the loss of other functions or properties. Substitutions can be conservative, i.e., one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art, and include, for example, alanine to serine, arginine to lysine, asparagine to glutamine or histidine, asparagine to glutamine, cysteine to serine, glutamine to asparagine, glutamate to aspartate, glycine to proline, histidine to asparagine or glutamine, isoleucine to leucine or valine, leucine to valine or isoleucine, lysine to arginine, methionine to leucine or isoleucine, phenylalanine to tyrosine, leucine or methionine, serine to threonine, threonine to serine, tryptophan to tyrosine, tyrosine to tryptophan or phenylalanine, and valine to isoleucine or leucine. Alternatively, substitutions may be non-conservative substitutions such that the function or activity of the polypeptide is affected. Non-conservative changes typically involve substitution of a residue with a chemically dissimilar one, e.g., substitution of a polar or charged amino acid with a non-polar or uncharged amino acid, and conversely, substitution of a non-polar or uncharged amino acid with a polar or charged amino acid.
[0330] The protein may be a recombinant protein or a protein synthesized in vitro. Alternatively, non-recombinant or recombinant proteins may be isolated from bacteria. It is also contemplated that bacteria containing such variants may be incorporated into compositions and methods. Therefore, it is not necessary to isolate the protein.
[0331] The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the 6 codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids.
[0332] It will also be understood that amino acid and nucleic acid sequences may contain additional residues, e.g., additional N- or C-terminal amino acids, or 5' or 3' sequences, respectively, and still be essentially similar to that shown in one of the sequences disclosed herein, provided that the sequence meets the above criteria, including maintenance of biological protein activity related to protein expression. The addition of terminal sequences applies particularly to nucleic acid sequences, which may include, for example, various non-coding sequences adjacent to either the 5' or 3' portion of the coding region.
[0333] The following is a discussion based on changing the amino acids of proteins to create equivalent or even improved second-generation molecules. For example, certain amino acids can be substituted for other amino acids in protein structures without appreciable loss of interactive binding ability. Structures such as enzymatic catalytic domains or interaction components can have substituted amino acids to maintain such functions. Because the interaction ability and properties of proteins define the biological functional activity of proteins, certain amino acid substitutions can be made within protein sequences and their underlying DNA coding sequences, and still produce proteins with similar properties. Therefore, the inventors believe that various changes can be made to the DNA sequences of genes without appreciable loss of their biological usefulness or activity.
[0334] In other embodiments, it is intended to change the function of a polypeptide by introducing one or more substitutions. For example, certain amino acids in a protein structure can be substituted for other amino acids to improve the interactive binding ability of interacting components. For example, structures such as protein interaction domains, nucleic acid interaction domains, and catalytic sites can have substituted amino acids to change such functions. Because the interaction ability and properties of a protein determine the biological functional activity of a protein, certain amino acid substitutions can be made in the protein sequence and its underlying DNA coding sequence, and still produce proteins with different properties. Therefore, the inventors believe that various changes can be made to the DNA sequence of a gene, which will appreciably change their biological usefulness or activity.
[0335] When making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is generally believed that the relative hydropathicities of amino acids contribute to the secondary structure of the resulting protein, which in turn determines the interaction of the protein with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.
[0336] It is also understood in the art that substitutions of similar amino acids can be made effectively based on hydrophilicity. U.S. Patent No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as determined by the hydrophilicity of its neighboring amino acids, correlates with the biological properties of the protein. It will be understood that an amino acid can be substituted for another having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.
[0337] Amino acid substitutions, as outlined above, are generally based on the relative similarity of the amino acid side-chain substituents, e.g., their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take into account the various characteristics described above are well known and include arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine.
[0338] In certain embodiments, all or part of the proteins described herein can be synthesized in solution or on a solid support according to conventional techniques.A variety of automated synthesizers are commercially available, and they can be used according to known protocols.See, for example, Stewart and Young, (1984); Tam et al., (1983); Merrifield, (1986); and Barany and Merrifield (1979), each of which is incorporated herein by reference.Alternatively, recombinant DNA technology can be used, in which a nucleotide sequence encoding a peptide or polypeptide is inserted into an expression vector, transformed or transfected into a suitable host cell, and cultured under conditions suitable for expression.
[0339] One embodiment involves the use of gene transfer into cells, including microorganisms, for protein production and / or display. The gene for the protein of interest can be transferred into a suitable host cell, and the cell can then be cultured under appropriate conditions. Nucleic acids encoding virtually any polypeptide can be utilized. The generation of recombinant expression vectors and the elements contained therein are discussed herein. Alternatively, the protein produced can be an endogenous protein normally synthesized by the cells used for protein production. VIII. Methods for generating iNKT cells
[0340] iNKT cells can be produced by any suitable method. The method may utilize one or more sequential steps for one or more modifications to the cells, and / or may utilize one or more simultaneous steps for one or more modifications to the cells. In certain embodiments, a starting cell source is modified to function as an iNKT cell, and then one or more steps are performed to impart one or more additional properties to the cells, such as the ability to be imaged, and / or the ability to be selectively killed, and / or the ability to be used allogeneically. In certain embodiments, at least a portion of the process for generating iNKT cells is carried out in a specific in vitro culture system. An example of a specific in vitro culture system is one that allows for high-efficiency and high-yield differentiation of certain cells. In certain embodiments, the in vitro culture system is an artificial thymic organoid (ATO) system. In further specific embodiments, the in vitro culture system does not include one or more of an ATO system, a three-dimensional culture system, a stromal cell feeder layer, and a Notch ligand or a fragment thereof.
[0341] In certain cases, iNKT cells are generated by: 1) genetic modification of donor HSCs to express iNKT TCRs (e.g., with a lentiviral vector) and to abolish expression of HLA-I / II molecules (e.g., by CRISPR / Cas9-based gene editing); 2) in vitro differentiation into iNKT cells by ATO culture; 3) in vitro purification and expansion of iNKT cells; and 4) formulation and cryopreservation and / or use. In some embodiments, iNKT cells are generated without the use of ATO culture (e.g., by the "feeder-free" culture system disclosed herein).
[0342] Some embodiments of the present disclosure provide a method for preparing a population of clonal invariant natural killer T (iNKT) cells, comprising: a) isolating CD34 iNKT cells from human peripheral blood cells (PBMCs); +a) selecting the cells; b) introducing one or more nucleic acids encoding a human iNKT T cell receptor (TCR); c) isolating the isolated human CD34 + ablation of surface expression of one or more HLA-I / II genes in the cells; and d) an isolated CD34 expressing an iNKT TCR. + The method includes culturing cells in an artificial thymic organoid (ATO) system to produce iNKT cells, wherein the ATO system comprises 3D cell aggregates containing a selected population of stromal cells that express a Notch ligand and a serum-free medium. - In an alternative embodiment, a culture system other than the ATO system is utilized, e.g., a CD34 - The method may further comprise isolating the cells. In some embodiments, a 2-D culture system or other forms of 3-D culture system (e.g., FTOC-like culture, Matrigel-supported culture) are applied.
[0343] Certain aspects of the present disclosure relate to cell culture systems, which may be two-dimensional or three-dimensional, for producing iNKT cells from less differentiated cells, such as embryonic stem cells, pluripotent stem cells, hematopoietic stem or progenitor cells, induced pluripotent stem (iPS) cells, or stem or progenitor cells, e.g., fetal liver, umbilical cord blood, and peripheral blood CD34 cells. + Any type of stem cell from a variety of sources can be utilized, including cells (either G-CSF mobilized or non-G-CSF mobilized).
[0344] In some embodiments, the system involves the use of serum-free medium. In certain aspects, the system uses serum-free medium suitable for cell development for the culture of the three-dimensional cell aggregates. Such a system produces sufficient quantities of iNKT cells. In some embodiments of the present disclosure, the cells or cell aggregates are cultured in serum-free medium containing insulin for a period sufficient for in vitro differentiation of stem or progenitor cells into iNKT cells or into precursor cells of iNKT cells.
[0345]
[0003] Embodiments of cell culture compositions can include cultures that use highly standardized serum-free components and stromal cell lines to foster robust and highly reproducible T cell differentiation from human HSCs. In certain embodiments, cell differentiation in this culture closely resembled endogenous thymocyte proliferation and, in contrast to monolayer cocultures, supported efficient positive selection of functional iNKT cells. Certain aspects of the culture compositions use serum-free conditions, avoid the use of human thymus tissue or proprietary scaffold materials, and foster the positive selection and robust generation of fully functional, mature human iNKT cells from source cells.
[0346] In some embodiments, the culture system can include co-culture of human HSCs with stromal cells expressing Notch ligands in the presence of an optimized medium containing FLT3 ligand (FLT3L), interleukin-7 (IL-7), B27, and ascorbic acid. Conditions that allow culture at the air-fluid interface can also be present. It has been determined that combinatorial signaling from soluble factors (cytokines, ascorbic acid, B27 components, and stromal cell-derived factors) along with 3D cell-cell interactions between hematopoietic cells and stromal cells promotes human T cell lineage commitment, positive selection, and efficient differentiation into functional mature T cells.
[0347] In some embodiments, the cell culture is grown on a physical matrix or scaffold containing CD34 + The method is produced by mixing transduced cells with a selected population of stromal cells. + The method further includes centrifuging the transduced cells and stromal cells to form a cell pellet that is placed on the physical matrix or scaffold. The Notch ligand expressed by the stromal cells can be intact, partially or modified DLL1, DLL4, JAG1, JAG2, or a combination thereof. In certain embodiments, the Notch ligand is a human Notch ligand, such as human DLL1.
[0348] The culture system used to generate iNKT cells is a CD34 stromal cell line. +In certain embodiments, the stromal cells and CD34 + The ratio of stromal cells to hematopoietic stem cells is approximately 1:5 to 1:20. The stromal cells can be a murine stromal cell line, a human stromal cell line, a selected population of primary stromal cells, a selected population of stromal cells differentiated in vitro from pluripotent stem cells, or a combination thereof. The stromal cells can be a selected population of stromal cells differentiated in vitro from hematopoietic stem or progenitor cells.
[0349] In methods for preparing a population of clonal iNKT cells, the step of selecting iNKT cells lacking surface expression of HLA-I and HLA-II molecules can include contacting the iNKT cells with magnetic beads that bind to the iNKT cells, positively selecting for these cells, and that bind to HLA-I / II-negative cells, negatively selecting for these cells. In certain embodiments, the magnetic beads are coated with monoclonal antibodies that recognize human iNKT TCR, HLA-I molecules, or HLA-II molecules. In specific embodiments, the monoclonal antibodies are clone 6B11 (recognizing human TCR Vα24-Jα18 and therefore recognizing human iNKT invariant TCR alpha chain), clone 2M2 (recognizing human B2M and therefore recognizing human HLA-I molecules displayed on the cell surface), clone W6 / 32 (recognizing HLA-A, B, C and therefore recognizing human HLA-I molecules), and clone Tu39 (recognizing human HLA-DR, DP, DQ and therefore recognizing human HLA-II molecules).
[0350] The cells produced by the preparation method can be frozen. The cells produced can be in a solution containing dextrose, one or more electrolytes, albumin, dextran, and DMSO. The solution can be sterile, non-purulent, and isotonic.
[0351] In certain embodiments, the culture system comprises CD34 - In some embodiments, the culture system does not use feeder cells.
[0352] The preparation method may further include a step of activating and expanding the selected iNKT cells, for example, the selected iNKT cells are activated with alpha-galactosylceramide (α-GC), and the feeder cells may be pulsed with α-GC.
[0353] The preparation method of the present disclosure comprises at least about 10 2 ~10 6 The method can produce a population of clonal iNKT cells comprising a total of at least about 10 clonal iNKT cells. 6 ~10 12 A cell population containing cells can be produced. The produced cell population can be frozen and then thawed. In some preparation methods, the method further includes introducing one or more additional nucleic acids, such as one or more additional nucleic acids encoding one or more therapeutic gene products, into the frozen and thawed cell population.
[0354] In certain embodiments, methods are provided for 3D or 2D culture compositions, comprising the developmental co-culture of MS-5 mouse stromal cells transduced with human DLL1 (hereafter MS5-hDLL1) with CD34 cells isolated from human umbilical cord blood, bone marrow, or G-CSF-mobilized peripheral blood. + Methods may be provided that involve aggregation with HSPCs. 6 No more than 10 HSPCs are mixed with MS5-hDLL1 cells at an optimal ratio (usually 1:10 HSPCs to stromal cells).
[0355] For example, aggregation can be achieved by centrifugation of the mixed cell suspension ("compression aggregation") followed by aspiration of the cell-free supernatant. In certain embodiments, the cell pellet can then be aspirated as a slurry in 5-10 μl of differentiation medium and transferred as a droplet onto a 0.4 μm nylon interwell culture insert, suspended in the well of differentiation medium with the lower side of the insert in contact with the medium and the upper side in contact with air.
[0356] For example, differentiation medium can contain RPMI-1640, 5 ng / ml human FLT3L, 5 ng / ml human IL-7, 4% serum-free B27 supplement, and 30 μM L-ascorbic acid. The medium can be completely replaced every 3–4 days around the culture insert. During the first 2 weeks of culture, cell aggregates can self-organize into ATOs, allowing commitment and differentiation to early T cell lineages. In certain embodiments, cells are cultured for at least 6 weeks to allow optimal T cell differentiation. Recovery of hematopoietic cells from cell culture can be achieved by disaggregating the cells by pipetting.
[0357] Varying the protocol allows for the use of alternative ingredients with different effects on efficacy, including:
[0358] The basal medium RPMI can be used in place of some commercially available alternatives (eg, IMDM).
[0359] The stromal cell line used is MS-5, a previously described murine myeloid cell line (Itoh et al., 1989), although MS-5 can be substituted with similar murine stromal cell lines (e.g., OP9, S17), human stromal cell lines (e.g., HS-5, HS-27a), primary human stromal cells, or human pluripotent stem cell-derived stromal cells.
[0360] Stromal cell lines are transduced with lentivirus encoding human DLL1 cDNA, although the method of gene delivery and the Notch ligand gene can be varied. Alternative Notch ligand genes include DLL4, JAG1, JAG2, and others. Notch ligands also include those described in U.S. Patent Nos. 7,795,404 and 8,377,886, which are incorporated herein by reference. Notch ligands further include Delta 1, 3, and 4, and Jagged 1 and 2.
[0361] HSC types and sources can include HSCs derived from bone marrow, umbilical cord blood, peripheral blood, thymus or other primary sources; or from human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs).
[0362] Cytokine conditions can be altered: for example, FLT3L and IL-7 levels can be changed to alter T cell differentiation kinetics, and other hematopoietic cytokines can be added, such as stem cell factor (SCF / KIT ligand), thrombopoietin (TPO), IL-2, and IL-15.
[0363] Genetic modifications can be introduced into certain components to generate antigen-specific T cells and model positive and negative selection. Examples of these modifications include transducing HSCs with lentiviral vectors encoding antigen-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) to generate antigen-specific, allele-exclusion naive T cells; transducing HSCs with genes to direct lineage commitment to specialized lymphoid cells. For example, transducing HSCs with invariant natural killer T cell (iNKT)-related TCRs to generate functional iNKT cells in cell culture or ATO; transducing stromal cell lines (e.g., MS5-hDLL1) with human MHC genes (e.g., human CD1d genes) to enhance the positive selection and maturation of both TCR-manipulated T cells or TCR-unmanipulated T cells in cell culture; and / or transducing stromal cells with antigens and costimulatory molecules or cytokines to enhance the positive selection of CAR T cells in culture.
[0364] When engineered iNKT cells were introduced, CD34 from human peripheral blood cells (PBMCs) was used. + Cells can be modified by introducing certain exogenous genes and by knocking out certain endogenous genes. +The method may further include culturing the cells in a medium prior to introducing one or more nucleic acids into the cells. The culturing step may in some cases comprise culturing a selected CD34 + This involves incubating the cells with a medium containing one or more growth factors, which may include, for example, c-kit ligand, flt-3 ligand, and / or human thrombopoietin (TPO). The growth factors may or may not be present at a certain concentration, such as between about 5 ng / ml and about 500 ng / ml.
[0365] In certain methods, the nucleic acid introduced into the cell is one or more nucleic acids comprising nucleic acid sequences encoding an α-TCR and a β-TCR. + The method may further include introducing a nucleic acid encoding a suicide gene into the cells. In certain embodiments, one nucleic acid encodes both α-TCR and β-TCR, or one nucleic acid encodes α-TCR, β-TCR, and the suicide gene. The suicide gene may be based on an enzyme such as thymidine kinase (TK), including a viral TK gene, such as that from the herpes simplex virus TK gene. The suicide gene product can be activated by a substrate, such as ganciclovir, penciclovir, or a derivative thereof. The cells may be modified to contain an exogenous nucleic acid encoding a polypeptide having a substrate that can be labeled for imaging. In some cases, the suicide gene product is a polypeptide having a substrate that can be labeled for imaging, such as sr39TK.
[0366] The cells can be engineered to lack surface expression of HLA-I and / or HLA-II molecules, for example, by disrupting the functional expression of genes encoding beta-2-microglobulin (B2M), major histocompatibility complex class II transactivator (CIITA), and / or HLA-I and HLA-II molecules. These production methods include the use of isolated human CD34 +Eliminating the surface expression of one or more HLA-I / II molecules in cells can include introducing CRISPR and one or more guide RNAs (gRNAs) corresponding to B2M, CIITA, or individual HLA-I or HLA-II molecules into cells. The CRISPR or one or more gRNAs are transfected into cells, in some cases, by electroporation or lipid-mediated transfection. In certain embodiments, the nucleic acid encoding the TCR receptor is introduced into cells using a recombinant vector, such as a viral vector, including at least a lentivirus, retrovirus, adeno-associated virus (AAV), herpesvirus, or adenovirus.
[0367] When producing engineered iNKT cells, the cells can be present in certain serum-free media, including serum-free media containing exogenously added ascorbic acid. In certain embodiments, the serum-free media further contains exogenously added FLT3 ligand (FLT3L), interleukin 7 (IL-7), stem cell factor (SCF), thrombopoietin (TPO), IL-2, IL-4, IL-6, IL-15, IL-21, TNF-alpha, TGF-beta, interferon-gamma, interferon-lambda, TSLP, thymopentin, pleiotrophin, midkine, or a combination thereof. The serum-free medium may further contain vitamins, including biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid, nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B12, or combinations or salts thereof. The serum-free medium may further contain one or more exogenously added (or non-exogenously added) proteins, such as albumin or biotin-containing serum albumin, a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or combinations thereof. The serum-free medium may further contain corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, or combinations thereof. The serum-free medium may contain B-27® supplement, Xenofree B-27® supplement, GS21™ supplement, or a combination thereof. Amino acids (including arginine, cysteine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or a combination thereof), monosaccharides, and / or inorganic ions (including, for example, sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or a combination or salt thereof) may be present in the serum-free medium.The serum-free medium may further comprise molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or a combination thereof.
[0368] Cell culture conditions can be provided for the 3D cell aggregates described herein, as well as for the production of T cells and / or their positive / negative selection. In certain embodiments, the starting cells of the selected population are at least or about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 The starting cell population may comprise at least or about 10, 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 The seeding density may be in cells / ml or any range derivable therein.
[0369] Culture vessels used to culture the 3D cell aggregates or their progeny can include, but are not limited to, flasks, tissue culture flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, multi-plates, multiwell plates, microslides, chamber slides, tubes, trays, CellSTACK® chambers, culture bags, and roller bottles, so long as stem cells can be cultured therein. Stem cells can be cultured in volumes of at least or about 0.2, 0.5, 1, 2, 5, 10, 20, 30, 40, 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml, 550 ml, 600 ml, 800 ml, 1000 ml, 1500 ml, or any range derivable therein, depending on the needs of the culture. In certain embodiments, the culture vessel can be a bioreactor, which can refer to any device or system that supports a biologically active environment. The bioreactor can have a volume of at least or about 2, 4, 5, 6, 8, 10, 15, 20, 25, 50, 75, 100, 150, 200, 500 liters, 1, 2, 4, 6, 8, 10, 15 cubic meters, or any range derivable therein.
[0370] The culture vessel can be either cell-adhesive or non-cell-adhesive, and can be selected depending on the purpose. The cell-adhesive cell vessel can be coated with a cell-adhesive substrate, such as an extracellular matrix (ECM), to improve cell adhesion to the vessel surface. The cell-adhesive substrate can be any material intended to adhere to stem cells or feeder cells (if used). Cell-adhesive substrates include collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin, and mixtures thereof, such as Marigel™, and dissolved cell membrane preparations.
[0371] A variety of defined matrix components can be used in the culture methods or compositions, for example, recombinant collagen IV, fibronectin, laminin, and vitronectin can be used in combination to coat culture surfaces as a means of providing a solid support for pluripotent cell growth, as described in Ludwig et al. (2006a; 2006b), the entire contents of which are incorporated herein by reference.
[0372] Matrix compositions can be immobilized on surfaces to support cells. The matrix composition can include one or more extracellular matrix (ECM) proteins and an aqueous solvent. The term "extracellular matrix" is recognized in the art. Its components include one or more of the following proteins: fibronectin, laminin, vitronectin, tenascin, entactin, thrombospondin, elastin, gelatin, collagen, fibrillin, merosin, anchorin, chondronectin, link protein, bone sialoprotein, osteocalcin, osteopontin, epinectin, hyaluronectin, undulin, epiligrin, and kalinin. Other extracellular matrix proteins are described in Kleinman et al. (1993), which is incorporated herein by reference. The term "extracellular matrix" is intended to encompass currently unknown extracellular matrices that may be discovered in the future, as it is believed that those skilled in the art will be able to readily determine their characteristics as extracellular matrices.
[0373] In some aspects, the total protein concentration in the matrix composition can be from about 1 ng / mL to about 1 mg / mL. In some embodiments, the total protein concentration in the matrix composition is from about 1 μg / mL to about 300 μg / mL. In more preferred embodiments, the total protein concentration in the matrix composition is from about 5 μg / mL to about 200 μg / mL.
[0374] Extracellular matrix (ECM) proteins can be of natural origin and purified from human or animal tissues. Alternatively, ECM proteins can be genetically engineered recombinant proteins or naturally synthesized. ECM proteins can be natural or engineered whole proteins or in the form of peptide fragments. Examples of ECM proteins that can be useful in cell culture matrices include laminin, collagen I, collagen IV, fibronectin, and vitronectin. In some embodiments, the matrix composition comprises synthetically generated peptide fragments of fibronectin or recombinant fibronectin.
[0375] In still further embodiments, the matrix composition comprises a mixture of at least fibronectin and vitronectin. In some other embodiments, the matrix composition preferably comprises laminin.
[0376] The matrix composition preferably contains a single type of extracellular matrix protein. In some embodiments, the matrix composition contains fibronectin, particularly for use in culturing progenitor cells. For example, a suitable matrix composition can be prepared by diluting human fibronectin, such as human fibronectin (catalog number 354008) sold by Becton, Dickinson & Co. (BD) of Franklin Lakes, NJ, with Dulbecco's phosphate-buffered saline (DPBS) to a protein concentration of 5 μg / mL to about 200 μg / mL. In certain examples, the matrix composition contains a fibronectin fragment, such as RetroNectin®. RetroNectin® is a (574 amino acid, approximately 63 kDa) protein containing the central cell-binding domain (type III repeats 8, 9, and 10), the high-affinity heparin-binding domain II (type III repeats 12, 13, and 14), and the alternatively spliced CS1 site within the IIICS region of human fibronectin.
[0377] In some other embodiments, the matrix composition can include laminin. For example, a suitable matrix composition can be prepared by diluting laminin (Sigma-Aldrich, St. Louis, Mo.; catalog numbers L6274 and L2020) with Dulbecco's phosphate-buffered saline (DPBS) to a protein concentration of 5 μg / ml to about 200 μg / ml.
[0378] In some embodiments, the matrix composition is xeno-free because the matrix, or its protein components, are exclusively human-derived. This may be desirable for certain research applications. For example, a xeno-free matrix for culturing human cells may use human-derived matrix components, in which case any non-human animal components may be excluded. In certain aspects, Matrigel™ may be excluded as a substrate from the culture composition. Matrigel™ is a gel-like protein mixture secreted by mouse tumor cells and is commercially available from BD Biosciences (New Jersey, USA). This mixture resembles the complex extracellular environment found in many tissues and is often used by cell biologists as a substrate for cell culture, but it may introduce unwanted xenoantigens or contaminants.
[0379] In certain embodiments, cells containing exogenous nucleic acid can be identified in vitro or in vivo by including a marker in the expression vector or exogenous nucleic acid. Such a marker will cause an identifiable change in the cell, allowing easy identification of cells containing the expression vector. Generally, a selection marker can confer a characteristic that allows selection. A positive selection marker can be one whose presence allows its selection, while a negative selection marker's presence prevents its selection. An example of a positive selection marker is a drug resistance marker.
[0380] Typically, the inclusion of a drug selection marker aids in the cloning and identification of transformants; for example, genes conferring resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin, and histidinol are useful selection markers. In addition to markers that confer a phenotype that allows for the differentiation of transformants based on the implementation of conditions, other types of markers are contemplated, including screenable markers such as GFP, whose criteria are colorimetric. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) can be used as negative selection markers. Those skilled in the art will also know how to utilize immunological markers, perhaps in conjunction with FACS analysis. The marker used is not believed to be important, so long as it can be expressed simultaneously with the nucleic acid encoding the gene product. Further examples of selection and screenable markers are well known to those skilled in the art.
[0381] Selectable markers can include reporter genes of the type used in microbiology, molecular biology, and genetic engineering to indicate successful transfection or other procedures intended to introduce foreign DNA into cells. Selectable markers are often antibiotic resistance genes; cells subjected to a procedure to introduce foreign DNA are grown in a medium containing the antibiotic; cells that are able to grow have successfully incorporated and expressed the introduced genetic material. Examples of selectable markers include the Abicr gene from Tn5, which confers antibiotic resistance to geneticin, or the Neo gene.
[0382] Screenable markers may include reporter genes that allow researchers to distinguish between desirable and undesirable cells. Certain embodiments of the present invention utilize reporter genes to indicate specific cell lineages. For example, reporter genes may be placed within expression elements and under the control of ventricular- or atrial-selective regulatory elements that are normally associated with the coding regions of ventricular- or atrial-selective genes for coexpression. Reporters allow cells of specific lineages to be isolated without placing them under drug or other selection pressure or otherwise jeopardizing cell survival.
[0383] Examples of such reporters include genes encoding cell surface proteins (e.g., CD4, HA epitope), genes encoding fluorescent proteins, genes encoding antigenic determinants, and genes encoding enzymes (e.g., β-galactosidase). Cells containing the vector can be isolated by FACS, for example, using fluorescently tagged antibodies against cell surface proteins or substrates that can be converted to fluorescent products by the enzymes encoded by the vector.
[0384] In certain embodiments, the reporter gene is a fluorescent protein. A wide range of fluorescent protein genetic variants have been developed, featuring fluorescence emission spectral profiles spanning nearly the entire visible light spectrum. Mutagenesis efforts initially focused on the Aequorea victoria jellyfish green fluorescent protein resulted in new fluorescent probes ranging in color from blue to yellow, and these probes are some of the most widely used reporter molecules in vivo in biological research. Longer wavelength fluorescent proteins emitting in the orange and red spectral regions have been developed from the marine sea anemone, Discosoma striata, and reef-building corals belonging to the class Anthozoa. Still other species have been identified to produce similar proteins with cyan, green, yellow, orange, and crimson fluorescence. Developmental research efforts continue to improve the brightness and stability of fluorescent proteins, thereby improving their overall utility.
[0385] In certain embodiments, cells can be engineered to contain one or more genetic alterations by genetically engineering the cells either before or after differentiation (U.S. Patent Application Publication No. 2002 / 0168766). When an exogenous nucleic acid or polynucleotide is introduced into a cell by suitable artificial manipulation means, or when the cell is a descendant of an originally engineered cell that inherited the polynucleotide, the cell is said to be "genetically altered," "genetically modified," or "transgenic." For example, cells can be engineered to increase their replicative potential by genetically altering the cells to express telomerase reverse transcriptase either before or after the cells progress to a restricted developmental lineage or to a terminally differentiated cell (U.S. Patent Application Publication No. 2003 / 0022367).
[0386] In certain embodiments, cells containing the exogenous nucleic acid construct can be identified in vitro or in vivo by including a marker, such as a selectable or screenable marker, in the expression vector. Such a marker may result in an identifiable change in the cells that allows for easy identification of cells containing the expression vector, or may facilitate enrichment or identification of differentiated cardiac cells by using tissue-specific promoters. For example, in cardiomyocyte differentiation, cardiac-specific promoters such as those for cardiac troponin I (cTnI), cardiac troponin T (cTnT), sarcomeric myosin heavy chain (MHC), GATA-4, Nkx2.5, N-cadherin, β1-adrenergic receptor, ANF, the MEF-2 family of transcription factors, creatine kinase MB (CK-MB), myoglobin, or atrial natriuretic factor (ANF) may be used. In neuronal differentiation, neuron-specific promoters may be used, including, but not limited to, TuJ-1, Map-2, Dcx, or synapsin. In hepatocyte differentiation embodiments, definitive endoderm-specific and / or hepatocyte-specific promoters can be used, including but not limited to ATT, Cyp3a4, ASGPR, FoxA2, HNF4a, or AFP.
[0387] Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one whose presence allows for its selection, while a negative selectable marker is one whose presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.
[0388] Typically, the inclusion of a drug selection marker aids in the cloning and identification of transformants; for example, genes conferring resistance to blasticidin, neomycin, puromycin, hygromycin, DHFR, GPT, zeocin, and histidinol are useful selectable markers. In addition to markers that confer a phenotype that allows for the differentiation of transformants based on the implementation of a condition, other types of markers are contemplated, including screenable markers such as GFP, whose criteria are colorimetric. Alternatively, screenable enzymes such as chloramphenicol acetyltransferase (CAT) can be utilized. Those skilled in the art will also know how to utilize immunological markers, perhaps in conjunction with FACS analysis. The marker used is not believed to be important, so long as it can be expressed simultaneously with the nucleic acid encoding the gene product. Further examples of selectable and screenable markers are well known to those skilled in the art.
[0389] In embodiments, cell is genetically modified, for example, genetically modified to add or reduce one or more characteristics, genetic modification can be carried out by any suitable method.For example, any genetic modification composition or method, for example, gene editing, homologous recombination or non-homologous recombination, RNA-mediated gene delivery, or any conventional nucleic acid delivery method can be used to introduce exogenous nucleic acid into cell or edit genomic DNA.Non-limiting examples of genetic modification methods can include gene editing, for example, gene editing by CRISPR / Cas9, zinc finger nuclease or TALEN technology.
[0390] Genetic modification can also include the introduction of selectable or screenable markers that facilitate in vitro or in vivo selection or screening. In particular, in vivo imaging agents or suicide genes can be exogenously expressed or added to the starting cells or progeny cells. In a further aspect, the method can include image-guided adoptive cell therapy.
[0391] Specific Embodiments
[0392] In certain embodiments of the present disclosure, there is provided a method for preparing a cell population comprising clonal invariant natural killer (iNKT) T cells, the method comprising: a) isolating CD34 T cells from human peripheral blood cells (PBMCs); + b) selecting cells; and c) selecting CD34 cells in a medium containing growth factors including c-kit ligand, flt-3 ligand, and human thrombopoietin (TPO). + c) culturing the cells; and + d) transducing the cells with a lentiviral vector containing nucleic acid sequences encoding α-TCR, β-TCR and thymidine kinase; and e) transducing the cells with a lentiviral vector containing nucleic acid sequences encoding α-TCR, β-TCR and thymidine kinase; + The methods include: introducing Cas9 and gRNA for beta-2 microglobulin (B2M) and / or CTIIA into cells to disrupt expression of the B2M or CTIIA gene, thereby eliminating surface expression of HLA-I and / or HLA-II molecules; e) culturing the transduced cells in 3D aggregate cell culture with an irradiated stromal cell line expressing an exogenous Notch ligand for 2-12 (or 2-10 or 6-12) weeks to expand iNKT cells; f) selecting iNKT cells lacking surface expression of HLA-I / II molecules; and g) culturing the selected iNKT cells with irradiated feeder cells. In certain embodiments, methods are provided that include culturing iNKT cells in 3D aggregate cell culture for 2-12 (or 2-10 or 6-12) weeks to expand iNKT cells. 8 ~10 13 iNKT cells were then transfected with selected CD34 + It is prepared from cells.
[0393] Thus, the present disclosure encompasses advanced, off-the-shelf, HSC-based iNKT cell therapies. Specifically, G-CSF-mobilized CD34 + HSCs can be obtained from healthy donors or from cell repositories. From a single donor, approximately 1-5 x 10 8HSCs can be harvested. In certain cases, these HSCs are engineered in vitro using the Lenti / iNKT-sr39TK lentiviral vector and CRISPR-Cas9 / B2M-CIITA-gRNA complex and then differentiated into iNKT cells in artificial thymic organoid (ATO) culture for 8 weeks. The iNKT cells are then purified and expanded in vitro for an additional 2-4 weeks before cryopreservation and lot release. In certain embodiments, approximately 10 12 iNKT c...
Claims
1. 1. A method for preparing a population of T cells, comprising: a) selecting stem or progenitor cells, said stem or progenitor cells being CD34 + Step 1: Containing Cells b) introducing one or more nucleic acids encoding at least one T cell receptor (TCR), said TCR comprising an invariant natural killer T cell (iNKT) TCR, selected to express an iNKT TCR in said stem or progenitor cells, said one or more nucleic acids comprising invariant alpha and beta chain polypeptides; and c) culturing the cells to induce differentiation of the cells into invariant natural killer T cells. Including, c) comprises a culture that is feeder-free; a) the cells are cultured in a medium containing IL-3, IL-7, IL-6, SCF, MCP-4, EPO, TPO, FLT3L, and retronectin; The method, wherein a), b) and / or c) does not include the step of contacting said cells with a feeder cell or population of feeder cells.
2. The method of claim 1, wherein the TCR comprises a TCR that specifically recognizes the NY-ESO-1 antigen.
3. 3. The method according to claim 1, wherein c) comprises culturing the cells in a differentiation and / or expansion medium.
4. 4. The method of any one of claims 1 to 3, wherein c) comprises contacting the cells with one or more of DLL1, DLL4, VCAM1, VCAM5, and / or retronectin.
5. The method of any one of claims 1 to 4, further comprising the step of stimulating and / or expanding the cells.
6. contacting the cells with one or more of human serum antibodies, glutamax, a buffer, an antibacterial agent, and N-acetyl-L-cysteine; and / or the expansion medium comprises one or more of human serum antibodies, glutamax, a buffer, an antibacterial agent, and N-acetyl-L-cysteine; and / or activating the cells by contacting the cells with anti-CD3 and / or anti-CD28 coated beads.
6. The method according to any one of claims 1 to 5.
7. The method of any one of claims 1 to 6, further comprising the step of transfecting the cells with a nucleic acid comprising a CAR molecule and / or an HLA-E gene.
8. 8. A cell or population of cells produced by the method of any one of claims 1 to 7.
9. 1. An engineered invariant natural killer T (iNKT) cell differentiated from a stem or progenitor cell in the absence of feeder cells, the iNKT cell expressing at least one invariant natural killer T cell receptor (TCR) expressed from one or more exogenous nucleic acids, the genome of the cell being modified to abolish surface expression of at least one HLA-I or HLA-II molecule, the iNKT cell comprising: high levels of NKG2D; Low or undetectable expression of KIR; and High levels of granzyme B [0033] The stem or progenitor cells are + Engineered iNKT cells comprising the cells and cultured in medium containing IL-3, IL-7, IL-6, SCF, MCP-4, EPO, TPO, FLT3L, and retronectin.
10. 10. The engineered cell of any one of claims 8 to 9, which has not been subjected to cell sorting.
11. 11. The engineered cell of any of claims 8 to 10, wherein the cell comprises an exogenous suicide gene and the at least one TCR is expressed from an exogenous nucleic acid and / or from an endogenous invariant TCR gene under the transcriptional control of a recombinantly modified promoter region.
12. 12. The engineered cell of any one of claims 8 to 11, which is derived from a hematopoietic stem cell from a subject not suffering from cancer.
13. A composition for treating a patient with T cells, the composition comprising the cells of any one of claims 8 to 12.
14. The composition of claim 13 , wherein the patient has cancer.
15. The composition of claim 14 , wherein the cancer comprises multiple myeloma.
16. The composition of claim 14 , wherein the cancer comprises leukemia.
17. The composition of claim 13 , wherein the patient has a disease or condition involving inflammation.
Citation Information
Patent Citations
Methods for producing t cells from stem cells and immunotherapeutic methods using said t cells
JP2018533364A
